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ABSTRACT 
 
 
Concurrent use of anti-retroviral drugs (ARVs) and progestin-based hormonal contraceptives 
is widespread. During times of stress and during glucocorticoid (GC) therapy, intracellular 
ARVs are in the presence of high concentrations of GCs, which regulate all aspects of immunity 
and inflammation via the glucocorticoid receptor (GR). However, the reciprocal modulation of 
ARV and steroid intracellular functions is relatively unexplored. In this study, the effects of the 
ARVs tenofovir disoproxil fumarate (TDF), dapivirine (DPV), and maraviroc (MVC) on 
activation of the GR and GR-regulated mRNA expression were investigated, in the absence 
and presence of select GR ligands. The effects of TDF and DPV on GR protein levels and 
phosphorylation were also determined. The inhibitory activity of these ARVs on HIV-1 
infection in the presence of the progestins medroxyprogesterone acetate (MPA) and 
levonorgestrel (LNG), and a GR agonist, dexamethasone (DEX) was also assessed. This study 
shows that (0.01 nM–10 µM) TDF, DPV and MVC do not transactivate reporter gene 
expression via the unliganded GR exogenously expressed in the steroid receptor-deficient 
U2OS human osteosarcoma cell line, or alter the reporter gene transcriptional activity of (100 
nM) MPA or LNG via the GR in these cells. However, (1 µM) TDF and DPV modulate the 
reporter gene transcriptional efficacy of (0.01 nM–10 µM) DEX via the GR. In the U2OS cell 
line model, (1 µM) TDF, but not DPV significantly decreased (1µM and 10µM) DEX-induced 
mRNA expression of the anti-inflammatory glucocorticoid-induced leucine zipper (GILZ) 
gene. TDF also appeared to decrease (1 µM) cortisol (CORT)- and MPA-induced GILZ 
mRNA expression. This may be mediated by the apparent increase in (100 nM and 1µM) DEX-
induced phosphorylation at Serine 226 on the GR, observed in the presence of (1µM) TDF in 
this study. DPV and TDF (at 1µM) did not significantly alter GR protein levels, or cell-viability 
in the absence and presence of (100 nM) DEX, CORT or MPA in U2OS cells. However, (1 
µM) DPV and TDF alone, significantly altered cell viability in peripheral blood mononuclear 
cells (PBMCs). In PBMCs, (1 µM) TDF, MVC and DPV alone altered basal GILZ mRNA 
expression and had variable, donor-specific effects on interleukin (IL)-6, IL-8, and interferon 
(IFN)-γ gene expression. In PBMCs from some of the nine donors tested, these ARVs had 
proinflammatory effects which may undermine their efficacy at preventing HIV-1 acquisition 
in pre-exposure prophylaxis products. Moreover, the ARVs proinflammatory effects may 
negatively impact HIV-1 disease progression and increase the risk of non-AIDS mortality in 
individuals using the ARVs therapeutically. Neither (1 µM) DPV, TDF nor MVC significantly 
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altered the effects of (100 nM) DEX on the immunomodulatory genes assessed in PBMCs. 
DEX, MPA and LNG (at 100 nM) did not affect the anti-HIV-1 activity of the ARVs (at 1 
µM) in PBMCs from the majority of the three donors tested in this study. Taken together, the 
results show that ARVs can modulate GR activity in an ARV-, steroid-, gene- and cell-specific 
manner, while the steroids investigated did not modulate ARV anti-HIV-1 activity.  
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CHAPTER 1 
 
LITERATURE REVIEW 
___________________________________________________________________________ 
 
 
1.1 HIV-1 prevalence, and incidence of unintended pregnancy in Sub-Saharan Africa 
 
In 2017, approximately 36.9 million people globally were living with HIV/AIDS (Joint United 
Nations Programme on HIV/AIDS (UNAIDS), 2018). Although only 6% of the global 
population inhabits East and Southern Africa, over half of those infected (19.4 million people in 
2017) reside in this region (UNAIDS, 2018). South Africa has the highest HIV-1 prevalence 
globally; with approximately 7.2 million people infected, it accounts for a third of all new infections 
in southern Africa (UNAIDS, 2018). 
 
Women and adolescent girls are disproportionately affected by the epidemic (Fig. 1.1). In Sub-
Saharan Africa, 75% of new infections among adolescents aged 15–19 years are in girls, and young 
women aged 15–24 years are twice as likely to be living with HIV than men (UNAIDS, 2018). In 
South Africa, women aged 15–24 years accounted for 37% of new infections in 2016 (South 
African National AIDS Council (SANAC), 2017). Socio-economic factors which disadvantage 
women, and physiological differences which render women more susceptible to HIV-1 acquisition 
than men are thought to be responsible (Greig et al., 2008). Innate and adaptive immune responses 
in men and women differ, due to the actions of the sex steroid hormones progesterone (P4) and 
estrogen (E2) in women, and testosterone in men. Sex chromosome genes also contribute to sex-
based immunological differences (reviewed by Klein and Flanagan, 2016). A further burden on 
women are unintended pregnancies, which too occur with the highest incidence in Sub-Saharan 
Africa (Sedgh et al. 2014). The consequences are often infant and maternal morbidity or mortality, 
unsafe abortions and, in HIV-1 positive women, mother-to-child transmission of the virus (Sedgh 
et al. 2014). As such, the use of hormonal contraceptives (HCs), for effective timing of pregnancy 
and family planning is widespread in the region (UN, 2015).  
 
As evidenced by the data presented here, there is a need for HIV-1 preventative strategies, targeted 
at women. Concurrently, there is a need for interventions which reduce the burden of unintended 
pregnancy, and to offer women control over their reproductive health. There are efforts underway 
to develop effective HIV-1 preventative interventions, targeted at women. Microbicides are topical 
products, applied intravaginally, to prevent the early events of heterosexual HIV-1 transmission 
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(Kelly and Shattock, 2011). The most clinically advanced microbicides are based on antiretroviral 
drugs (ARVs) (Verma et al., 2011). Multipurpose prevention technologies (MPTs) are ARV and 
HC combination products for the simultaneous prevention of unintended pregnancy and HIV-1 
acquisition in women (reviewed by Friend et al., 2013; Jean-Pierre et al., 2016). 
 
 
 
Figure 1.1: HIV-1 prevalence is higher in women in Sub-Saharan Africa . Female rate is shown as a 
percentage of the population infected with HIV-1 (aged 15 or older) in 2017. Data was published by World 
Bank at http://data.worldbank.org/data-catalog/world-development-indicators, and is based on UNAIDS 
estimates (UNAIDS, 2018). Figure is adapted from https://ourworldindata.org/hiv-aids#hiv-aids-and-
gender.  
 
1.2 Progestins in common hormonal contraceptives 
 
 HCs differ in their mode of delivery (oral, intramuscular or subcutaneous injection, transdermal 
patch or intravaginal implant), the frequency with which they are administered, as well as the type 
and dose of progestogen they contain (reviewed by Stanczyk et al., 2013; Hapgood et al., 2018). 
Progestogens are defined as compounds which alter the state of the endometrium of the uterus, 
from secretory to proliferative, thereby preventing ovulation and pregnancy (Stanczyk and Henzl, 
2001). Ovulation in women is inhibited by high levels of P4, the endogenous progestogen 
(reviewed by Stanczyk and Henzl, 2001). Progestins are synthetic progestogens which, like P4, 
exert their progestogenic effects via the progesterone receptors (PR) (reviewed by Stanczyk et al., 
2013; Hapgood et al., 2014a). Depending on their chemical structure, they may bind to other 
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members of the nuclear receptor family, acting as agonists, partial agonists or antagonists 
(Stanczyk et al., 2013; Hapgood et al., 2014a). 
 
Long-acting injectable hormonal contraceptives (IHCs) are the most widely used form of 
contraception in Sub-Saharan Africa, with approximately 16.5 million women using IHCs in 2015 
(UN, 2015). Although protective against unintended pregnancy, they are not protective against 
sexually transmitted diseases (unlike the condom) (Baeten et al., 2001). IHCs are favoured in 
developing countries because of the relatively long interval between injections and because they 
allow for discreet usage, without the need for partner co-operation (Affandi, 2002). 
 
1.2.1 Medroxyprogesterone acetate 
 
The most common IHC used in southern Africa is 150 mg medroxyprogesterone acetate (MPA), 
administered as an intramuscular injection at three monthly intervals as Depo-Provera or Depot-
MPA (DMPA) (Affandi, 2002). MPA is structurally related to P4 (Stanczyk, 2003), and has been 
used for more than 30 years, both in HCs and for postmenopausal hormone replacement therapy 
(HRT) (Stanczyk et al., 2013). Reported peak serum concentrations for DMPA are relatively high 
compared to progestins used in many other forms of HC, and vary between individuals and 
between studies (Hapgood et al., 2018). Inconsistency in time post-injection at which serum 
concentrations are determined, number of injections and experimental methodologies between 
studies are likely to account for many of the discrepancies between studies (Hapgood et al., 2018). 
Peak serum concentrations are typically reported in the range of 10–40 nM following an 
intramuscular injection (see Table 1.1) (Kirton and Cornette, 1974; Virutamasen et al., 1996; Fang 
et al., 2004), and concentrations as high as 100 nM have been reported in some users (Koetsawang, 
1977). MPA serum concentrations typically plateau to approximately 2.6 nM (Mishell, 1996). 
 
MPA use is associated with several adverse effects, including a loss in bone mineral density (BMD) 
and increased risk of breast cancer (Hapgood et al., 2018). Moreover, meta-analysis of higher 
quality observational and clinical studies suggests MPA, unlike other HCs, significantly increases 
the risk of HIV-1 acquisition by 1.4-fold (Polis et al., 2016). It is important to note that the 
interpretation of the results of observational studies is confounded by factors like condom usage 
and frequency of sexual acts, which, in these studies, are difficult to control for (Hapgood et al., 
2018). A growing body of clinical, animal and ex vivo studies, recently reviewed comprehensively 
by Hapgood et al., support biological mechanisms consistent with an increased risk of HIV-1 
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infection in MPA users (Hapgood et al., 2018). These mechanisms include increasing the risk of 
acquiring other sexually transmitted infections (including chlamydia and herpes simplex virus type 
2 (HSV-2) (Deese et al., 2018), enhanced activation and recruitment of HIV-1 target cells to the 
FGT through modulation of cytokine and chemokine expression and enhanced HIV-1 entry and 
replication within these cells (Hapgood et al. 2018). Additional mechanisms include increased 
genital injury signatures, alterations to the vaginal microbiota and impaired integrity of the 
cervicovaginal mucosa (Hapgood et al. 2018). 
 
Like other progestins, MPA has a high affinity for the PR. As steroid receptors have structurally 
related ligand binding domains (LBDs), dependent on their structure, progestins are able to bind 
to other members of the steroid receptor family (Stanczyk et al., 2013; Hapgood et al., 2014a). 
Whereas binding to the ER has not been reported, progestins have varying affinities for the 
androgen receptor (AR), glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) 
(Stanczyk et al., 2013; Hapgood et al., 2014a). Unlike other progestins, MPA has a relatively high 
affinity for the GR, binding with a higher affinity than both P4 and cortisol (CORT), the 
endogenous ligand for the GR. Like many other progestins, MPA exhibits binding to the AR 
(Stanczyk et al., 2013; Hapgood et al., 2014a). However, binding affinity does not equal biological 
activity, which is determined by the conformation the ligand induces in the receptor LBD and 
other receptor domains, which influence transcriptional co-regulator recruitment and 
transcriptional activity (Ronacher et al., 2009). Nevertheless, MPA has been shown to be a 
relatively potent partial agonist for upregulation of several GR-regulated genes, and a relatively 
potent full agonist for the downregulation of GR-regulated genes, including proinflammatory 
cytokines and chemokines (Koubovec et al., 2004, 2005; Govender et al., 2014; Hapgood et al., 
2014b).  
 
1.2.2 Levonorgestrel 
 
Levonorgestrel (LNG) is a progestogen structurally related to testosterone, and is the biologically 
active form of norgestrel (Stanczyk, 2003). LNG is delivered in intrauterine devices (IUDs), trans-
epidermal implants and combined oral contraceptive (COC) pills (Stanczyk, 2003). LNG peak 
serum concentrations are typically in the range of 0.3–28 nM, and are dependent on the mode of 
administration (see Table 1.1) (Sivin et al., 1997; Licea-Perez et al., 2007; Hidalgo et al., 2009). It 
should be noted that serum levels required for effective contraception have not been established 
for most progestins, including MPA and LNG (Hapgood et al. 2018). Unlike MPA, LNG exhibits 
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no binding affinity for the GR, or transcriptional activity via the GR, but does bind to the AR 
(Stanczyk et al., 2013; Hapgood et al., 2014a). MPA and LNG have been reported to increase genital 
permeability in mice, which was associated with a decrease in cell-adhesion molecules, as well as 
an influx of inflammatory cells into the genital tract (Quispe Calla et al., 2016). Quispe Calla et al. 
also reported that LNG and MPA increased the risk of vaginal HSV-2 transmission in these mice 
(Quispe Calla et al., 2016). Additional basic and clinical studies are required to determine the effects 
of MPA and LNG on genital tract barrier function in humans. 
 
Table 1.1: MPA and LNG mode of administration, peak serum concentrations and relative binding 
affinities to steroid receptors. 
 
Progestin Mode of administration Peak serum 
concentration (nM) 
 
Steroid receptor relative 
binding affinities 
(% relative binding 
affinity)•10 
 
 
 
MPA 
3 monthly injection: 
 
                 AR: 151 
                ER: – 
                GR: 74 
                PR: 65–98 
                MR: 0.13 
Intramuscular (DMPA-IM) 
 
10–401–3 
Subcutaneous (DMPA-SQ) 2.5–44–6 
 
 
LNG 
1 year IUD 
3 or 5 year implant 
Daily COC pills 
Emergency contraceptive pills 
 
 
 
0.3–287–9 
                AR: 58 
                ER: – 
                GR: 1–7.5 
                PR: 23–96 
                MR: – 
 
References: [1] Kirton and Cornette, 1974; [2] Virutamasen et al., 1996; [3] Fang et al., 2004; [4] Jain et al., 
2004; [5] Toh et al., 2004; [6] Halpern et al., 2014; [7] Sivin et al., 1997; [8] Licea-Perez et al., 2007; [9] Hidalgo 
et al., 2009; [10] Hapgood et al., 2014a. Symbols; [•] Relative binding affinities are relative to 100% for 
reference steroids for each steroid receptor, which were as follows: PR, P4; AR, dihydrotestosterone; GR, 
dexamethasone; MR, aldosterone and ER, E2.  
 
  
1.3 The female genital mucosa and HIV-1 infection 
 
HIV-1 transmission in women typically occurs at the mucosa of the FGT (reviewed by Hladik and 
McElrath, 2008; Roan and Jakobsen, 2016). Here, several mechanisms are protective against HIV-
1 infection (reviewed by Wira and Fahey, 2004; Wira et al., 2005; Reis Machado et al., 2014), as 
evidenced by the relatively low transmission rate per vaginal sex act (reported to be as low as 0.07–
0.08%) (Boily et al., 2009). To establish successful infection, HIV-1, which is present in male 
ejaculate, must withstand several innate and adaptive immune mechanisms in the FGT, traverse 
the genital epithelium, and establish infection in the underlying lamina propria in cluster of 
differentiation (CD)4+ target cells (Hladik and McElrath, 2008). 
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1.3.1 Mechanisms of innate immune protection in the female genital tract 
 
Continuously sloughed stratified squamous epithelium provides an effective barrier against HIV-
1 invasion in the lower reproductive tract (vagina and ectocervix) (Wira and Fahey, 2004). In 
contrast, tight junctions between single-layered columnar epithelial cells (ECs) in the upper 
reproductive tract (endocervix, endometrium and fallopian tubes) are a less robust means of 
mechanical protection (Wira and Fahey, 2004). Innate immune cells; ECs, macrophages, dendritic 
cells (DCs) and natural killer (NK) cells, recognise foreign pathogens through pattern recognition 
receptors (PRRs)–germ-line encoded sensors which recognize conserved pathogen-associated 
molecular patterns expressed by microorganisms (Akira et al., 2006). PRRs can be divided broadly 
into two groups; toll-like receptors (TLRs), which are expressed on cell surfaces, or found in 
endosomes (TLRs have recently been reviewed extensively by Vidya et al., 2018), and intracellular 
nucleic acid sensors found in the cytoplasm (reviewed by Sparrer and Gack, 2015). HIV-1 
components recognised by PRRs include its single stranded (ss)RNA genome and the reverse 
transcribed DNA intermediates produced early during infection (reviewed by Jakobsen et al., 
2015). Secondary structured HIV-derived RNAs are recognised by retinoic acid-inducible gene I 
(Solis et al., 2011), and HIV-1 DNA is recognised by cyclic guanosine monophosphate-adenosine 
monophosphate synthase (Gao et al., 2013).  
 
Innate immune cells secrete microbial compounds which contribute to preventing pathogenic 
infection. These include lysozyme, cytokines and chemokines (including interleukin (IL)-6, IL-8 
and macrophage inflammatory protein (MIP)-1b), as well as defensins (reviewed by Wira et al., 
2005). Defensins are antimicrobial peptides with broad anti-HIV-1 activity, achieved through 
blocking viral entry into cells, interfering with viral replication, direct viral inactivation and 
increasing the production of other antiviral factors (the role of defensins in HIV-1 pathogenesis 
has been reviewed by Pace et al., 2017). Pro-inflammatory cytokines and chemokines are chemo-
attractants for neutrophils, monocytes and T cells, which enhance inflammation and destroy 
invading pathogens through cytotoxic killing or phagocytosis (Wira et al., 2005). HIV-1 infection 
is profoundly influenced by the effects of cytokines and chemokines, which may inhibit HIV-1 
infection (as do interferon (IFN)-a (Shirazi and Pitha, 1992), IFN-b (Gessani et al., 1994), 
macrophage inflammatory protein (MIP)-1a and MIP-1b (Cocchi et al., 1995)), stimulate HIV-1 
infection (for example, macrophage colony-stimulating factor (Kalter et al., 1991) and IL-1 
(Osborn et al., 1989)) or have both inhibitory and stimulatory effects, which are dependent on 
their concentration, the presence of other cytokines and the point during infection at which they 
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are present (examples include IL-4 (Kazazi et al., 1992; Wang et al., 1998), IL-6 (Kazazi et al., 1992; 
Wang et al., 1998), IL-8 (Nagira et al., 1999; Lane et al., 2001), tumour necrosis factor (TNF)-a 
(Osborn et al., 1989; Lane et al., 1999) and IFN-g (Kornbluth et al., 1990; Roff et al. 2013)). Innate 
and adaptive immune responses in the FGT are under the control of P4 and E2, the production of 
which varies cyclically over the course of the menstrual cycle (reviewed by Wira et al., 2005). 
Protection therefore varies depending on the menstrual cycle; during the secretory phase of the 
cycle (when P4 levels are relatively high and E2 levels are relatively low), immune responses are 
dampened to support pregnancy and fertilization, increasing susceptibility to STIs, including HIV-
1 (reviewed by Wira et al., 2014). 
 
The main HIV-1 target cells are DCs, macrophages and T cells (Hladik and McElrath, 2008). HIV-
1 infection requires interaction with host CD4 receptors, which are expressed on the surface of 
the aforementioned cells (Wyatt and Sodroski, 1998). DCs are a primary HIV-1 target and 
contribute greatly to dissemination of the virus to submucosal cells and subsequently, associated 
lymph nodes (reviewed by Wu and KewalRamani, 2006). Based on experiments in cervical 
explants, DCs have been predicted to account for up to 90% of HIV-1 dissemination (Hu et al., 
2004). DCs are antigen-presenting cells, which constantly take up extracellular fluid, antigens and 
pathogens by micropinocytosis, endocytosis and phagocytosis respectively (the immunology of 
DCs is reviewed by Banchereau et al., 2000). C-type lectins, expressed on the surface of DCs, 
attach to HIV-1 envelope glycoprotein, and are the principle means of HIV-1 capture (Banchereau 
et al., 2000; Wu and KewalRamani, 2006). Infection of CD4+ T cells, which are the primary targets 
of HIV-1 infection, and account for up to 60% of immune cells in the FGT (Givan et al. 1997), 
occurs through an infectious synapse (Garcia et al., 2005), trans-infection through DC-derived 
exosomes (Wiley and Gummuluru, 2006) or by cis-infection with HIV-1 virions released following 
replication in DCs (Kawamura et al., 2003). Macrophages, like CD4+ T cells, are productively 
infected by HIV-1, and, due to their longer lifespan following infection, act as long-term reservoirs 
of HIV-1 infection (Sharova et al., 2005; Waki and Freed, 2010). Like DCs, macrophages 
disseminate HIV-1 to CD4+ T cells by cell-cell transmission through infectious synapses or by 
cis-infection (Waki and Freed, 2010).  
 
 
1.3.2 HIV-1 replication in target host cells 
 
 
An intricate, multistep process involving interaction of HIV envelope gp160 glycoproteins with 
host receptors facilitates the entry of HIV into its target cells (Wilen et al., 2010; Wyatt and 
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Sodroski, 1998). HIV gp160- initially synthesized as a polyprotein and subsequently proteolytically 
cleaved–is composed of gp120; an exterior envelope glycoprotein non-covalently bound to gp41, 
which spans the viral membrane (Wilen et al., 2010; Wyatt and Sodroski, 1998). HIV gp120 binds 
to the surface of cells via the CD4 receptor, whereas gp41 facilitates the fusion of viral and cellular 
membranes (Wilen et al., 2010; Wyatt and Sodroski, 1998). The binding of gp120 to the CD4 
receptor induces a conformational change which exposes the gp120 coreceptor binding site (Wilen 
et al., 2010; Wyatt and Sodroski, 1998). Subsequently, gp120 binds to its coreceptor; either the 
chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) (Wu et al., 
1996; Berger et al., 1999). Virus which preferentially utilizes CCR5 as its coreceptor is termed 
(CC)R5 tropic whereas virus which utilizes CXCR4 as its coreceptor is termed X4 tropic (or 
CXCR4 tropic) (Berger et al., 1998). The greater proportion (more than 95%) of transmitted HIV 
strains are R5 tropic (Margolis and Shattock, 2006). Binding of gp120 to its coreceptor triggers a 
conformational change in gp41, which exposes a hydrophobic fusion protein that facilitates fusion 
of viral and host membranes (Doms and Trono, 2000). HIV-1 gp120 and gp41 are recognised by 
the PRRs TLR10 (Henrick et al., 2019) and TLR2, respectively (Henrick et al., 2015). 
 
Subsequently, the viral core, containing the ssRNA genome is released into the host cytoplasm 
(Wilen et al., 2010). HIV-1 reverse transcriptase in translated (by free cytoplasmic ribosomes) as 
part of the Gag-Pol polyprotein, which consists of gag (structural capsid, nucleocapsid and matrix 
proteins) and pol (reverse transcriptase, integrase and protease) (Li et al., 1992). The ssRNA genome 
is reverse transcribed into dsDNA, translocated into the nucleus and integrated into the host 
chromosome in a process mediated by viral integrase (Craigie and Bushman, 2012). The integrated 
genome is transcribed into viral RNA, which is exported to the cytoplasm and translated 
(Sundquist and Kräusslich, 2012). The resulting products are assembled into virions at the plasma 
membrane (Sundquist and Kräusslich, 2012). Virions bud off from the cell surface, obtaining their 
lipid envelope, after which HIV-1 protease mediates maturation of the virions (Sundquist and 
Kräusslich, 2012). Matured virions are able to infect new host target cells (Sundquist and 
Kräusslich, 2012).  
 
1.3.3 HIV-1 disease progression 
 
Immediately following HIV-1 transmission, during the eclipse period of infection, HIV-1 
replicates in the mucosa, submucosa and associated lymph tissues close to the site of transmission, 
and is undetectable in the plasma (Cohen et al., 2011). Acute HIV-1 infection is the earliest 
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detectable phase of infection (Haase, 1999; Cohen et al., 2011). It is characterized by a surge in 
plasma viremia, as HIV-1 rapidly disseminates into, and replicates in gut-associated lymphoid 
tissue (Brenchley et al., 2004; Brenchley and Douek, 2008). The gut contains approximately 60% 
of the body’s T cells (Guy-Grand and Vassalli, 1993), and undergoes the greatest depletion of 
these cells through all stages of HIV-1 infection (Brenchley et al., 2004). Due to constant exposure 
to foreign antigens and proinflammatory cytokines, a large proportion of CD4+ T cells in the gut 
are activated, and express CCR5 (Unutmaz et al., 1994; Brenchley et al., 2004; Brenchley and 
Douek, 2008). Importantly, upon activation, T cells are generally destined to undergo activation-
induced cell death (reviewed by Green et al., 2003). Both uninfected and infected T cells die during 
HIV-1 infection; the latter undergo a programmed cell death associated with intense inflammation 
and cytoplasmic expulsion termed pyroptosis (Doitsh et al., 2014). Alternatively, activation of 
DNA-dependent protein kinase in response to viral integration (Cooper et al., 2013), or the 
expression of cytotoxic HIV-1 protease (Ventoso et al., 2005) induce death in infected T cells. 
Uninfected T cells, which account for the most T cell death (Finkel et al., 1995), die either as a 
result of activation-induced cell death, the cytopathic effects of HIV-1 proteins or the over 
expression of death-ligands (reviewed by Cummins and Badley, 2014). Immune responses 
mounted in the lamina propria of the gut in response to HIV-1 infection result in villous atrophy 
and enterocyte apoptosis (Batman et al., 1989), which, along with HIV-induced CD4+ T cell 
depletion and immunodeficiency, results in a loss of the structural and immunological integrity of 
the gut (Brenchley et al., 2004; Brenchley and Douek, 2008). With a loss in integrity, microbial 
translocation occurs; a process in which gut microbial products are exposed systemically, activate 
immune cells, and stimulate proinflammatory cytokine production (Brenchley et al., 2006).  
 
Acute HIV-1 infection is also characterized by a cytokine storm–a surge in cytokine and 
chemokine production by innate immune cells–which also promotes systemic immune activation 
and inflammation (Stacey et al., 2009). In an effort to restore the body’s CD4+ T cell balance, the 
immune system triggers the activation and proliferation of remaining CD4+ T cell pools, which, 
rather than replenishing CD4+ T cells, drives HIV-1 disease progression by increasing the number 
of viral targets (Douek et al., 2003). In addition to activation by HIV-1 antigens, HIV-1 proteins 
have also been shown to induce T cell activation (Abbas and Herbein, 2013). During the acute 
phase of infection a reservoir of latently infected CD4+ T cells is established (Chun et al., 1998), 
and an HIV-1 specific cellular immune response develops (Koup et al., 1994). Long-lived central 
memory CD4+ T cells are thought to be the most important reservoir for latent HIV-1 (Brenchley 
et al., 2004). Other cell types including ECs, fibrocytes and astrocytes have been suggested to 
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contribute to the latent reservoir, but it is uncertain whether this is the case in vivo (reviewed by 
Kandathil et al., 2016). 
 
Following the acute phase of infection, HIV-1 infection enters into an asymptomatic, chronic 
phase, which may last several years (reviewed by Ford et al., 2009). It is characterized by a 
progressive decline in the remaining CD4+ T cells, and chronic immune activation (Ford et al., 
2009). Due in part to HIV-1 specific immune responses, and the massive attrition of CD4+ T 
cells during the acute phase of infection, viral loads during this period may be up to a 1000-fold 
lower than during the acute phase of infection (reviewed by Haase, 1999; Douek et al., 2003; 
Boasso and Shearer, 2008). During this period, HIV-1 viral replication persists, albeit in a small 
number of activated CD4+ T cells and both CD4+ and CD8+ T cells are chronically activated 
(Haase, 1999; Brenchley et al., 2004). HIV-associated chronic immune activation is associated with 
transforming growth factor (TGF)-b production in secondary lymphoid tissues, which induces 
collagen deposition and fibrosis, eventually destroying these sites of T cell production (Schacker 
et al., 2002). Moreover, chronic immune activation directly inhibits the function of B cells NK 
cells, DCs and monocytes, impairing their ability to control viral replication, which compounds 
immune activation (reviewed by Muller-Trutwin and Hosmalin, 2005; Moir and Fauci, 2009). Over 
the course of HIV-1 infection, in approximately 50% of individuals, an HIV-1 phenotypic switch 
from R5 virus to X4 virus occurs (Berger et al., 1999; Regoes and Bonhoeffer, 2005; Mosier, 2009). 
The reasons behind this are unclear, but it has been proposed that R5 viruses have higher fitness 
for transmission, or that conditions in the host, for example the proportion of T cells expressing 
either coreceptor, change to favor X4 virus over the course of disease progression (Regoes and 
Bonhoeffer, 2005; Kamp, 2009; Mosier, 2009). Immunodeficiency, established during the acute 
phase of infection, supports the reactivation of latent infections, like the highly prevalent 
cytomegalovirus (CMV) or influenza, which further induce immune activation and inflammation 
(Doisne et al., 2004). Evidently, chronic immune activation and inflammation are central to the 
pathogenesis of HIV-1 infection, and drive a vicious cycle in which HIV-1 infection induces 
immune activation, inflammation and immune dysfunction, which in turn advance infection 
(Brenchley et al., 2004, Brenchley et al., 2006; Brenchley and Douek, 2008; Ford et al., 2009). 
 
Besides progressive immunodeficiency, HIV-1-induced chronic immune activation and 
inflammation are associated with other health complications (reviewed by Deeks, 2011). Notably, 
numerous studies have shown HIV-1 infection is associated with an increased risk of 
cardiovascular and hepatic disease (Currier et al., 2008; Smith et al., 2014). On reaching the liver, 
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microbial products released following the destruction of the gut may induce a cascade of immune 
cell activation, as well as the release of coagulation factors which increase the risk of blood clotting, 
and contribute to liver dysfunction, reduced protein synthesis and reduced microbial clearance 
(Deeks, 2011). In this way, microbial translocation increases the risk of liver fibrosis and 
cardiovascular disease (Deeks, 2011). HIV-1 infection is also associated with increased 
inflammation in arteries, concurrent with increased markers of macrophage activation (Burdo et 
al., 2011). Some inflammatory cytokines have been implicated in the development of coronary 
heart disease (Yudkin et al., 2000; Crowe et al., 2010). For example IL-6, which is elevated in 
individuals infected with HIV-1 (Funderburg et al., 2013), and is associated with atherosclerosis 
and coronary disease, reduces the expression of lipases which metabolize circulating triglycerides 
and increases the uptake of lipids by macrophages, (Yudkin et al., 2000). Moreover, systemic 
inflammation induces the secretion of chemoattractant cytokines in endothelial cells on the 
interior surface of blood vessels, which enhances migration of macrophages into blood vessels, 
and inhibits their emigration out of them (Westhorpe et al., 2009). Inflammation also promotes 
the expression of adhesion factors, in the endothelium and on macrophages and monocytes 
(Murphy et al., 2008). Atherosclerosis, which may lead to coronary disease, develops when 
activated macrophages and monocytes infiltrate the endothelium of blood vessel walls, where they 
adhere, phagocytize lipids and other toxins, and form foam cells, leading to the formation of 
atherosclerotic plaques (Crowe et al., 2010). When plaques are dislodged or rupture, the 
coagulation process is activated, and blood vessels are blocked, resulting in tissue damage 
(reviewed by Bentzon et al., 2014). 
 
1.3.4 Genital inflammation is a risk factor for HIV-1 acquisition 
 
Genital inflammation is associated with an increased risk of sexual HIV-1 acquisition (Passmore 
et al., 2016). Major causes of genital inflammation include changes to the vaginal microbiome and 
pre-existing STIs (which may be asymptomatic) (reviewed by Passmore et al., 2016). In the Centre 
for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial, which assessed the 
effectiveness of a 1% tenofovir (TFV) gel at preventing HIV-1 acquisition, the presence of genital 
inflammatory cytokines, including MIP-1α, MIP-1β, and IL-8, in cervicovaginal lavages from 
women who participated in the trial was shown to be associated with HIV-1 seroconversion 
(Masson et al., 2015). Masson et al. also showed that the presence of genital inflammation in HIV-
1 seroconvertors was associated with viruses of lower replicative fitness establishing productive 
HIV-1 infection (Masson et al. 2015). Subsequent post-hoc analysis of the levels of 
 12 
proinflammatory cytokines in cervicolavages from women involved in the CAPRISA 004 trial 
found, in women without genital inflammation, TFV was 57% protective against HIV-1, but was 
only 3% protective in women with significantly elevated levels of genital proinflammatory 
cytokines (Mckinnon et al., 2018). When systemic cytokine and immune mediators in women in 
the CAPRISA 004 trail were assessed, it was concluded that innate immune activation, through 
activation of cytokine and NK cell immune mediators, individually or in combination, was 
associated with HIV-1 acquisition (Naranbhai et al., 2012). Naranbhai et al. suggested addition of 
a suppressor of innate immunity to the TFV gel as a potential means of enhancing its effectiveness 
(Naranbhai et al., 2012). Early failed microbicide candidates cellulose sulfate and nonoxynol-9 
enhanced IL-1α and IL-8 expression and activated the NF-κB pathway, which was proposed to 
have caused inflammation in the FGT, as well as the interruption of tight junctions. All these  
mechanisms have been suggested to be involved in the enhancement of HIV-1 acquisition 
(Fichorova, 2004a, 2004b; Mesquita et al., 2009). 
 
1.3.5  Immune quiescence may be protective against HIV-I infection 
 
A phenotype of low immune activation systemically, and in the FGT, has been shown to be 
protective against HIV-1 infection (reviewed by Card et al., 2013). While HIV-1 can infect non-
activated T cells, viral replication is inefficient in these cells as a large number of host factors 
essential for HIV-I replication are expressed preferentially in activated T cells (Vatakis et al., 2010). 
Moreover, some T cell subsets are more prone to infection with HIV-1 than others–in the human 
FGT, Th17 cells have been reported to be most susceptible to HIV-1 infection (Rodriguez-Garcia 
et al., 2014). Similar findings have been reported in a macaque model of SIV infection (Stieh et al., 
2016). It may be that the proportion of Th17 cells at mucosal sites varies between individuals and 
predicts infectability, but this remains to be determined. Immune quiescence is implicated in 
protection in several highly HIV-1 exposed seronegative (HESN) cohorts, who demonstrate 
natural immunity to HIV-1 (Card et al., 2013). Microarray analysis of blood from HESN female 
sex workers in Nairobi found NK cell cytotoxicity and T cell receptor signalling pathways were 
more downregulated compared to HIV-1 negative controls, suggesting immune quiescence was a 
mechanism of protection in these individuals (Songok et al., 2012). Furthermore, in another cohort, 
T cells from HESN individuals were determined to express lower levels of immune activation 
markers, compared to another group of individuals who underwent seroconversion over the 
course of the study (Koning et al., 2005). Moreover, HESN individuals have higher proportions 
of regulatory T cells (Tregs) (Fowke et al., 2012), which are an immunosuppressive subpopulation 
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of T cells that suppress the proliferation and activation of effector T cells, as well as cytokine 
production (the immunobiology of Tregs has been reviewed by Kondelkova et al., 2010).  
 
1.4 Antiretroviral therapy 
 
Although a functional cure for HIV/AIDS is not available, the use of combination highly active 
antiretroviral therapy (HAART) has significantly extended the life expectancy of HIV-1 positive 
individuals by decades, when correctly adhered to (reviewed by Arts and Hazuda, 2012). HAART 
involves the use of three or more antiretroviral drugs (ARVs), which target two or more stages in 
the HIV-1 replication cycle, thus forestalling drug resistance (Arts and Hazuda, 2012). In Southern 
Africa, the preferred first-line ARV treatment regimens are tenofovir disoproxil fumarate (TDF) 
and emtricitabine (FTC), in combination with either efavirenz (EFV), dolutegravir or ripivirine 
(Meintjes et al., 2017). In South Africa and globally, 61% and 79%, respectively, of those aware of 
their HIV-1 positive status were on HAART in 2017 (UNAIDS, 2018).  
 
1.4.1 Pre-exposure prophylaxis 
 
Pre-exposure prophylaxis (PrEP) involves the use of ARVs to prevent HIV-1 acquisition in high- 
risk individuals (reviewed by Riddell et al., 2018). In 2012, PrEP consisting of a fixed dose 
combination of TDF and FTC was approved for use in individuals at high risk of HIV-1 infection 
(Riddell et al., 2018). The most clinically advanced and efficacious microbicides under development 
incorporate the ARVs TFV/TDF, dapivirine (DPV) and maraviroc (MVC), either alone or in 
combination (Thurman et al., 2013).  
 
1.4.2 Tenofovir disoproxil fumarate 
 
 TDF is a nucleotide analog reverse transcriptase inhibitor (NRTI), indicated for use in the 
prevention and treatment of HIV-1 infection (Gallant and Deresinski, 2003). It is also used to 
treat chronic hepatitis B virus infection and has antiviral activity against HIV-2 (a distinct lineage 
of HIV) (Gallant and Deresinski, 2003). TDF is a prodrug of TFV (Grim and Romanelli, 2003; 
Gallant and Deresinski, 2003), and given its relatively benign safety profile and high efficacy in 
both treatment-naïve and experienced patients, is the most commonly administered NRTI (Arts 
and Hazuda, 2012). TDF requires initial diester hydrolysis for conversion to TFV, which is then 
converted to its active form, tenofovir diphosphate (TFV-DP), through two consecutive 
phosphorylation steps (Balzarini et al., 1991). TFV-DP competes with intracellular deoxyadenosine 
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triphosphate for incorporation into the nascent complementary (c)DNA strand by HIV-1 reverse 
transcriptase. Seeing as TFV-DP lacks a 3’ hydroxyl group, its incorporation into the DNA strand 
results in the termination of further synthesis (De Clercq, 2007; Kelly and Shattock, 2011).  
 
TFV was the first ARV to demonstrate effectiveness and safety for use as a microbicide (Kelly 
and Shattock, 2011). The CAPRISA 004 trial was a two-arm, double-blind, randomized, placebo- 
controlled study that assessed the effectiveness of a 1% TFV vaginal gel in South African women 
and concluded the microbicide reduced the incidence of HIV-1 acquisition by an estimated 39% 
(54% in high adherers) (Abdool Karim et al., 2010). However, the Vaginal and Oral Interventions 
to Control the Epidemic (VOICE) and Follow-on African Consortium for Tenofovir Studies 
(FACTS) 001 confirmatory trials failed to demonstrate the effectiveness of the TFV gel at 
preventing HIV-1 infection, which was ascribed to low adherence by participants (Marrazzo et al., 
2015; Delany-Moretlwe et al., 2018). TDF and TFV, unlike many other ARVs, are not metabolised 
by the cytochrome P450 family of drug-metabolizing enzymes; TFV is excreted unchanged, renally 
(Kearney et al., 2004). TDF peak serum and cervical tissue concentrations and in vitro IC50 in 
peripheral blood mononuclear cells (PBMCs) are detailed in Table 1.2, and the chemical structure 
of TFV and TDF are shown in Fig. 1.2.  
 
1.4.3 Dapivirine  
 
DPV is a non-nucleoside reverse transcriptase inhibitor (NNRTI); a lipophilic compound which 
specifically inhibits the replication of HIV-1 (but not other retroviruses, including HIV-2) by 
binding to a specific allosteric site of HIV-1 reverse transcriptase ( Ding et al., 1995; De Clercq 
2004). Binding of NNRTIs to this allosteric site, which is thought to have a flexible structure that 
allows for effective DNA polymerization, prevents its mobility and therefore cDNA synthesis 
(Ding et al., 1995).  
 
The International Partnership for Microbicides (IPM) is evaluating the use of DPV as a 
microbicide in the form of a monthly intravaginal ring (IVR), a 90-day MPT IVR combining DPV 
and LNG, as well as a daily intravaginal gel (Baeton et al., 2016, 2018; Nel et al., 2018). A Study to 
Prevent Infection with a Ring for Extended Use (ASPIRE), was a randomized, double blind, 
placebo-controlled trial of a monthly DPV IVR in Sub-Saharan African women, that concluded 
that the IVR reduced the overall incidence of HIV infection by 27% (Baeten et al., 2016). ASPIRE 
found no adverse effects in women using the IVR; its safety was equivalent to that of the placebo 
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IVR utilized in the study (Baeten et al., 2016). A similar study, The Ring Study, found that HIV-1 
acquisition in users of a monthly DPV ring was 31% lower than in users of a placebo IVR (Nel et 
al., 2016). The results of ASPIRE and The Ring Study represent the first time two separate Phase 
III trials have shown a microbicide to be clinically efficacious. Interim results from the HIV Open 
Label Prevention Extension (HOPE) and Dapivirine Ring Access and Monitoring (DREAM) 
studies (open-label extension trials of ASPIRE and The Ring Study, respectively) demonstrated 
HIV-1 incidence at half of the expected rate in DPV IVR users (Baeton et al., 2018; Nel et al., 
2018). In vitro, DPV has been shown to be metabolised by several members of the cytochrome 
P450 family of enzymes (To et al., 2013). DPV peak serum and cervical tissue concentrations and 
in vitro IC50 in PBMCs are reported in Table 1.2, and DPVs chemical structure is shown in Fig. 
1.2. 
 
1.4.4 Maraviroc 
 
Maraviroc (MVC) is a potent, selective, reversible antagonist of the CCR5 chemokine receptor 
(Lieberman-Blum et al., 2008). Its antiretroviral effects arise from binding competitively to the 
CCR5 receptor, thereby preventing R5 tropic HIV-1gp120 from binding to its coreceptor. As a 
result, the conformational changes required for the activation of gp41 do not occur, the virus is 
unable to gain entry into the cell and productive infection is not initiated (Dorr et al., 2005). The 
IPM conducted a Phase I clinical study assessing the pharmacokinetics and pharmacodynamics of 
IVRs containing DPV only, MVC only or DPV and MVC in combination (Chen et al., 2015). It 
concluded that the levels of DPV, but not MVC in cervical tissue of IVR users were sufficient to 
prevent HIV-1 viral replication (Chen et al., 2015). Likewise, Fletcher et al. showed MVC (at 
concentrations up to 1 µM) had no significant anti-HIV-1 activity in ectocervical tissue (Fletcher 
et al., 2016). MVC is metabolized extensively by members of the cytochrome P450 family of drug-
metabolizing enzymes (Tseng et al., 2018). MVC peak serum concentrations and in vitro IC50 are 
reported in Table 1.2, and MVCs chemical structure is shown in Fig.1.2.  
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Table 1.2: TDF, DPV and MVC peak serum concentrations, cervical tissue concentrations and in 
vitro IC50 in PBMCs.  
 
ARV Mode of 
administration 
Peak serum 
concentration  
(nM) 
 
Cervical tissue 
concentration 
(µM) 
In vitro IC50¨ 
in PBMCs (nM) 
 
 
TDF 
365 mg TDF ring 
 
1.2–5.21  9–301  
 
 
5–103  
300 mg TDF/200 mg 
FTC oral PrEP 
(once daily) 
77–872 792 
300 mg TDF oral pills 
(HAART) 
(multiple daily doses) 
1100–11403 - 
DPV 25 mg DPV ring 0.7–0.894 2–215-7 2.48  
MVC 
 
300 mg oral 
(twice daily)• 
11709 - 1.210 
 
References: [1] Keller et al., 2016; [2] Hendrix et al., 2016; [3] Fung et al., 2002; [4] Chen et al., 2015; [5] 
Romano et al., 2009; [6] Nel et al., 2009; [7]; Nel et al., 2016; [8] Fletcher et al., 2009; [9] Abel et al., 2008; [10] 
Dorr et al., 2005. Symbols; [•] United States Food and Drug Administration general recommended dose in 
adults; [¨] IC50 is defined as the concentration of drug required to inhibit HIV-1 replication by 50%. 
 
 
 
 
Figure 1.2: Chemical structures of TFV, TDF, DPV and MVC. TDF requires initial diester hydrolysis 
for conversion to TFV, which is then is converted to its active form TFV-DP, through two consecutive 
phosphorylation steps. DPV binds to a specific allosteric site of HIV-1 reverse transcriptase, thus inhibiting 
its action, MVC is a reversible antagonist of the CCR5 chemokine receptor. Chemical structures were 
obtained from ChemSpider at http://www.chemspider.com. 
 
Tenofovir Tenofovir disoproxil fumarate
Dapivirine Maraviroc
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1.5 Immunomodulatory and adverse effects of ARVs 
 
For the development of successful PrEP strategies, it is necessary their immunomodulatory effects 
be characterised. TDF, DPV and MVC have been shown to have immunomodulatory effects, 
independent of their antiviral effects.  
 
I.5.1 TFV modulates cytokine production 
 
TFV appears to selectively modulate cytokine production in PBMCs (Melchjorsen et al., 2011). In 
monocytes, following stimulation with TLR ligands, tumor necrosis factor (TNF)-α or live 
pathogens, TFV decreases IL-8 and MIP-1α cytokine secretion (Melchjorsen et al., 2011). TFV 
similarly decreases MIP-1α protein levels, as well as anti-inflammatory IL-10 and increases 
proinflammatory IL-12 protein and mRNA expression levels in human PBMCS (Melchjorsen et 
al., 2011). Melchjorsen et al. also found no effect of TDF on NF-κB or mitogen activated protein 
kinase (MAPK) signaling (Melchjorsen et al., 2011). Another group showed human PBMCs 
exposed to TFV had significantly increased secretion of regulated upon activation, normal T cell 
expressed and secreted (RANTES) and MIP-1α, but not MIP-1b or IL-6 (Zidek et al., 2007).  
 
Hladik et al. showed a reduced glycerin rectal 1% TFV gel altered the expression of a broad range 
of genes in rectal biopsies, including innate immune function genes and genes involved in DNA 
damage repair (Hladik et al., 2015). In this study, approximately 500 and 100 genes were 
downregulated and upregulated, respectively. Notably, several transcription factors, including 
nuclear factor of activated T cells (NFAT) and cyclic AMP response element-binding protein 
(CREB)1 were amongst the genes downregulated (Hladik et al., 2015). In addition, application of 
the TFV gel induced proinflammatory chemokine C-C motif ligand (CCL)19 and CCL21 gene 
expression and suppressed anti-inflammatory IL-10 and TGF-b expression (Hladik et al., 2015). 
The authors postulated IL-10 suppression by the TFV gel may have been mediated by 
downregulating the expression of (CREB)1 and its coactivator CREB-binding protein (CBP) 
(Hladik et al., 2015). In another study, TFV was shown to increase proinflammatory IL-8 and 
TNF-α secretion in endometrial and ectocervical primary epithelial cells (Biswas et al., 2014). TNF-
a has been shown to disrupt tight junction proteins between intestinal and genital ECs in vitro, and 
in this way impair barrier function (Nazli et al., 2010). Similarly, in endometrial and cervical ECs 
and fibroblasts, TFV has been shown to compromise tight junctions, and inhibit wound closure 
in vitro (Rodriguez-Garcia et al., 2017). A possible link between TFV-induced decreases in mucosal 
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permeability, delayed wound healing and increased risk of HIV-1 infection deserves further 
investigation. The mechanism through which TFV modulates cytokine and chemokine production 
in the in vitro studies reported here remains undetermined. Whether these effects are mediated via 
the GR, which broadly regulates immunomodulatory function, including cytokine and chemokine 
production (see Section 1.6) has not been investigated directly. Moreover, whether TDF has 
similar immunomodulatory effects in vivo, and if so, the implications on HIV-1 susceptibility in 
women using the ARV prophylactically, has not been established.  
 
1.5.2  TDF use is associated with osteoporosis and bone fractures 
 
HIV-1 infected individuals have higher incidences of osteoporosis and bone fractures compared 
to the general population (Brown and Qaqish, 2006). Multiple factors, including the effect of 
inflammatory cytokines (Steeve et al., 2004), HIV-1 proteins (Fakruddin and Laurence, 2005), as 
well as HAART on bone are thought to be responsible (Brown et al., 2009). Although studies have 
shown a loss of BMD following HAART initiation, irrespective of regimen, TDF-containing 
regimens are associated with greater losses in BMD (Brown et al., 2009). Numerous clinical, animal 
and in vitro studies support the association of TDF use with decreases in BMD and increases in 
markers of bone turnover. A recent observational cohort study found TDF treatment, over a 
period of 5 years or more, significantly increased the risk of osteoporosis related bone fractures in 
young Japanese men (Komatsu et al., 2018). In human osteoblast primary cell cultures, TDF has 
been shown to dose-dependently decrease both mineralization, as well as the expression of 
collagen, the main component of bone matrix (Barbieri et al., 2018). In another study, microarray 
analysis of TDF-treated primary murine osteoblasts identified 79 transcripts with significantly 
altered expression profiles in TDF- vs. non-TDF-treated cultures (Grigsby et al., 2010). Notably, 
the expression of genes involved in cell signaling transduction pathways, amino acid metabolism 
and biosynthesis were downregulated, the effects of which are likely to be reductions in osteoblast 
growth and differentiation (Esposito et al., 2015). Significant changes in genes involved in the 
Wingless/Integrated (Wnt), TGF-b, Hedgehog and MAPK signaling pathways were identified 
(Grigsby et al., 2010). Whether the effects of TDF on bone are mediated by the GR and GCs, 
which regulate bone cell differentiation, development and function (see Section 1.6.8) has not 
been determined.  
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1.5.3 Immunomodulatory effects of DPV 
 
The limited studies performed with DPV, which has not currently been approved for clinical use, 
have shown some proinflammatory effects. In endometrial cancer cells, at relatively high 
concentrations (10 µM and 100 µM), DPV has been shown to induce proinflammatory IL-8 
secretion (Gali et al., 2010). Similarly, in VK2/E6E7, CaSki and Caco-2 cells 100 µM DPV has 
been shown to induce apparent increases in IL-6 and IL-8 secretion (des Neves et al., 2013). 
Conversely, another study by des Neves et al. found DPV-loaded nanoparticles did not increase 
IL-8, IL-6, MIP-3α, IL-1α or IL-1ß expression in a murine model (des Neves et al., 2014). Adverse 
systemic effects resulting from the use of DPV have not been reported; in the DPV IVR trials 
conducted to date, the adverse effects reported have mostly been as a result of IVR fitment and 
immunomodulatory effects have not been investigated (Nel et al., 2009, 2014). The few in vitro 
studies that have assessed the immunomodulatory effects of DPV have not determined the 
mechanism through which DPV induces cytokine and chemokine production in some cells. 
Whether DPV in some way alters GR activity has not been investigated. It is unclear whether DPV 
has similar immunomodulatory effects in vivo, and if so, the implications on HIV-1 susceptibility 
in women using the ARV prophylactically.  
 
1.5.4 Immunomodulatory effects of MVC 
 
MVC is currently the only approved ARV that targets a human protein (Lieberman-Blum et al., 
2008). Numerous CCR5 ligands in tandem stimulate T cell activation, the initiation of immune 
responses and migration of immune cells to sites of infection (reviewed by Lederman et al., 2006). 
CCR5 also promotes IL-2-dependent events, NFAT activation, lymphocyte recruitment and 
proliferation (Gaitan et al., 2010). Although the immunological effects of CCR5 inhibition are not 
well established, MVC has been demonstrated to induce proinflammatory gene expression in 
several studies. A recent study showed MVC-dependent NF-κB (but not AP-1 or NFAT) 
activation, and increases in the expression of NF-κB dependent proinflammatory gene expression 
(IL-6, IL-10 and TNF-α) both in resting CD4+ T cells from HIV-1 positive patients taking MVC, 
and in a CCR5 expressing cervical cell line (Madrid-Elena et al., 2018). The mechanism was 
determined to be dependent on MVC binding CCR5 and subsequent induction of downstream 
signalling pathways (Madrid-Elena et al., 2018). MVC induced NF-κB activation was associated 
with the reversal of HIV-1 latency in infected CD4+ T cells in the same study (Madrid-Elena et 
al., 2018). A recent randomized, placebo-controlled study in HIV-1 positive individuals found 
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MVC intensification caused increases in rectal and peripheral blood T cell activation, increases in 
MIP-1ß, as well as increases in neutrophil levels and monocyte activation (Hunt et al., 2018). In 
contrast, other studies have shown decreases in T cell activation upon initiation of HAART 
regimens with MVC (Wilkin et al., 2012). An in vitro study found MVC treatment tended to decrease 
expression of markers of immune activation in both CD4+ and CD8+ T cells, and dose-
dependently inhibited chemokine-induced T cell migration (Arberas et al., 2013). Whether MVCs 
immunomodulatory effects contribute to its failure to suppress HIV-1 infection in mucosal tissues 
when used as PrEP has not been determined. 
 
1.5.5 Interactions between antiretroviral drugs and progestins  
 
Most ARVs used in HAART or PrEP have limited effects on the contraceptive efficacy of HCs 
(reviewed extensively by Nanda et al., 2017). The NNRTI efavirenz (EFV) is an exception, and 
has been reported to reduce serum concentrations of both LNG and etonorgestrel (ETG, another 
progestin used in subdermal implants) (Nanda et al. 2017). In one study, HAART with EFV 
reduced ETG levels by up to 70% in women using the progestin subdermal implant, compared to 
HAART without EFV (Vieira et al., 2014). Similarly, in women using COCs with LNG, EFV 
alone, or in combination with other ARVs reduced progestin levels by approximately 60% 
(Sevinsky et al., 2011; Landolt et al., 2013). LNG levels were reduced by a similar extent in 
emergency contraceptive pill users after using EFV (Carten et al., 2012). The mechanism by which 
EFV reduces ETG and LNG serum concentrations is thought to be through EFV-induced 
expression of the enzyme cytochrome P450 3A in hepatocytes, which metabolizes these progestins 
(Hariparsad et al., 2004; Korhonen et al., 2005) Studies have shown HAART with EFV does not 
impact MPA serum concentrations or ovulation in the weeks following a 150 mg MPA injection 
(Cohn et al., 2007; Nanda et al., 2008). It should be noted however that changes in HC levels do 
not necessarily translate to reduced contraceptive efficacy; progestin serum concentrations vary 
greatly between individuals, suggesting prescribed doses are far above what is required for 
contraceptive efficacy (see Table 1.1) (Hapgood et al., 2018). The effects of progestins on EFV 
pharmacokinetics is less clear, although it appears progestins differentially influence EFV serum 
concentrations (Nanda et al. 2017). While one study has shown that compared to historical 
controls, COCs with the progestin desogestrel reduced EFV serum concentrations in HIV-1 
positive women (Landolt et al., 2014), other studies have shown no effect of COCs with the 
progestin norgestimate, or DMPA on EFV levels (Burger et al., 2006; Cohn et al., 2007; Sevinsky 
et al., 2011).  
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TDF-FTC oral PrEP does not affect the contraceptive efficacy of several HCs (Nanda et al., 2017). 
Co-administration of TDF and COCs with norgestimate, or implants with LNG has been shown 
to result in no significant drug-drug interactions, or effects on contraceptive efficacy (Kearney and 
Mathias, 2009; Todd et al., 2015) . Retrospective analysis of two TDF-FTC PrEP trials found TDF-
FTC PrEP had no effect on pregnancy rates among users of implants, COCs or MPA injectables 
(Murnane et al., 2014; Callahan et al., 2015). MVC has been shown not to alter COC LNG levels, 
or the pharmacokinetics of other ARVs (Abel, et al., 2008). Abel et al. also reported MPA use did 
not alter MVC serum levels in women (Abel, et al., 2008). When assessing factors such as CD4+ 
T cell counts, plasma HIV-1 viral loads and death, studies have found no effect of MPA 
injectables, LNG implants or COCs on the effectiveness of HAART with NNRTIs or protease 
inhibitors (Watts et al., 2008; Nanda et al., 2017). Furthermore, concurrent use of HAART and 
progestins does not appear to alter adverse side effects (Nanda et al., 2017). Both TDF and MPA 
use are associated with BMD loss. However, in women using TDF-FTC PrEP and MPA 
concurrently, no significant alterations in BMD were reported (Kasonde et al., 2014).  
 
 A study reported DMPA did not affect the efficacy of TDF-FTC PrEP in heterosexual Kenyan 
and Ugandan HIV-1 serodiscordant couples (Heffron et al., 2014). In contrast, one in vitro study 
reported MPA suppressed the protective effect of TFV on HIV-1 infection and lowered TFV-DP 
concentrations in blood CD4+ T cells, unlike LNG, P4 or another injectable HC, norethisterone 
(Shen et al., 2017). Shen et al. also showed MPA supressed tenofovir alafenamide (TAF, another 
prodrug of TFV) inhibition of HIV-1 infection and lowered TFV-DP concentrations in 
endometrial CD4+ T cells (Shen et al., 2017). A study assessing if pregnancy reduces TFV and 
TFV-DP concentrations in Ugandan and Kenyan women using TDF-FTC oral PrEP concluded 
TFV and TFV-DP serum concentrations were 45–58 % lower during pregnancy, although it was 
not clear if this undermined the effectiveness of PrEP in these women (Pyra et al., 2018). Other 
studies have reported higher TFV clearance during pregnancy, compared to periods women were 
not pregnant (Benaboud et al., 2012; Best et al., 2015). However, viremic suppression in these 
studies was found to be similar between pregnant and non-pregnant women using TFV 
(Benaboud et al., 2012; Best et al., 2015).  
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1.6 The glucocorticoid receptor  
 
The GR is a ubiquitous intracellular steroid receptor, and a member of the nuclear receptor 
superfamily (reviewed extensively by Lu et al., 2006). Nuclear steroid receptors share a similar 
structural organization comprised of a central highly conserved zinc-finger DNA-binding domain 
(DBD), a less conserved carboxy-terminal ligand-binding domain (LBD) and dissimilar amino-
terminal domains (NTD) (reviewed by Weikum et al., 2018). Like other steroid receptors, the GR 
is a ligand-activated transcription factor (Yudt and Cidlowski, 2016). Glucocorticoids (GCs) acting 
via the GR, regulate virtually all aspects of physiology, including stress responses, metabolism, 
immune function, growth, reproduction and homeostasis (reviewed by Baschant and 
Tuckermann, 2010). In response to physiological and psychological stressors, cortisol (CORT), an 
endogenous GC secreted from the adrenal cortex in response to adrenocorticotropic hormone 
(ACTH), is released (Padgett and Glaser, 2003; Schäcke et al. 2016). Through regulating cellular 
trafficking, proliferation, cytolytic activity, differentiation, effector function, cytokine and 
chemokine secretion and antibody production in leukocytes and lymphocytes, CORT exerts 
potent immunosuppressive and anti-inflammatory effects in the context of infection, increased 
immune activation or inflammation (Padgett and Glaser, 2003; Lu et al., 2006).  
 
1.6.1 GR mechanism of action  
 
A single gene, produces two GR isoforms; GRα, the predominant GR isoform and GRb, an 
alternative isoform present in the nucleus of some cells (Hollenberg et al., 1985). Unlike GRα, 
GRb is unable to bind to known GCs, and does not transcribe the majority of GC-responsive 
genes (de Castro et al., 1996). Although they modulate each other’s transcriptional activity on a 
few genes, GRb transcribes a mostly distinct array of genes from GRα (Kino et al., 2009). GRbis 
a dominant negative isoform, and therefore an inhibitor of GC action (Bamberger et al., 1995; 
Zhou and Cidlowski, 2005). Throughout this text, GR refers to GRα. 
 
Prior to ligand binding, the GR is typically localized in the cytoplasm as part of a multiprotein 
complex which includes heat shock proteins (Hsp)90, Hsp70, Hsp40 and Hsp23, immunophilins, 
phosphatases and Hsp90 co-chaperone p23, and is held in an inactive but receptive conformation 
(Ramamoorthy and Cidlowski, 2013). In the serum, CORT is predominantly bound to 
corticosteroid-binding globulin, the levels of which determine the proportion of serum free, 
bioavailable CORT (Gardill et al., 2012). Upon ligand binding, ligands induce ligand-specific 
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conformations both in the LBD, and other domains of the GR, which determine co-regulator 
association, as well as GR binding to its recognition elements (Gass et al., 1998, Ronacher et al., 
2009). Two modes of GR transcriptional regulation, termed transactivation and transrepression, 
are best characterized.  
 
1.6.2 Transactivation and transrepression  
 
Typically, the GR binds to glucocorticoid response elements (GREs) in the promoters of target 
genes as a dimer (Zhou and Cidlowski, 2005). GREs are palindromic nucleotide sequences, with 
a consensus sequence of GCTACAnnnTCTTCT (Nordeen et al., 1990). Variability in the sequence 
allows for variant GR/DNA binding, and consequently, varying gene-specific GR responses 
(Kumar et al., 1999). The GR is thought to act as a pioneering factor through recruiting chromatin 
remodelling complexes, and cofactors necessary for transcription initiation, in this way allowing 
access for basal transcription machinery to the promoters of GC-responsive genes (reviewed. By 
Burd and Archer, 2013). Through transactivation, the GR regulates anti-inflammatory genes (for 
example MAPK phosphatase-1 (MKP-1) (Lasa et al., 2002), inhibitor of kappa B alpha (IκB-α) and 
glucocorticoid induced lysine zipper (GILZ) (Deroo and Archer, 2001).  
 
Transrepression typically involves the GR tethering to pro-inflammatory transcription factors like 
NF-κB, AP-1 and NFAT, and downregulating the expression of pro-inflammatory genes, for 
example IL-6 and IL-8 (De Bosscher et al. 2000; Nissen and Yamamoto, 2000). This is achieved 
through the recruitment of chromatin remodelling complexes and co-repressors (Chinenov et al. 
2013). However, transrepression mechanisms involving direct DNA-binding of the GR to 
negative GREs have been described (Ramamoorthy and Cidlowski, 2013). Transrepression and 
transactivation are depicted in Fig. 1.3. 
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Figure 1.3: Genomic actions of glucocorticoids. Transactivation typically involves the GR binding to 
GREs in the promoters of target genes as a dimer, recruiting chromatin remodelling complexes and 
transcription machinery and activating transcription of anti-inflammatory and regulatory genes. 
Transrepression typically involves the GR tethering to pro-inflammatory transcription factors like NF-κB 
AP-1, and downregulating the expression of pro-inflammatory genes. Figure adapted from (Stahn and 
Buttgereit, 2008).  
 
In addition to the classical genomic actions described above, GCs have rapid non-genomic actions 
(Buttgereit and Scheffold, 2002; Stahn and Buttgereit, 2008). At high concentrations, GCs can 
intercalate into membranes, and affect their permeability (Buttgereit and Scheffold, 2002; Stahn 
and Buttgereit, 2008). In this way, GCs can decrease adenosine triphosphate (ATP) synthesis, as 
well as calcium and sodium shuttling across the membrane, which are essential for the actions of 
immune cells, including phagocytosis, cytokine and chemokine production, migration and antigen 
processing and presentation (Buttgereit and Scheffold, 2002; Stahn and Buttgereit, 2008). 
Members of the multiprotein complex to which the GR is bound, which are released upon ligand-
binding, for example steroid receptor co-activator (SRC) and MAPK1 are thought to mediate 
some of the rapid non-genomic effects of GCs (Croxtall et al., 2000; Buttgereit and Scheffold, 
2002). Membrane-bound GR has been identified in human PBMCs (Bartholome et al., 2004), and 
is thought to be involved in pro-apoptotic, immunomodulatory and metabolic effects which prime 
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the actions of the cytosolic GR (Vernocchi et al., 2013). Upon GCs binding to membrane-bound 
GR, signal transduction cascades are induced in the cell via the activation of kinases, including p38 
MAPK, which mediate GC rapid non-genomic effects (Strehl and Buttgereit, 2014). In addition, 
activation of signal transduction pathways may result in changes in gene expression (Strehl and 
Buttgereit, 2014). 
 
It should be noted that apart from control at the level of transcription initiation, mRNA 
posttranscriptional processing, mRNA trafficking from the nucleus to the cytoplasm and control 
at the level of translation contribute to the regulation of GR-mediated gene expression (Kumar. 
et al., 2014). Post-transcriptional regulation often involves alterations to the rate of mRNA decay, 
mediated through deadenylation-dependent pathways or endonucelases (reviewed by Garneau et 
al., 2007). mRNA decay has been shown to account for up to 50% of changes in mRNA levels in 
some responses (Garneau et al., 2007). In addition, alterations to mRNAs 5’ terminal cap or 3’ 
poly(A) tail allow RNA-binding proteins to repress or activate translation (Baker and Coller, 2009). 
Post-transcriptional regulation may also involve micro-RNAs, which inhibit translation initiation 
or elongation, as well as post translational modifications of ribosomes and translational apparatus 
(Baker and Coller, 2009). 
 
1.6.3 The chromatin landscape determines cell-specific GC responses  
 
Although the GR is ubiquitously expressed, it regulates gene expression in a cell-specific manner 
(Burd and Archer, 2013). It has become apparent the model of GR transactivation described above 
is insufficient, and does not encompass the diversity of genomic interactions and mechanisms 
which determine GR specificity (Burd and Archer, 2013). The majority of GR binding sites, in 
fact, occur far from classical promoter sequences (Hakim et al., 2009; Reddy et al., 2009). The GR 
is now understood to mediate its effects through interactions with distal enhancer elements, many 
kB from the promoters of target genes, through tethering and alternate recognition motifs (Hakim 
et al., 2009; Reddy et al., 2009). The genome is believed to be organized in a manner which allows 
linkage of these distal enhancer sites to genes by altering chromatin dynamics, DNA topology and 
specialized chromatin structures (Hager and Varticovski, 2012; Burd and Archer, 2013). Contrary 
to the views of the classical model, the GR has been shown to preferentially bind to 
deoxyribonuclease (DNAse) I hypersensitive sites, where chromatin exists in an accessible state 
(John et al., 2008). Therefore, variation in the distribution of DNAse I hypersensitive sites in 
chromatin further allows the programming of cell-specific GR responses (Burd and Archer, 2013).  
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1.6.4 Co-regulators modulate GR activity  
 
In excess of 400 co-regulators, which are intrinsically involved in the regulation of all aspects of 
physiology, have been described (Lonard and O’Malley, 2012). These are typically classified as 
either co-activators, which classically interact with ligand-bound receptor and assist in the 
activation of gene expression, or co-repressors, which typically bind to unliganded receptor to 
repress gene expression (Lonard and O’Malley, 2012). Co-activator and co-repressor function, 
which are gene-promoter dependent, can be altered through post-translational modifications, 
further fine-tuning transcriptional control (Chinenov et al., 2012; Lonard and O’Malley, 2012). GR 
interactions with the steroid receptor co-activator (SRC) family of transcription factors, SRC-1, 
SRC-2 (also known as GRIP-1) and SRC-3 are well characterized (Clarisse et al., 2017). These co-
activators participate in the formation of multiprotein complexes, which include chromatin 
remodelling enzymes (Lee and Stallcup, 2017), and are crucial for the recruitment of basal 
transcription machinery and the ordered, dynamic process of transcription initiation (Lonard and 
O’Malley, 2012). Co-activators which commonly interact with the GR in multiple cells types 
include SRC-1/2/3, peroxisome proliferator-activated receptor gamma co-activator 1-alpha, 
receptor-interacting protein 140 and DAX-1 (Clarisse et al., 2017). 
 
1.6.5 GR phosphorylation  
 
The GR is regulated through direct phosphorylation by serine/threonine kinases (reviewed 
extensively by Hapgood et al., 2016; Kino, 2018). Five serine (Ser) residues in the GR NTD–
Ser124, Ser203, Ser211, Ser226 and Ser404 have been identified as serine/threonine kinase targets 
for phosphorylation (Fig. 1.4) (Hapgood et al., 2016, Kino, 2018). Phosphorylation of the GR at 
Ser203 by cyclin dependent kinase (CDK) 1 and 5 has been shown to occur in the absence of 
ligand, and is associated with cytoplasmic (Blind and Garabedian, 2008) and perinuclear (Chen et 
al., 2008) retention of the GR. GR phosphorylation at Ser203 therefore restricts nuclear import, 
and subsequent GR recruitment to the promoters of target genes (Blind and Garabedian, 2008). 
Phosphorylation of the GR at Ser134 by Ak strain transforming (AKT)1 inhibits GR translocation 
to the nucleus and suppresses GC-induced gene expression (Piovan et al., 2013). 
 
Phosphorylation of the GR at Ser211, which occurs upon ligand binding, has been shown to be 
associated with GR recruitment to the promoter of target genes (Blind and Garabedian, 2008), 
and achieving a maximal GR transactivational response (Chen et al., 2008, Avenant et al., 2010a). 
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CDK5 (Kino et al., 2007) and c-Jun N-terminal kinase (JNK) (Itoh et al., 2002) have been shown 
to phosphorylate the GR at Ser211. Adenosine 5’ monophosphate-activated protein kinase 
(AMPK) activates the GR indirectly, through phosphorylating MAPK which in turn 
phosphorylates Ser211 (Nader et al., 2010). Ser226 on the GR is hyperphosphorylated in the 
presence of ligand by CDK5, and has been shown to modulate cofactor recruitment to DNA- 
bound GR (Kino et al., 2007). Phosphorylation of the GR at Ser226 has been shown to enhance 
nuclear export (Itoh et al., 2002) and is thus associated with blunting GR responses (Kino et al., 
2007). A Ser226 to alanine mutation is associated with increased GR transactivational responses 
(Avenant et al. 2010b). The GR is phosphorylated at Ser404 by glycogen synthase kinase (GSK)3b, 
which has been shown to alter cofactor recruitment to the GR and GC-dependent NF-κB 
transrepression, thus attenuating pro-inflammatory responses (Galliher-Beckley et al., 2008). 
 
 
Figure 1.4: The GR is phosphorylated at Ser124, Ser203, Ser211, Ser226 and Ser404 in the NTD by 
serine threonine kinases. Phosphorylation at these residues modulate GR transactivation, 
transrepression, co-regulator recruitment and nuclear translocation. NTD; amino-terminal domain, DBD; 
DNA binding region, HR; hinge region, LBD; ligand binding domain. Figure adapted from (Kino, 2018). 
 
 
1.6.6 GC-independent modulation of GR activity 
 
The GR can be activated in the absence of GCs, by a variety of factors, through cross-talk between 
signal transduction pathways (Hapgood et al., 2016). Gonadotropin releasing hormone (GnRH) 
has been shown to induce GR transactivation of a GRE-reporter gene in a mouse 
gonadotrope LβT2 cell line, through a mechanism involving GnRH receptor activation, and 
protein-kinase-C- and MAPK-dependent phosphorylation of the GR at a residue equivalent to 
Ser226 on the human GR (Kotitschke et al., 2009). TNF has been shown to activate the 
endogenous GR in the absence of GCs, and to repress IL-6 expression in the End/E6E7 human 
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endocervical cell line (Verhoog et al., 2011). Using ChIP, Verhoog et al. determined that TNF 
enhanced GR and GRIP-1 recruitment to the IL-6 promoter, as well as GR phosphorylation at 
Ser226, in the absence of GCs (Verhoog et al., 2011). Alternatively, non-GC ligands can modulate 
GR activity through synergism, which occurs when two factors, which individually induce a 
response, induce a response greater than the sum of their individual responses when in 
combination (Chou, 2006). For example, LPS and GCs have been shown to inhibit inflammation 
in macrophages by synergistically upregulating sphingosine kinase 1 expression, possibly mediated 
by their synergistic effect on GR recruitment to the promoters of genes (Vettorazzi et al., 2015). 
Additionally, the coactivation of the GR and the transcription factors NF-κB and AP-1 is known 
to enhance proinflammatory responses (reviewed by Busillo and Cidlowski, 2013).  
  
 The GR’s activity can also be primed/sensitized by growth factors, cytokines and b2-
adrenoreceptor agonists, which on their own do not activate the GR, but rather, increase 
transcriptional responses in the presence of GCs (Hapgood et al., 2016). ln cultured human airway 
smooth muscle cells, Hu et al. showed that the proinflammatory cytokine IL-13, in the absence of 
GC, did not induce transcription of a synthetic GRE-reporter gene, but in combination with GC, 
the reporter gene was transcribed to a greater extent than with GC alone (Hu et al., 2013). IL-13 
also potentiated GC-induced phosphorylation at Ser211 and GC-induced nuclear translocation 
(Hu et al., 2013). Moreover, IL-13, in the absence of GC, induced phosphorylation of the GR at 
Ser203 and Ser211, in a process mediated by extracellular signal regulated kinase (ERK)-1/2 and 
JNK, and allowed the unliganded GR to bind to the mediator complex subunit-14 co-activator 
(Hu et al., 2013). Long-acting b(2)-adrenoreceptor agonists (LABAs) have been shown to 
potentiate GC effects, and are used to enhance the clinical efficacy of GCs used therapeutically 
(reviewed by Newton and Giembycz, 2016). For example, the LABA salmeterol has been shown 
to increase GC-induced transactivation of the MKP-1 gene, and a GRE-reporter gene in primary 
macrophages, presumably through its enhancement of GC-induced nuclear translocation and 
DNA-binding (Haque et al., 2013). Another LABA, formoterol, and has been shown to enhance 
GR nuclear translocation in PBMCs, as well as TNF-induced IL-8 production, through a 
mechanism involving a decrease in total GR phosphorylation, which was associated with 
decreased activation of the kinases JNK and p38-MAPK, which are known to enhance nuclear 
export of the unliganded GR (Mercado et al., 2011). Moreover, salmeterol and formoterol have 
been shown to increase MKP-1 mRNA and protein expression in a manner involving the cAMP-
PKA pathway in primary airway smooth muscle cells, concomitant with increasing GR nuclear 
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translocation and DNA-binding, as well as increasing GC-induced IL-6 and IL-8 production 
(Manetsch et al., 2013).  
 
 On the other hand, some factors desensitize GR signaling, resulting in decreased responses to 
GC (Hapgood et al., 2016). GC-independent phosphorylation of the GR at Ser134, mediated by 
p38 MAPK, and induced by a diverse range of cellular stressors, has been shown to gene-
specifically desensitize response to GCs in U2OS cells (Galliher-Beckley et al., 2011). In these cells, 
phosphorylation of the GR at Ser134 altered GR and 14-3-3 protein binding to the promoters of 
genes on chromatin (Galliher-Beckley et al., 2011). Several cytokines have also been shown to 
desensitize GR signaling. For example IL-13, and the combination of IL-2 and IL-4, have been 
shown to reduce GC binding affinity to the GR, and ligand-bound GR nuclear translocation (Kam 
et al., 1993; Spahn et al., 1996). In A549 human epithelial cells, IL-1β has been shown to reduce 
the expression of some GC-induced genes, which was associated with IL-1β-induced reductions 
in cytoplasmic GR levels, the inhibition of GC-dependent GR nuclear translocation and 
phosphorylation of the unliganded GR at Ser203 and Ser211 (Escoll et al., 2015). Taken together, 
ligand-independent modulation of GR activity appears to involve several diverse mechanisms, 
including site-specific alterations in GR phosphorylation, altered nuclear translocation of the 
unliganded GR, altered GR and cofactor recruitment or binding to the promoters of genes, as well 
as the altered activity or levels of signaling proteins, including kinases and cofactors, in the GR 
pathway. 
 
1.6.7 Potency, efficacy and biocharacter of a ligand 
 
Transcriptional responses induced by ligand-bound receptor are defined using dose-response 
curves. The shape of this curve allows the efficacy, potency and biocharacter of the ligand to be 
determined (Hapgood et al., 2014a; Hapgood et al., 2018). Efficacy refers to the maximal response 
elicited by a ligand, and potency is defined as the concentration of ligand required to achieve half 
maximal response (EC50) (Hapgood et al., 2014a, Hapgood et al., 2018). The EC50 is dependent on 
the cell type, promoter and receptor concentrations and is variable between experiments 
(Robertson et al., 2013; Hapgood et al., 2014a). The efficacy is influenced by the affinity of the 
ligand for the receptor, receptor concentrations and the cell-specific relative concentrations of co-
regulators (Ronacher et al., 2009). Biocharacter is defined by the shape of the dose-response curve 
relative to a reference agonist, and a ligand may be an agonist (if it elicits the same maximal 
response as the endogenous ligand), partial agonist (if it elicits less than this maximal response) or 
antagonist (if it reduces the efficacy of an agonist) (Hapgood et al., 2014a; Hapgood et al., 2018). 
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1.6.8 Therapeutic use of glucocorticoids 
 
GCs are widely used clinically as systemic and topical therapies for reducing inflammation and 
immune activation associated with a broad range of conditions including rheumatoid arthritis, 
allergies, inflammatory bowel syndrome, asthma, septic shock, pneumonia, adrenal insufficiency 
and skin conditions like eczema and dermatitis (Schäcke et al., 2002). The majority of the 
therapeutic anti-inflammatory and immunosuppressive effects of GCs are mediated by 
transrepression (reviewed by Baschant and Tuckermann, 2010; Ramamoorthy and Cidlowski, 
2013). In addition, GCs have anti-proliferative effects, through inducing cell cycle arrest, and their 
inhibition of cytokine production and DNA synthesis (Guichard et al., 2015), as well as 
vasoconstrictive effects, mainly through inhibition of histamine and vasodilator synthesis (Yang 
and Zhang, 2004).  
 
When used in medication, CORT is known as hydrocortisone (Garrod, 1958). Hydrocortisone is 
amongst the least potent GCs used therapeutically, is administered topically, orally or by injection, 
has both GC and mineralocorticoid activity and has a short duration of action (Garrod, 1958; 
Fardet and Fève, 2014, Nicolaides et al., 2018). Reported endogenous and therapeutically 
administered CORT concentrations vary considerably; inconsistency in methods of 
administration, time post-administration at which serum concentrations are determined and 
experimental methodologies between studies are likely to account for many of the discrepancies 
between studies (see Table 1.3). Dexamethasone (DEX) is a long-acting potent synthetic GC with 
minimal mineralocorticoid activity that is administered orally, intravenously or by injection 
(Weijtens et al., 1998; Wenting-Van Wijk et al., 1999; Fardet and Fève, 2014). As with CORT, 
reported DEX serum concentrations (see Table 1.3) vary considerably. Prolonged exposure to 
GCs is associated with adverse local and systemic effects including central obesity, osteroporosis, 
hyperglycemia, diabetes, bone necrosis, delayed wound healing, and an increased risk to 
opportunistic infection as a result of prolonged immunosuppression (Liu et al., 2013; Shäcke et al., 
2002). The majority of GR metabolic and adverse effects are mediated by transactivation (Shäcke 
et al., 2002; Baschant and Tuckermann, 2010; Ramamoorthy and Cidlowski, 2013). 
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Table 1.3: CORT and DEX peak serum concentrations.  
 
Glucocorticoid 
 
 
Mode of 
administration 
Serum 
concentration 
(nM) 
Relative 
GR 
activity¨6 
Relative MR 
activity¨6 
 
CORT 
Basal total 496 ± 1321  
 
 
1 
 
 
 
1 
Basal free 36.9 ± 17.21 
Major stress total  811.4 ± 2681 
Major stress free 107.8 ± 561 
 
Hydrocortisone 
20 mg (oral) 179 ± 20•2 
50 mg (intravenous)  694 ± 112•2 
 
DEX 
3.75 mg (injection) 142.7 ± 48.43 
(11.2 – 530.0) 
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0 1 mg (oral) 11.7  ±5.94 
(0.8 – 25.7) 
7.5 mg (oral) 157+5  
(6.4 – 250.0) 
 
Serum concentrations are given as mean ± standard deviation unless otherwise indicated. Ranges are 
indicated in parentheses where available. References; [1] Christ-crain et al., 2015; [2] Jung et al., 2014; [3] 
Weijtens et al., 1997; [4] Asvold et al., 2012; [5] Weijtens et al., 1998; [6] Nicolaides et al., 2018. Symbols; [•] 
serum free concentration; [+] median; [¨] Relative binding affinities are relative to 100% for reference 
steroids for each steroid receptor; GR, hydrocortisone; MR, aldosterone. 
 
1.6.9 Mechanism of glucocorticoid-induced osteoporosis 
 
 GCs regulate bone cell replication, differentiation and function (reviewed by Canalis and Delany, 
2002). Long- term exposure to GCs, even at low physiological doses, is associated with increased 
risk of osteoporosis and bone fractures (Canalis and Delany, 2002; Lane, 2006). GC association 
with osteroporosis is thought to be through increased GC-induced expression of the cytokine 
receptor activator of NF-κB ligand (RANKL) and GC-induced repression of osteoprotegerin 
(OPG), which results in increased bone resorption (Canalis and Delany, 2002; Steeve et al., 2004; 
Lane, 2006). The maintenance of healthy bone is dependent on both bone resorption by 
osteoclasts and bone formation by osteoblasts; when osteoclast activity exceeds that of 
osteoblasts, bone resorption exceeds bone formation, and osteoporosis develops (Canalis and 
Delany, 2002; Steeve et al., 2004; Lane, 2006). Osteoclastogenesis is the complex multistage 
process which involves osteoclast commitment, differentiation and activation of immature 
osteoclasts (Canalis and Delany, 2002; Steeve et al., 2004; Lane, 2006). RANKL expression by 
osteoblasts induces osteoclastogenesis, and inhibits osteoclast apoptosis through binding to its 
receptor RANK, expressed in cells of the monocyte lineages which differentiate into osteoclasts, 
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as well as in mature osteoclasts (Steeve et al., 2004). OPG is a decoy receptor for RANKL, and 
through binding RANKL, is able to inhibit its actions via RANK and consequently, 
osteoclastogenesis (Steeve et al., 2004).  
 
1.7 Rationale, aims and hypotheses of the current study 
 
HAART allows HIV-1 infection to be managed as a chronic disease, rather than a fatal infection 
(Deeks et al., 2013), and HCs allow women control over their reproductive health, through timing 
of pregnancy and family planning (Sedgh et al. 2014). A large number of HIV-1 positive women 
therefore use HCs and HAART concurrently. The most commonly used progestin for HC in Sub-
Saharan Africa is MPA (UN 2015; Hapgood et al., 2018).  
 
Biomedical HIV-1 preventative interventions targeted at women are under development, in an 
effort to reduce disease burden amongst women, who are disproportionately affected by the HIV-
1 epidemic (Kelly and Shattock, 2011). These include MPTs, which are combination ARV-
progestin combination products for the simultaneous prevention of HIV-1 infection and 
unintended pregnancy (Friend et al., 2013; Doncel et al., 2016). TDF is widely used in HAART, as 
well as oral PrEP, and is a leading candidate for use in microbicides and MPTs (Arts and Hazuda, 
2012; Thurman et al., 2013; Riddell et al., 2018). DPV is an ARV developed for use in microbicides 
and MPTs, and so far it the only microbicide to demonstrate efficacy in two independent Phase 
III clinical trials (IPM, 2016). MVC is widely used in HAART, and was an early candidate for use 
in vaginal microbicides (Dorr et al., 2005; Lieberman-Blum et al., 2008; Chen et al., 2015; Fletcher 
et al., 2016). The progestin of choice in all MPTs under development is LNG (IPM, 2016).  
 
Genital inflammation is a risk factor for HIV-1 acquisition in women and has been linked to the 
failure of early microbicides, some of which in fact increased HIV-1 acquisition in users 
(Fichorova et al., 2004a, Naranbhai et al., 2012, McKinnon, 2017). Moreover, chronic immune 
activation and inflammation are central to the pathogenesis of HIV-1 infection, drive HIV-1 
disease progression, and may contribute to non-AIDS mortality (Ford, Puronen and Sereti, 2009; 
Cohen et al., 2011). Therefore, to fully understand the effects of ARVs on HIV-1 disease 
progression when used therapeutically and on risk factors for HIV-1 acquisition when used 
prophylactically, it is important that their immunomodulatory effects, and the mechanisms 
thereof, be characterized. MVC TDF and DPV have been shown to have immunomodulatory 
effects in vitro, but the mechanisms through which they occur have not been determined (Gali et 
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al., 2010; das Neves et al., 2013; Hladik et al., 2015; Madrid-Elena et al., 2018). It is conceivable 
some of the ARVs immunomodulatory effects are mediated via the GR; a ubiquitous ligand 
activated transcription factor which regulates all aspects of immune function (Baschant and 
Tuckermann, 2010; Yudt and Cidlowski, 2016).  
 
It is clear the use of ARVs and progestins is widespread, and set to increase, but few studies have 
assessed reciprocal modulation of their intracellular activity (Nanda et al., 2017). Those that have, 
have predominantly assessed ARVs effects on the pharmacodynamics, pharmacokinetics and 
contraceptive efficacy of progestins (Nanda et al., 2017). The few studies that have assessed the 
effects of MPA on the anti-HIV-1 efficacy of TDF are contradictory (Heffron et al., 2014; Shen et 
al., 2017). Strikingly, Shen et al. showed MPA reduced the anti-HIV-1 activity of TDF in CD4+ T 
cells in vitro (Shen et al., 2017). However, the mechanism through which this occurred was not 
determined. MPA use is associated with a significantly increased risk of HIV-1 acquisition, and its 
immunomodulatory effects via the GR, for which it is a partial agonist for transactivation, and a 
full agonist for transrepression, have been implicated as a contributing factor (Hapgood et al., 
2018). Shen et al. did not investigate whether MPA was acting via the GR in decreasing the anti-
HIV-1 efficacy of TDF (Shen et al., 2017). MPAs effects on the anti-HIV-1 efficacy of DPV have 
not been assessed. It is important the combined immunomodulatory effects of progestins and 
ARVs be investigated, to determine implications for HIV-1 susceptibility, off-target side effects 
and HIV-1 disease progression in individuals using ARVs and progestins concurrently. 
 
Given the pleiotropic effects of GCs, ARVs are likely to be in the presence of these steroids nearly 
continuously intracellularly. However, whether GCs, produced endogenously, or used 
therapeutically, alter the antiviral efficacy of TDF, DPV, or other ARVs, has not been explored. 
Whether ARVs alter GC action via the GR has also not been evaluated. Intriguingly, some of the 
adverse effects observed in patients using TDF are similar to those in individuals on long-term 
GC therapy, for example, decreases in BMD and osteoporosis (Brown and Qaqish, 2006). Given 
that GCs acting via the GR regulate bone cell differentiation, replication and function, it is 
tempting to speculate these may occur in part through TDF transcriptionally activating the GR, 
or modulating GC activity via the GR. Given the critical role of GCs in regulating immunity, 
investigating the combined immunomodulatory effects of ARVs and GCs informs how ARVs 
may influence HIV-1 susceptibility and HIV-1 disease progression. It also informs on the off-
target side effects which may be experienced in HIV-1 positive individuals using GCs 
therapeutically. Against this background, the current study evaluated the immunomodulatory 
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effects of DPV and TDF via the GR, a ubiquitous and critical regulator of immunity and 
inflammation, and virtually all other physiological processes (Baschant and Tuckermann, 2010).  
 
The central hypothesis of this study is that TDF and DPV have off-target effects via the 
GR, either by activating the GR directly, or modulating the activity of GCs via the GR, 
which may explain their immunomodulatory effects, and some adverse effects reported 
with prolonged use of the ARVs. These effects may be mediated by altering GR activity, 
expression levels, and/or GR phosphorylation. The ARVs may also modulate the GR 
activity of the progestin MPA which is a full agonist/partial agonist for the receptor. GCs 
and MPA may modulate the antiviral efficacy of DPV and TDF, possibly through their 
immunomodulatory effects via the GR. Conversely, progestins with no GR activity, like 
LNG, would not modulate ARV anti-HIV-1 efficacy. 
 
The aims of the current study are to: 
 
i. Determine if DPV and TDF have transcriptional activity via the GR. This will be 
investigated in the U2OS human osteosarcoma cell line exogenously expressing the GR 
using GRE-luciferase reporter assays. 
ii. Determine if DPV and TDF can modulate the transcriptional activity of GCs and 
progestins via the GR.. The ability of the ARVs, in the absence and presence of DEX, 
MPA and LNG, to modulate GRE-luciferase reporter gene transcription via the GR will 
be assessed in U2OS cells. 
iii. Determine if DPV and TDF have effects on GC- and progestin-induced 
endogenous GR-regulated mRNA expression. The effects of the ARVs on DEX-, 
CORT-, LNG- and MPA-induced gene expression will be investigated in U2OS cells. The 
mRNA expression of the select GR transactivated genes GILZ and IκB-ɑ will be assessed. 
iv. Determine the effects of DPV and TDF on GR protein levels and GR 
phosphorylation. The effects of the ARVs, in the presence and absence of DEX will be 
investigated in the U2OS cell line model. Total GR protein levels, and phosphorylation at 
Ser226 on the GR will be assessed by western blotting. 
v. Determine the effects of DPV and TDF on immunomodulatory gene expression, 
alone and in the presence of GC in peripheral blood mononuclear cells. The effects 
of the ARVs on DEX-induced mRNA expression will be investigated in PBMCs from 
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female donors. The mRNA expression of select GR-regulated anti-inflammatory genes 
GILZ and IκB-ɑ, and proinflammatory genes IL-6, IL-8 and IFN-γ will be assessed. 
vi. Determine the effects of GC and progestins on the HIV-1 inhibitory effects of DPV 
and TDF. The effects of DEX, MPA and LNG on the ARVs anti-HIV-1 efficacy will be 
investigated in PBMCs. 
 
Secondarily, the ability of MVC to activate the GR, and modulate the transcriptional activity of 
DEX, MPA and LNG will be assessed in COS-1 cells using luciferase promoter-reporter assays. 
The immunomodulatory effects of MVC in PBMCs, in the absence and presence of DEX will be 
compared to those of DPV and TDF.  
 
U2OS human osteosarcoma cells are steroid-deficient cells (Niforou et al., 2008), with a high 
transfection efficiency (Tang et al., 2005). As such, they are well suited to exploring the first five 
aims of this study, outlined above. The low level of steroid receptors in U2OS cells allows the 
effects of ARVs in the presence and near-absence of GR to be assessed. In addition, interpretation 
of any effects observed is not confounded by the presence of other steroid receptors. GILZ is 
strongly induced by GCs, and a critical mediator of the anti-inflammatory and immunosuppressive 
effects of GCs (Riccardi, 2010). Through inhibiting the action of AP-1 and NF-κB, it prevents the 
transcription of pro-inflammatory cytokines like IL-6 and IL-8, and in macrophages, GILZ 
prevents activation (Berrebi et al., 2003; Riccardi, 2010). IκB-α, like GILZ, is regulated by GR 
transactivation, and has been shown to be rapidly upregulated by GCs (Deroo and Archer, 2001). 
IκB-α has been shown to cause cytoplasmic retention of NF-κB by sequestering nuclear 
localization signals essential for nuclear import (Jacobs and Harrison, 1998), inducing export of 
NF-κB from the nucleus, inhibiting DNA binding by NF-κB, and inhibition of cAMP-dependent 
protein kinase, whose actions are necessary for NF-κB nuclear translocation (Ghosh et al., 1998).  
 
IL-6 and IL-8 are proinflammatory cytokines, regulated by GR transrepression (Baschant and 
Tuckermann, 2010; Ramamoorthy and Cidlowski, 2013). IL-8 is a potent chemoattractant of 
neutrophils to sites of inflammation (Bickel, 1993). Elevated IL-8 levels have been reported in the 
lymphoid tissue of HIV-1 positive, and AIDS patients (Lane et al., 2001). The role of IL-8 in HIV-
1 replication and disease progression is somewhat controversial, with several contradictory 
reports. For example, Capobianchi et al. reported no effect of IL-8 on HIV-1 replication in 
monocyte-derived macrophages (Capobianchi et al., 1998), while another study reported a slight 
inhibitory effect of IL-8 on HIV-1 replication in CD4+ T cells (Mackewicz et al., 1994). In contrast, 
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IL-8 has also been reported to increase gene expression from the HIV-1 long terminal repeat 
(Marechal et al., 1999), and to dose-dependently stimulate HIV-1 replication in macrophages and 
T cells in vitro (Lane et al., 2001). IL-6 is rapidly produced at sites of infection, and, as well as 
inducing differentiation of activated B cells into antibody producing cells, induces production of 
acute phase proteins in hepatocytes (reviewed by Tanaka et al., 2014). Acute phase proteins amplify 
local inflammation by enhancing the detection of pathogens, promoting leukocyte recruitment 
into blood circulation and increasing blood flow to sites of infection (Jain et al., 2011). However, 
IL-6 also has anti-inflammatory properties; endogenous IL-6 may dampen local and acute 
inflammatory responses by modulating proinflammatory (but not anti-inflammatory) cytokine 
levels (Xing et al., 1998). Elevated levels of pro-inflammatory cytokines, including IL-6 and IL-8 
have recently been shown to have undermined the effectiveness of a TFV microbicidal gel in 
preventing HIV-1 acquisition in women (Mckinnon et al., 2018). Furthermore, early failed 
microbicide candidates which increased HIV-1 infection also elevated IL-8 levels (Fichorova et al., 
2004a, 2004b; Naranbhai et al., 2012, McKinnon, 2017). IFN-γ has broad and varied 
immunoregulatory effects, including inducing lymphocyte activation, antigen presentation and 
pro-inflammatory antiviral responses (Roff et al. 2013). Although its ability to inhibit HIV-1 
replication in monocytes and macrophages (Kornbluth et al., 1990; Roff et al. 2013) may be 
protective against HIV-1 infection in vivo, it’s pro-inflammatory effects and effects on lymphocyte 
activation may be detrimental (Roff et al. 2013). As immune responses are influenced by sex, only 
PBMCs from female donors were used in this study (Klein and Flanagan, 2016). 
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CHAPTER 2 
 
MATERIALS AND METHODS 
___________________________________________________________________________ 
 
 
 
2.1 Ethics and biosafety 
 
This research formed part of a sub-study of HREC 210/2011, which was approved by the Human 
Research Ethics Committee at the University of Cape Town. Approval included the use of human 
blood from the Western Province Blood Transfusion Services. All procedures were sanctioned 
and carried out in accordance with established guidelines. This study adhered to the biosafety 
procedures established by the Health and Safety Committee of the Department of Molecular and 
Cell Biology at the University of Cape Town.  
 
2.2 Test compounds  
 
The ARVs 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile (dapivirine, DPV) and 
9-[(R)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate 
(tenofovir disoproxil fumarate, TDF) were purchased from Selleck Chemicals (USA). 4,4-
Difluoro-N-[(1R)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-azabicyclo[3.2.1]octan-
8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide (maraviroc, MVC) was obtained from the NIH 
AIDS Reagent Program (USA). DPV, TDF and MVC were dissolved in dimethyl sulfoxide 
(DMSO) from Sigma-Aldrich (South Africa), to a stock concentration of 10 mM, which was 
further serially diluted. The steroids (11b,16a)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-
diene-3,20-dione (dexamethasone, DEX), (11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione 
hydrocortisone (cortisol, CORT), 6α-methyl-17α-hydroxy-progesterone acetate 
(medroxyprogesterone acetate, MPA) and 13β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one 
(levonorgestrel, LNG) were obtained from Sigma-Aldrich (South Africa), and were prepared in 
absolute ethanol (EtOH). ARVs and steroids were added to cells such that all incubations 
contained 0.1% (v/v) DMSO or EtOH respectively. Where cells were treated with combinations 
of steroids and ARVs, all incubations contained 0.1% (v/v) DMSO and 0.1% (v/v) EtOH. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was procured from Sigma Aldrich 
(South Africa). 
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2.3 Cell culture 
 
U2OS human osteosarcoma cells and COS-1 African green monkey kidney fibroblast-like cells 
were purchased from America Type Culture Collection (USA). Cells were cultured in 75 cm2 flasks 
(Greiner Bio-One International, Austria) in Dulbecco’s modified Eagle’s medium (DMEM) 
(Sigma-Aldrich, South Africa) supplemented with 1 mM sodium pyruvate (Sigma-Aldrich, South 
Africa), 44 mM sodium bicarbonate (Sigma-Aldrich, South Africa), 10% (v/v) foetal bovine serum 
(FBS) (Thermo Scientific, South Africa), 100 U/mL penicillin and 100 mg/mL streptomycin 
(Gibco, Invitrogen, UK), from hereon referred to as full DMEM. In all experiments, cells were 
cultured in a water jacketed incubator at 37°C, 90% humidity and 5% CO2. To sub-culture, cells 
were washed with warm 1 ´ phosphate-buffered saline (PBS, Sigma Aldrich, South Africa) and 
incubated at 37°C with 2 mL 0.25% trypsin/0.1% EDTA in PBS (Highveld Biological, South 
Africa) for 3 min. Trypsin was neutralized by the addition of full DMEM. Cells were routinely 
checked for mycoplasma contamination by Hoescht staining and fluorescence microscopy 
(Freshney, 2010), with only mycoplasma-negative cells utilized in experiments. Average and 
maximum passage numbers were approximately 30 and 40, respectively, for COS-1 cells, and 50 
and 65, respectively, for U2OS cells. For all experiments performed in this study using cell lines, 
independent biological repeats were performed on different days, using cells which had been 
passaged at least once since their previous use. 
 
2.4 Plasmids, plasmid transformation and purification  
 
The empty vector, pcDNA3.1, containing a cytomegalovirus promoter and lacking further 
downstream DNA sequence, was obtained from Invitrogen (UK). The glucocorticoid expression 
vector pcDNA3-hGR, comprising full-length human GRα cloned into the pcDNA3 vector, was 
a gift from D. W. Ray (University of Manchester, UK) (Ray et al., 1999). The luciferase reporter 
plasmid, pTAT-GRE-E1b-LUC, containing two GREs from the rat tyrosine amino transferase 
gene (TAT), regulated by the E1b promoter was a gift from G. Jenster (Erasmus University of 
Rotterdam, Netherlands) (Sui et al., 1999). 
 
Plasmids were transformed into Escherichia coli DH5α cells using heat shock as previously described 
(Sambrook and Russell, 2006). Briefly, competent DH5α cells (100 µL) were incubated on ice for 
30 min with 10 ng plasmid DNA. Thereafter, cells were incubated at 42°C for 2 min and 
immediately placed on ice for 2 min. Following this, 900 µL Luria broth (LB, 1% (w/v) tryptone, 
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0.5% (w/v) yeast extract, 0.5% (w/v) NaCl) was added, and the mixture incubated on an orbital 
shaker at 37°C for 1 hour. Transformed cells were then plated onto LB-agar plates (1% (w/v) 
tryptone, 0.5% yeast extract, 1% NaCl, 1.5% agar) containing 100 µg/mL ampicillin (Sigma 
Aldrich, South Africa) and incubated overnight at 37°C. To confirm selection of transformed cells, 
cultures were also plated onto LB-agar plates not containing ampicillin. Day cultures of 5 mL LB 
containing 100 µg/mL ampicillin were inoculated with single colonies and incubated at 37°C for 
8 hours with shaking. Overnight cultures of 200 mL LB containing 100 µg/mL ampicillin 
inoculated with 200 µL day culture cell suspension were incubated at 37°C on an orbital shaker 
for 16 hours. The NucleoBondâ Xtra Maxi plasmid DNA purification kit (Macherey-Nagel) was 
used for plasmid purification according to manufacturer’s instructions. The purity and yield of the 
extracted plasmids were evaluated using a Nanodrop ND-1000 spectrophotometer (NanoDrop 
Technologies). Samples were electrophoresed on a 1 ´  Tris-Acetate-EDTA (TAE) 1% agarose gel 
containing 10 µg/mL ethidium bromide (Sigma Aldrich, South Africa) at 100 V for 1 hour to 
assess plasmid integrity, conformation, and RNA contamination. Samples were visualized under 
ultraviolet light using a Syngene G:Box (Vacutec, UK) and images acquired using GeneSnap 
version 7.08 (SynGene, UK). 
 
2.5 Restriction enzyme digests 
 
Plasmid identity and integrity was confirmed by restriction enzyme digest. Identity was confirmed 
by assessing restriction enzyme banding patterns. Each restriction enzyme digest mixture 
comprised 300 ng of DNA, 1 U/mL of the restriction enzyme (or an equivalent volume of 
nuclease free water (Thermo Scientific, USA) for undigested controls), 1 ´ Fast Digest buffer 
(Fermentas, Thermo Scientific, USA) and nuclease free water to a final volume of 20 µL. The 
reaction mixture was incubated for 10 min at 37ᵒC. The resulting digests were electrophoresed on 
a 1 ´  TAE 0.8% agarose gel containing 10 µg/mL ethidium bromide (Sigma Aldrich, South Africa) 
at 100 V for 1 hour. Samples were visualized under ultraviolet light using a Syngene G:Box 
(Vacutec, UK) and images acquired using GeneSnap version 7.08 (SynGene, UK). 
 
2.6 Plasmid transfection  
 
For promoter-reporter assays, 1.5 ´ 106 U2OS cells were seeded into 10 cm dishes (Greiner Bio-
One International, Austria) in full DMEM. After a 24-hour incubation, to ensure consistent 
transfection efficiency cells were transiently bulk-transfected with 10 µg pcDNA3-hGR or the 
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empty vector pcDNA3.1 as a negative control and 3.75 µg pTAT-GRE-E1b-LUC using X-
tremeGENE 9 (Roche, South Africa) according to the manufacturer’s instructions. The use of 
lower concentrations (2.5 µg and 5 µg) of GR expression vector was initially tested, but GR-
mediated responses in these experiments were not robust (data not shown). Where endogenous 
GR-regulated mRNA expression was determined, cells were transfected as above, with the 
exclusion of pTAT-GRE-E1b-LUC.  
 
2.7 Luciferase reporter assays  
 
U2OS cells were transiently bulk-transfected with the GR expression vector pcDNA3-hGR and 
luciferase reporter pTAT-GRE-E1b-LUC as specified above. After 24 hours, cells were 
trypsinized and seeded into 96-well plates (Greiner Bio-One International, Austria) at a density of 
1 ´ 104 cells per well in 200 µL full DMEM. Following a 24-hour incubation, cells were washed 
with warm 1 ´ PBS. To evaluate the activity of DPV and TDF via the GR, cells were stimulated 
with DPV and TDF at concentrations ranging from 0.01 nM – 10 µM, in the absence or presence 
of 100 nM DEX in serum free DMEM (DMEM supplemented as indicated elsewhere in this 
chapter, with the exclusion of FBS) for 24 hours. To evaluate the capacity of DPV and TDF to 
modulate steroid activity via the GR, cells were treated with DEX, MPA or LNG at the 
concentrations indicated in figures, in the presence or absence of 1 µM DPV or TDF for 24 hours. 
Thereafter, cells were washed with ice cold 1 ´ PBS and harvested in 25µL 1 ´ luciferase reporter 
lysis buffer by shaking on a rotating shaker following a freeze-thaw step at -21ᵒC. Luciferase 
activity was assessed using the Luciferase Assay System (Promega, USA). Relative light units 
(RLU) in 10 µL cell lysate upon the addition of 50 µL luciferin substrate in white 96-well plates 
(Greiner Bio-One International, Austria) were determined using a Modulus microplate 
luminometer (Turner Biosystems, USA). Luciferase activity was normalized to protein content per 
well, as determined by a Bradford assay (Bradford, 1976). To evaluate the activity of MVC via the 
GR, the same procedures outlined above were performed using COS-1 African green monkey 
kidney fibroblast-like cells, purchased from America Type Culture Collection (USA). The number 
of experimental repeats is indicated in figure legends throughout this text. ` 
 
2.8 PBMC isolation and culture  
 
Whole blood from healthy female donors was obtained from the Western Province Blood 
Transfusion Services (Cape Town, South Africa). Donors tested negative for HIV-1, syphilis and 
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hepatitis B and C. PBMCs were isolated by Histopaque (H1077 Hybri-Max, Sigma-Aldrich, South 
Africa) density centrifugation using Leucosep tubes (Greiner Bio-One International, Austria). At 
room temperature, 15 mL Histopaque was centrifuged in Leucosep tubes at 400 ´ g for 1 min 
using a Heraeus Megafuge 40 centrifuge (Thermo Scientific, South Africa). Whole blood was 
diluted in unsupplemented Roswell Park Memorial Institute (RPMI) 1640 (Lonza, Switzerland) 
and PBS at a ratio of 2:1:1 in 50 mL tubes, following which it was transferred to the Leucosep 
tubes and centrifuged at 400 ´ g for 15 min without brakes. The white buffy coat containing 
separated PBMCs was collected and washed twice with 1 ´ PBS supplemented with 1% (v/v) 
charcoal stripped (cs)-FBS by centrifugation at 250 ´ g for 5 min. Cell number and viability was 
determined by trypan blue staining, where PBMCs were added to trypan blue solution (Lonza, 
Switzerland) at a ratio of 1:10. PBMCs were then added to a freezing media comprised of 20% 
DMSO (v/v) in cs-FBS and stored at -80°C until required.  
 
PBMCs were cultured in RPMI 1640 media (Lonza, Switzerland), supplemented with 10% (v/v) 
cs-FBS (Thermo Scientific, South Africa), 2mM L-glutamine (Sigma-Aldrich, South Africa), 100 
U/mL penicillin and 100 mg/mL streptomycin. (Gibco Invitrogen, UK) and 30 U/mL IL-2 
(Gentaur, Belgium) (from here on termed full RPMI), at 37°C. For experiments, frozen PBMC 
stocks were thawed and seeded into sterile 50 mL V-bottomed tubes (Greiner Bio-One 
International, Austria), at a concentration of 1 million cells/mL in 45 mL full RPMI. Cells were 
incubated overnight, following which PBMCs were pelleted and washed twice by centrifugation 
at 250 ´ g in 1 ´ PBS supplemented with 1% (v/v) cs-FBS. Cells were seeded into 5 mL Falcon 
tubes (Becton Dickson Scientific, South Africa) at a density of 2 million cells in 2 mL full RPMI. 
Subsequently, PBMCs were stimulated with ARVs and steroids for 48 hours as indicated in figure 
legends. Thereafter, PBMCs were pelleted by centrifugation at 250 ´ g for 5 min and harvested in 
400 µL TriReagent® (Sigma-Aldrich, South Africa) for RNA isolation. To ensure oxygenation of 
PBMC media, the lids of falcon tubes were left partially unscrewed. 
 
2.9 Viral propagation  
 
HEK293T human embryonic kidney cells (America Type Culture Collection, USA) were seeded 
into 10 cm plates at a density of 4 ´ 106 in full DMEM and incubated overnight at 37°C, 90% 
humidity and 5% CO2. Subsequently media was replaced and cells were transfected with 12 µg 
HIV-1BaL-Renilla or a control (DMEM) using X-tremeGENE 9 DNA transfection reagent in 
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accordance with the manufacturer’s instructions. HIV-1BaL-Renilla is an infectious, replication-
competent molecular clone created by insertion of a luciferase gene next to env in the HIV-1 NL4-
3 backbone, NL-LucR.T2A-BaL.ecto, and was a gift from Dr. Christina Ochsenbauer (Edmonds 
et al., 2010). Following a 48-hour incubation, the media was harvested and passed through a 0.22 
µm filter. cs-FBS was added to the filtered media to a final concentration of 12.5%. This was then 
aliquoted into 2 mL cryovial tubes (Nunc, Germany), and stored at -80°C until required. Viral 
titres were determined using the TZM-bl assay as described in (Edmonds et al., 2010). After a 72- 
hour incubation, cells were harvested in 120 µL Bright-Glo luciferase lysis buffer (Promega, USA) 
and transferred to white 96-well plates (Greiner Bio-One International, Austria) and luminescence 
was determined on a luminometer (Modulus Microplate, Promega, USA). The titre of the virus 
stock was determined using the Reed-Muench method and expressed as log infectious units 
(IU)/mL (Reed and Muench, 1938). 
 
2.10 PBMC infection assays  
 
PBMCs were prescreened for infectability, owing to the high inter-donor variability in HIV-1 
infection observed in the laboratory of the present author, following which they were stored at -
80 degrees. Thereafter, infectible PBMCs were thawed and seeded into sterile 50 mL V-bottomed 
tubes (Greiner Bio-One International, Austria), at a concentration of 1 million cells/mL in 45 mL 
full RPMI. Cells were incubated overnight and subsequently, 2 million cells were seeded into 5 
mL Falcon tubes (Becton Dickson Scientific, South Africa) and stimulated with ARVs and steroids 
for 48 hours as indicated in figure legends. Following this, PBMCs were infected with 10 IU/mL 
HIV-1BaL-Renilla or an equivalent volume of no virus control, in the presence of the ARVs and 
steroids (multiplicity of infection= 5 ´ 10-6) and incubated for 2 hours. No dose-response 
experiments for infection with HIV-1BaL-Renilla were performed. PBMCs were then pelleted by 
centrifugation at 800 ´ g for 5 min and washed 3 times in 1 ´ PBS supplemented with 1% cs-FBS. 
After the addition of 2 mL full RPMI, cells were incubated for 5 days, with no additional change 
in media. Following this, PBMCs were transferred into two 96-well U-bottom plates (Greiner Bio-
One International, Austria) in quadruplicate, at a density of 2 ´ 105 cells per well. Into one plate, 
20 uL filter sterilized MTT solution (5 mg/mL MTT in PBS) was added, to a final concentration 
of 0.5 mg/mL and incubated for 2 hours. Cells were pelleted by centrifugation at 250 ´ g for 5 
min and resuspended in 70 µL solubilizing solution (0.1 N HCl in isopropanol) per well, 50 µL of 
which was transferred into a new 96-well plate. Cell viability was determined by measuring 
absorbance at 595 nm on a spectrophotometer (Thermo Scientific, USA). Cells in the second plate 
 43 
were pelleted by centrifugation at 250 ´ g, and were harvested to determine infection, represented 
by Renilla luciferase expression using Renilla luciferin according to the manufacturer’s 
specifications (Promega, USA). Briefly, PBMCs were resuspended in 70 µL/well 1 ´ reporter lysis 
buffer with Renilla luciferin after incubation for 10 min in the dark at room temperature. Lysed 
cells were transferred into a white 96-well plate (Greiner Bio-One International, Austria) and 
luminescence in RLU was measured on a luminometer (Modulus Microplate, Promega, USA). 
Infection was calculated by dividing the RLU obtained for each sample by the average MTT 
absorbance value for that sample group. Relative infection was then calculated by setting vehicle 
control (EtOH + 0.1% (v/v) DMSO) to 100% infection. 
 
2.11 Western blotting and antibodies  
 
For positive controls, COS-1 cells were seeded into 12-well plates (Greiner Bio-One International, 
Austria) at a density of 1 ´ 105 cells per well and incubated for 24 hours. Thereafter, cells were 
transiently transfected with 1 µg/well of the GR expression vectors using X-tremeGENE 9 and 
incubated for 24 hours. Cells were then washed in ice-cold 1´ PBS, lysed with 50 µL 2 ´ SDS 
sample buffer (5 ´ SDS sample buffer: 100 mM Tris pH 6.8, 5% v/v SDS, 20% v/v glycerol, 5% 
v/v β-mercaptoethanol, 0.1% w/v bromophenol blue), then boiled at 100°C for 10 min and stored 
at -20°C until use. For experiments, following transfection of U2OS cells with the GR expression 
vector as described in Section 2.6, cells were trypsinized and seeded into 12-well plates (Greiner 
Bio-One International, Austria) at a density of 1 ´ 105 cells per well. Cells were stimulated as 
indicated in figure legends for 24 hours, after which they were washed in ice cold 1 ´ PBS, lysed 
with 50 µL 2 ´ SDS sample, boiled at 100°C for 10 min and stored at -20°C until use. Equal 
volumes of lysate were loaded on a 10% SDS-polyacrylamide gel. Samples were separated by 
electrophoresis at 75 V for 25 min then 150 V for 1 hour in 1 ´ running buffer (25 mM TRIS-
HCl, 250 mM glycine and 0.1% (v/v) SDS pH 8.4) using a Bio-Rad Mini Protean II electrophoresis 
system (Bio-Rad, South Africa). Subsequently, sample was transferred onto a Hybond-ECL 
nitrocellulose membrane (Amersham, South Africa) for 1 hour at 0.18 A in ice cold 1 ´ transfer 
buffer (25 mM TRIS, 200 mM glycine, 20% (v/v) methanol). Subsequently, nitrocellulose 
membranes were blocked in 4% (w/v) ECL blocking reagent powder in 1 ´ TRIS-buffered saline 
(50 mM TRIS, 150 mM NaCl, pH 7.6; TBS) containing 0.1% (v/v) Tween (TBS-Tween; TBST) 
for 1 hour. Nitrocellulose membranes were then incubated in 10 mL of 4% ECL-TBST containing 
primary antibodies and shaken gently overnight at 4°C. Primary and secondary antibodies are 
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detailed in Table 2.1 below. Following this, membranes were washed 2 times in 1 ´ TBST for 5 
min and once for 10 minutes. Membranes were then incubated at room temperature with 
secondary antibodies diluted in 5% (w/v) skim milk powder in 1 ´ TBST, on a rotating shaker for 
1 hour. After three washes in 1 ´ TBST as above, membranes were placed in 1 ´ TBS followed 
by a 1 min incubation with Pierce ECL-chemiluminescent western blotting substrate (Thermo 
Scientific, USA). Proteins were visualized by autoradiography using Amersham Hyperfilm™ MP 
high performance autoradiography film (AEC-Amersham, South Africa). Densitometric 
quantification of film was carried out using ImageJ software (NIH, USA). 
 
Table 2.1: Primary and secondary antibodies used for Western blotting 
 
Primary Antibody Detected Size 
(kDa) 
Primary Antibody 
Dilution 
Secondary 
Antibody 
Secondary 
Antibody 
Dilution 
GR⍺ (G-5, sc-393232; 
Santa Cruz 
Biotechnology) 
 
95 
 
1:4000 
Anti-mouse HRP 
linked antibody (sc-
516102; Santa Cruz 
Biotechnology) 
 
1:4000 
Phosho Ser226-GR 
(D9D3V, #97285 Cell 
Signaling Technology) 
 
95 
 
1:3000 
Anti-rabbit HRP 
linked antibody 
(#7074; Cell 
Signaling 
Technology) 
 
1:3000 
GAPDH (0411, sc-
47724, Santa Cruz 
Biotechnology) 
 
37 
 
1:2000 
Anti-mouse HRP 
linked antibody (sc-
516102; Santa Cruz 
Biotechnology 
 
1:1000 
 
2.12 RNA isolation and cDNA synthesis  
 
After the addition of 400 µL TriReagent® (Sigma-Aldrich, South Africa), 12-well plates (Greiner 
Bio-One International, Austria) were scraped and the contents transferred into microfuge tubes. 
Following the addition of 80 µL chloroform, tubes were vortexed vigorously for 30 seconds and 
incubated at room temperature for 3 min, after which they were centrifuged at 20 000 ´ g at 4°C 
for 15 min. The aqueous phase was then transferred into a new microfuge tube, into which 200 
µL isopropanol (Merck, South Africa) and 1 µL glycogen (Roche, South Africa) was added. After 
mixing by inversion, samples were incubated for 15 min at room temperature. Samples were then 
centrifuged at 20 000 ´ g at 4°C for 10 minutes. The supernatants were discarded and the pelleted 
RNA washed in 400 µL of 75 % (v/v) EtOH in diethyl pyrocarbonate (DEPC)-treated water. 
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Subsequently, the RNA pellet was air dried and resuspended in 20 µL DEPC-treated water. 
Samples were then incubated at 55°C for 5 min and immediately placed on ice. RNA was 
precipitated by the addition of 40 µL 100% (v/v) EtOH and 6 µL 3 M sodium acetate pH 5.5 and 
stored at -80°C overnight. Following this, RNA was pelleted by centrifugation at 20 000 ´ g for 
15 min at 4°C, washed in 700 µL of 75 % (v/v) EtOH in DEPC-treated water, air dried and 
resuspended in DEPC-treated water as above. RNA concentration and integrity was then 
determined by spectrophotometry (NanoDrop Technologies). Minimum acceptable 260:280 and 
260:230 ratios were both approximately 1.8. Integrity was further assessed by denaturing 
formaldehyde agarose gel electrophoresis (Sambrook and Russell 2006). Briefly, 250 ng RNA was 
added to sample loading buffer [12% (v/v) DEPC-treated water, 5% (v/v ) bromophenol blue, 7% 
(v/v) glycerol, 10% (v/v) 10 ´ MOPS buffer (0.2 M MOPS in DEPC-treated water, 0.05 M sodium 
acetate, 0.01 M EDTA), 17% (v/v) 12.3 M formaldehyde and 49% (v/v) formamide] and 20 µg/mL 
EtBr. Following this, samples were electrophoresed on a 1% formaldehyde agarose gel (70% (v/v) 
DEPC-treated water, 10% (v/v) 10 ´ MOPS buffer, 20% (v/v) formaldehyde) in 1 ´ MOPS buffer 
(40 mM MOPS; 10 mM sodium acetate; 1 mM EDTA, pH 8.00) at 70 V for 35 min. Samples were 
visualized under ultraviolet light on a Syngene, G:Box (Vacutec, UK) and images acquired using 
GeneSnap version 7.08 (SynGene, UK). 250 ng RNA was reverse transcribed using the High-
Capacity cDNA Reverse Transcription Kit (Applied Science, South Africa). RNA samples were 
precipitated and stored at -80°C.  
 
2.13 Primers and Real-Time PCR  
 
For quantitative real-time polymerase chain reaction (qRT-PCR), equal volumes of synthesised 
cDNA were used as a template using the FastStart Essential DNA Green Master kit (Roche 
Applied Science, South Africa) and the primers listed in Table 2.2. Analysis was performed on a 
RotorGene 3000 qRT-PCR machine (Qiagen, Netherlands). Cycling parameters consisted of an 
initial 10 min denaturation at 95°C, 35 cycles of 10 seconds at 95°C, 15 seconds annealing at 60°C 
and 10 seconds elongation at 72°C. For IκB-α, cycling parameters were as above, with the 
inclusion of a final 10 min extension at 72°C. mRNA transcript levels were normalized to GAPDH 
mRNA transcript levels, and calculated using the Pfaffl method (Pfaffl, 2001). It was determined 
that the standard deviation of Ct values for GAPDH between different treatment and replicate 
samples was less than 1, indicating its suitability for use as a reference gene in both PBMCs and 
U2OS cells. RT-PCR product samples were analysed by 2% agarose gel electrophoresis in 1 ´ 
TAE at 70 V for 1 hour, to check for correct expected product sizes. The primer efficiency was 
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determined by standard curves. Fold change was calculated relative to the vehicle control set to 1, 
or as indicated in figures. 
  
Table 2.2 : Sequences, amplicon sizes and concentrations of primers used for real time-PCR 
 
Gene Sequence Product 
Size (bp) 
Final 
Conc. 
Reference 
GAPDH F: 5’ -TGAACGGGAAGCTCACTGG- 3’ 
R: 5’ -TGTCAGTTGATAAAACCGCTGCC- 3’ 
307 200 nM (Ishibashi et 
al., 2003) 
GILZ Quantitect Primer QT00091035 69 1X Qiagen, 
Netherlands 
IL-6 F: 5’ -TCTCCACAAGCGCCTTCG- 3’ 
R: 5’ -CTCAGGGCTGAGATGCCG- 3’ 
193 250 nM (Wolf et al., 
2002) 
IL-8 F: 5’ -TGCCAAGGAGTGCTAAAG- 3’ 
R: 5’ -CTCCACAACCCTCTGCAC- 3’ 
197 500 nM Wolf et al., 
2002) 
IFN-γ 
 
F: 5’ -AATGCAGGTCATTCAGATGTAGCGG- 3 ’ 
R: 3’ -GGATGAGTTCATGTATTGCTTTGCG- 3’ 
298 250 nM (Scott et al., 
1999) 
IκB-α F: 5’ -ACTCGTTCCTGCACTTGGCC- 3’ 
R: 5’ -TGCTCACAGGCAAGGTGTAG- 3’ 
238 200 nM (Emmerich et 
al., 1999) 
 
 
2.14 Data analysis  
 
Data was analysed using GraphPad Prism (version 7) software from GraphPad Software Inc. (La 
Jolla, California, USA). For dose-response curves, DEX were used as the reference ligand and set 
to 100% by subtracting the average control reading from all other conditions, unless otherwise 
specified in figure legends. Dose-response curves were plotted using a non-linear regression model 
using “log agonist vs response”, with a fixed Hill slope of 1. Statistical analysis is described in 
figure legends, and data was plotted as mean ± standard error of the mean (SEM).  
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CHAPTER 3 
RESULTS 
___________________________________________________________________________ 
 
The ability of DPV and TDF to independently transcriptionally activate the GR, was assessed by 
reporter gene analysis in U2OS cells exogenously expressing the GR. In addition, their capacity to 
modulate GC-induced mRNA levels via the GR was similarly investigated in these cells. Their 
effects on GR-regulated mRNA levels of immunoregulatory genes was investigated in PBMCs, as 
were the effects of DEX, MPA and LNG on the efficacies of DPV and TDF in inhibiting HIV-1 
replication. Concentrations of ARVs within the range of those detected intravaginally, as well as 
peak serum concentrations following oral administration, were used (see Table 1.2). 
Concentrations of GCs and progestins were also within physiologically relevant ranges (see Table 
1.1 and Table 1.3). 
 
3.1  DPV and TDF do not independently transcriptionally activate the GR 
 
To evaluate the capacity of DPV and TDF to activate the GR, U2OS cells exogenously expressing 
the GR (+GR) and a GRE-luciferase reporter were stimulated with DPV (Fig. 3.1c) or TDF (Fig. 
3.1e), at concentrations ranging from 0.01 nM–10 µM, in the absence and presence of 100 nM 
DEX. In the absence of DEX, neither DPV nor TDF significantly induced the reporter above 
basal levels at the concentrations tested, suggesting they do not independently activate the GR. At 
a concentration of 10 µM, TDF (p>0.999) to induced a non-statistically significant increase in 
reporter gene expression of approximately 25-fold relative to vehicle. This represents the average 
of three values, one of which was much higher than the others, possibly due to a technical error. 
The addition of 100 nM DEX significantly induced the reporter by approximately 200-fold relative 
to vehicle, with no significant differences observed in the presence of DPV or TDF at any of the 
concentrations tested. In cells transfected with the empty vector control (-GR) (Fig. 3.1b & d), as 
expected, neither DEX nor the ARVs significantly induced the luciferase reporter above basal 
levels. Successful GR transfection was confirmed by western blotting (Fig. 3.1a). GR protein was 
not detected in cells transfected with the empty vector control, consistent with the lack of DEX-
induced luciferase activity observed. Protein levels of other steroid receptors beyond the GR were 
not assessed directly by the author; however, others in the authors laboratory have shown (by 
western blotting) that U2OS cells do not express detectable levels of AR, PR or MR protein (data 
not shown). Upon agonist binding, it has been shown that GR levels in cells rapidly decline 
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(Wallace and Cidlowski, 2001; Avenant et al., 2010b). Predictably DEX, unlike its vehicle control, 
significantly reduced GR protein levels in cells exogenously expressing the GR, by approximately 
40% (Fig. 3.1a). Recognizing that the relatively high concentration of DEX used may overwhelm 
any modulatory effect of the ARVs in U2OS cells, similar experiments, using 10-fold lower 
concentrations of DEX were performed (data not shown). However, in these experiments, DEX-
induced effects via the GR were not robust or reproducible. Unlike DEX, LNG (100 nM) did not 
significantly induce the reporter above basal levels, which remained unchanged in the presence of 
DPV or TDF (at concentrations of 100 nM and 1 µM) (Appendix Fig. A1a & c). DPV and TDF 
also had no significant effect on the transcriptional activity of MPA, which induced a non-
statistically significant increase in reporter gene expression of approximately 100-fold relative to 
vehicle (Appendix Fig. A1b & d).  
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Figure 3.1: DPV and TDF do not independently activate the GR. U2OS cells were co-transfected with 
the GR expression vector (+GR) or its empty vector control (-GR), and the GRE-luciferase reporter 
construct. Equal volumes of cell lysate, including a GR positive control (GR +ve) were analysed by western 
blotting with a GR-specific antibody, and GAPDH as a loading control, to confirm successful GR 
transfection. A representative western blot is shown in the left panel and pooled results of five experiments 
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in the right panel of (a). Subsequently, cells were treated with increasing concentrations of DPV (b) and 
(c) or TDF (d) and (e), in the absence or presence of 100 nM DEX, or vehicle (0.1% v/v EtOH and 
DMSO) for 24 hours. Luciferase activity was normalized to protein content per well, as determined by a 
Bradford assay. Data are plotted as mean ± SEM, and are the pooled results of three or more independent 
experiments, each performed in triplicate. Data is plotted relative to fold induction for vehicle control (in 
the absence of DEX, black bar), which was set to 100% in (a) and 1 in (b–e). Statistical significance was 
determined using unpaired t-tests in (a) and a two-way ANOVA with a Tukey’s multiple comparisons post-
test in (b–e). Asterisks or p values above bars indicate significance compared to vehicle control, with ****, 
***, ** and * indicating p<0.0001, p<0.001, p<0.01 and p<0.05, respectively. 
 
Like DPV and TDF, MVC was shown to not significantly induce expression of the reporter above 
basal levels at concentrations ranging from 0.01 nM–10 µM and did not significantly alter the 
transcriptional activity of DEX, MPA or LNG in COS-1 cells (Appendix Fig. A2). Experiments 
with MVC were performed in the COS-1 model system, prior to all other experiments. The use 
of COS-1 cells was discontinued in favor of using U2OS cells, which, unlike COS-1 cells, are of 
human origin, and therefore, better suited to the objectives of this study. Due to time constraints 
the experiments with MVC were not repeated in U2OS cells.  
 
 
3.2 DPV and TDF modulate the efficacy, but not potency of a GR agonist 
  
 
Although DPV and TDF may not activate the GR directly, they have the potential to modulate 
GC action, possibly through affecting one or more of the numerous proteins involved in GR 
signaling. Using promoter-reporter assays, the effect of 1 µM DPV (Fig. 3.2a) or TDF (Fig. 3.2b) 
on the efficacy and potency (EC50) of DEX was investigated. TDF significantly increased the 
efficacy of DEX transcriptional activity via the GR by 33% (Fig. 3.2c); DPV had a similar non-
statistically significant effect (p=0.0531), increasing DEX transcriptional activity by 25% (Fig. 
3.2c). DPV and TDF did not significantly alter the EC50 of DEX (Fig. 3.2d & e). These effects 
were not detectable in Fig. 3.1 for 1 µM ARV, where the effects of only 100 nM GR ligand were 
investigated. Taken together, although DPV and TDF do not independently transactivate the GR 
(Fig. 3.1), they modulate GC transcriptional activity in these reporter assays (Fig. 3.2) via the GR 
in U2OS cells.  
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Figure 3.2: DPV and TDF increase the transcriptional efficacy of DEX via the GR. U2OS cells were 
co-transfected with the GR expression vector (+GR) or its empty vector control (-GR), and the GRE- 
luciferase reporter construct. Subsequently, cells were treated with increasing concentrations of DEX, in 
the presence or absence of 1 µM DPV (a) or TDF (b), or vehicle (0.1% v/v EtOH and DMSO). Luciferase 
activity was normalized to protein content per well, as determined by a Bradford assay. The maximal value 
of DEX was set to 100% to obtain relative fold induction. Relative potencies of the resulting dose-response 
curves are shown in (c), and relative EC50 values in (d) and (e), where the EC50 and its error are indicated 
above relevant bars. Data are plotted as mean ± SEM, and are the pooled results of three or more 
independent experiments, each performed in triplicate. Statistical significance for EC50 values and efficacies 
were determined using unpaired t tests. ** denotes p< 0.01 and n.s (not significant) p>0.05.  
 
3.3       DPV and TDF do not alter U2OS cell viability 
 
Alterations in cell viability may result in changes in the transcriptional efficacy of GCs via the GR, 
as well as GC-induced mRNA expression. The capacity of DPV and TDF to affect cell viability 
alone, and in combination with DEX (Fig. 3.3a), CORT (Fig. 3.3b) or MPA (Fig. 3.3c) was 
investigated. Cells were treated with DEX or MPA at concentrations ranging from 0.01 nM–10 
µM and CORT at concentrations ranging from 10 nM–1 µM, with or without the addition of 1 
µM DPV or TDF. At the concentrations tested, DEX, MPA and CORT did not significantly alter 
the viability of U2OS cells compared to vehicle. The addition of DPV or TDF had no significant 
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effect. These results suggest that the ARV-induced increases in DEX transcriptional efficacy via 
the GR observed in Fig 3.2 were not due to differential effects on cell viability.  
 
To this point DPV and TDF have been shown to not independently transcriptionally activate the 
GR, or alter U2OS cell viability, alone or in the presence of GCs. However, DPV and TDF 
modulate the transcriptional efficacy of DEX on a GRE-reporter gene in these cells.  
  
 
Figure 3.3: DPV and TDF, in the absence and presence of GR ligands, do not significantly alter the 
viability of U2OS cells. U2OS cells were transfected with the GR expression vector and subsequently, 
cells were treated with DEX (a), CORT (b) or MPA (c), or vehicle (0.1% v/v EtOH and DMSO), in the 
absence or presence of 1 µM DPV or TDF for 24 hours as indicated. Cell viability was determined using 
MTT assays. Data are plotted relative to vehicle control (black bar), which was set to 100%. Data are plotted 
as mean ± SEM and are the pooled results of three or more independent experiments, each performed in 
quadruplicate. Statistical significance was determined using a two-way ANOVA with a Tukey’s multiple 
comparisons post-test. No statistically significant differences were observed, but p values above bars 
indicate significance compared to vehicle control (black bar), unless otherwise indicated with lines.  
 
 
3.4        TDF modulates DEX-induced mRNA expression in U2OS cells 
 
Following observations that DPV and TDF increased the transcriptional efficacy of DEX on a 
GRE-reporter gene, their capacity to modulate GR-regulated mRNA levels of immune function 
genes was assessed (Fig. 3.4). Prior to cDNA synthesis, the integrity of all isolated RNA was 
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assessed by denaturing formaldehyde gel electrophoresis, as shown in the insert in (Fig. 3.4a), 
where distinct 28S and 18S RNA bands are visible. DEX, at concentrations of 1 µM and 10 µM, 
significantly induced GILZ mRNA expression by approximately 7-fold relative to vehicle. 
Contrary to the reporter gene results, the addition of 1 µM TDF, but not DPV significantly 
decreased DEX-induced GILZ maximal mRNA expression by approximately 5-fold (Fig. 3.4a & 
b). There were no significant differences in the EC50 observed. In cells transfected with the empty 
vector control, (0.01 nM–1 µM) DEX did not induce GILZ mRNA expression (see Appendix 
Fig. A3). Although both DPV and TDF increased the expression of CORT-induced GILZ 
mRNA at some of the concentrations tested, the effect was not statistically significant. The overall 
maximal efficacy of CORT decreased slightly, but the effect was not statistically significant 
(p=0.415) in the presence of TDF (Fig. 3.4d). Neither ARV significantly altered MPA-induced 
GILZ maximal mRNA expression (Fig. 3.4e). The mRNA expression of IκB-α was also assessed. 
As with GILZ, IκB-α expression is known to be upregulated by GCs (Deroo and Archer, 2001). 
However, in these experiments DEX did not significantly induce IκB-α mRNA expression above 
basal levels after 24 hours, and the addition of 1 µM DPV or TDF did not alter expression (Fig. 
3.4c). Given the large errors in the dose-response analysis (Fig. 3.4a, d & e), the observed 
differential effects of TDF on DEX-, CORT- and MPA-induced GILZ mRNA expression were 
further investigated. Cells were treated with 1 µM DEX, CORT or MPA, in the absence or 
presence of 1 µM TDF in parallel (Fig. 3.4f). Similar to the results obtained earlier (Fig. 3.4a), 
DEX significantly induced GILZ mRNA expression, by approximately 5-fold relative to vehicle 
and TDF decreased DEX-induced GILZ mRNA expression, but this effect was not statistically 
significant. However, the degree of change in DEX-induced GILZ mRNA expression in the 
presence of TDF was less than previously observed and not significant statistically (p=0.089). 
CORT and MPA induced non-statistically significant increases in GILZ mRNA expression by 
approximately 2.5-fold and 4-fold, respectively (Fig. 3.4f), and TDF decreased MPA and CORT-
induced GILZ mRNA expression, but these effects were not statistically significant.  
 
While both DPV and TDF increase the transcriptional efficacy of DEX in reporter assays in U2OS 
cells (Fig. 3.2), the ARVs have differential effects on DEX-induced GR-regulated mRNA 
expression. TDF, but not DPV, significantly decreases DEX-induced endogenous GILZ mRNA 
expression, and has similar apparent effects on CORT- and MPA-induced GILZ mRNA 
expression in U2OS cells. However, the effect of TDF on (1 µM) DEX-induced GILZ mRNA 
expression proved to be highly variable (Fig. 3.4f). These ARV effects are unlikely to be due to 
differential effects on cell viability (Fig. 3.3). 
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Figure 3.4: TDF alters DEX-induced GILZ mRNA levels in U2OS cells. U2OS cells were transfected 
with the GR expression vector. Subsequently, cells were treated with increasing concentrations of DEX 
(a–c), CORT (d) or MPA (e), or vehicle (0.1% v/v EtOH and DMSO) in the absence or presence of 1 µM 
DPV or TDF for 24 hours as indicated. RNA was isolated, and its integrity assessed by denaturing 
formaldahyde gel electrophoresis as shown in the insert (bottom) in (a). cDNA was synthesized and the 
expression of GILZ and IκB-α mRNA was determined and normalized to GAPDH mRNA levels. Data 
are plotted as mean ± SEM and are the pooled results of three or more independent experiments, with the 
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exception of (c) and (e), which are the pooled results of two independent experiments. All experiments 
were performed in triplicate. A subset of the data shown in (a) is also shown in (b), plotted as bar graphs 
with statistical comparisons. Relative fold change in expression was determined by setting vehicle control 
(for steroid without ARV) to 1. Statistical significance was determined using a two-way ANOVA with a 
Tukey’s multiple comparisons post-test in (a-e) and unpaired t-tests in (f). Asterisks or p values above bars 
indicate significance compared to vehicle control (black bar), unless otherwise indicated with lines. ****, 
***, ** and * indicate p<0.0001, p<0.001, p<0.01 and p<0.05, respectively. 
 
 
3.5.       The effect of DPV and TDF on GR protein levels and GR phosphorylation  
 
To gain mechanistic insight into the observed effects of DPV and TDF on the transcriptional 
activity of DEX (Fig. 3.2) and DEX-induced mRNA levels (Fig. 3.4), their effects on GR protein 
expression and phosphorylation at Ser226 (pSer226-GR) in U2OS cells were assessed by western 
blotting (Fig. 3.5). Ser226 is hyperphosphorylated in the presence of GCs and has been shown to 
enhance nuclear export, (Itoh et al., 2002) and is thus associated with blunting GR responses (Kino 
et al., 2007). As expected and previously observed in (Fig. 3.1a) DEX, at concentrations of 100 
nM and 1 µM induced reductions in GR protein levels of approximately 50%, although these 
effects were not statistically significant (Fig. 3.5b). DEX, at concentrations of 100 nM and 1 µM, 
induced 200% and 300 % non-statistically significant increases, respectively, in pSer226-GR levels 
(Fig. 3.5c). The addition of DPV and TDF resulted in non-statistically significant increases in (1 
µM) DEX-induced phosphorylation of the GR at Ser226 by approximately 19% and 68%, 
respectively (Fig. 3.5c). Interestingly, at a concentration of 1 µM DEX, GR levels were 
approximately 50% lower in the presence of TDF, but this effect was not statistically significant 
(Fig. 3.5b). Individual western blots are shown and quantified in the Appendix (Fig. A4-A6).  
 
No statistically significant differences were obtained between GR levels or phosphorylation at 
Ser226 for different conditions in these pooled data. Given the large number of variables, relatively 
small apparent differences and inherent technical error in the quantification, it was not possible to 
establish whether the apparent differences observed were statistically significant or not, without 
performing more experiments with fewer variables. 
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Figure 3.5. DPV and TDF effect on GR protein levels and GR phosphorylation in U2OS cells. U2OS 
cells were transfected with the GR expression vector and subsequently stimulated with 1 µM DPV or TDF 
in the absence or presence of 100 nM DEX, 1 µM DEX or vehicle (0.1% v/v EtOH and DMSO) for 24 
hours. Equal volumes of cell lysate were analysed by western blotting with GR and pSer226-GR specific 
antibodies, with GAPDH as a loading control. A representative western blot is shown in (a). Quantification 
of GR protein levels is shown in (b) and relative pSer226-GR levels in (c). Data are plotted as mean ± SEM 
and are the pooled results of three independent experiments. Relative fold change in expression was 
determined by setting vehicle control (black bar) to 100%. Statistical significance was determined using 
unpaired t-tests. No statistically significant differences were observed, but p values above bars indicate 
significance compared to vehicle control, unless otherwise indicated with lines.  
 
3.6 DPV, TDF and MVC modulate GR-regulated mRNA expression in PBMCs in a 
donor-specific manner 
 
 To further assess the ability of DPV, TDF, as well as MVC to modulate the expression of 
immunomodulatory genes, PBMCs were treated with 1 µM DPV, TDF or MVC, alone or in 
combination with 100 nM DEX for 48 hours (previous experiments with steroids and progestins 
in the authors laboratory have shown 48 hours is reasonable to invoke robust inflammatory 
responses in PBMCs) (Fig. 3.6). In PBMCs from the majority of donors, DPV, TDF and MVC 
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significantly decreased the expression of anti-inflammatory GILZ mRNA (Fig. 3.6a). DEX 
induced GILZ mRNA expression by approximately 6-fold, but this effect was not statistically 
significant (p=0.050), which remained unchanged in the presence of either ARV in the majority of 
donors. DEX significantly repressed IL-6 mRNA expression by approximately 2-fold relative to 
vehicle (Fig. 3.6b), but did not significantly alter IL-8 (Fig. 3.6c) or IFN-γ (Fig. 3.6d) mRNA 
levels. DPV, TDF and MVC had no overall significant effects on IL-6, (Fig. 3.6b), IL-8 (Fig. 
3.6c) or IFN-γ (Fig. 3.6d) mRNA expression when examining pooled data. However, apparent 
donor-specific effects on the mRNA levels of all genes were observed, and are shown in Appendix 
Fig. A7–A10. The addition of DEX significantly reversed the apparent ARV-induced increases in 
IL-6 and IL-8 mRNA expression (Fig. 3.6b & c). As in U2OS cells, DEX and the ARVs had no 
significant effect on IκB-α mRNA levels (Fig. 3.6e). DPV and TDF significantly decreased the 
viability of PBMCs by 5% and 6% relative to vehicle, respectively (Fig. 3.6f). Treatment with 
DEX significantly reduced the viability of PBMCs by approximately 20% relative to vehicle, which 
was unchanged in the presence of MVC, DPV or TDF (Fig. 3.6f).  
 
The results in Fig 3.6 suggest there are large inter-donor differences in responses, which was 
investigated by subgroup analysis (Appendix Fig. A7–A10). Whether the effects in these 
subgroups are statistically significant was not investigated since they were grouped post the 
accumulation of the data set. The groups are shown to illustrate the possibility that there may be 
donor-specific effects that are masked by pooling all the data. However further experiments are 
needed to investigate the statistical significance of these effects, by perhaps selecting donors 
beforehand based on some exclusion criteria. MVC, DPV and TDF decreased GILZ mRNA levels 
by 2-fold or more in PBMCs from seven of the nine donors tested (Appendix Fig. A7a–c). MVC 
decreased IL-6 mRNA levels by 2-fold or more in PBMCs from one donor, while DPV and TDF 
did so in PBMCs from two donors (Appendix Fig. A8a–c). MVC increased IL-6 mRNA 
expression by 2-fold or greater in PBMCs from four donors, and DPV and TDF had the same 
effect in PBMCs from two donors (Appendix Fig. A8g–i). MVC and TDF decreased IL-8 mRNA 
expression (by 2-fold or greater) in PBMCs from two donors, and DPV did so in PBMCs from 
three donors (Appendix Fig. A9a–c). MVC and TDF increased IL-8 mRNA levels by more than 
2-fold in PBMCs from four donors, and DPV had a similar effect in PBMCs from three donors 
(Appendix Fig. A10g–i). MVC and TDF reduced IFN-γ mRNA expression by 2-fold or more in 
PBMCs from one donor, and DPV did so in PBMCs from two donors (Appendix Fig. A10a–c). 
MVC increased IFN-γ mRNA expression by 2-fold or more in PBMCs from four donors, and 
DPV and TDF had a similar effect in PBMCSs from three donors (Appendix Fig. A10g–i).  
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Figure 3.6: DPV, TDF and MVC selectively alter immunomodulatory gene mRNA levels in 
PBMCs. PBMCs were stimulated with or 1 µM MVC, DPV or TDF, in the absence or presence of 100 
nM DEX, or vehicle (0.1% v/v EtOH and DMSO) for 48 hours. Subsequently, relative changes in GILZ 
(a) IL-6 (b) IL-8 (c) IFN-γ (d) and IκB-α (e) mRNA expression were determined by real time qPCR, and 
normalized to GAPDH mRNA levels. The effects of treatments on cell viability were determined using an 
MTT assay (f). Relative fold change in expression was determined by setting vehicle control (black bar) to 
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1 (a–e) or 100% (f). Pooled results of nine donors are shown. Data are plotted as mean ± SEM. Individual 
donors are depicted with specific black symbols. Statistical significance was determined using unpaired t-
tests, ****, ***, ** and * indicate p<0.0001, p<0.001, p<0.01 and p<0.05, respectively. 
 
 
3.7        DEX and MPA do not alter HIV-1 inhibitory effects of DPV or TDF 
 
Lastly, the potential of progestins and GCs to modulate the anti-HIV-1 effects of DPV and TDF 
was examined (Fig. 3.7). DPV and TDF at concentrations of 1 µM completely inhibited the 
replication of HIV-1BaL-Renilla in PBMCs from two and three donors, respectively. In PBMCs from 
most donors, the addition of DEX, MPA and LNG had no significant effect on the efficacy of 
DPV and TDF to inhibit HIV-1BaL-Renilla replication. However, in PBMCs from one donor, the 
addition of LNG apparently reduced the efficacy of TDF to inhibit HIV-1 replication, by 
approximately 50% relative to control. As such, TDF in the presence of LNG did not significantly 
inhibit infection relative to control for pooled results from three donors. In another donor, DPV 
alone repressed infection by 80%, and completely when in the presence of DEX, MPA and LNG. 
It may be that the steroids had no effect on the anti-HIV activity of the ARVs as they were used 
at a relatively high concentration, and any modulatory effect of the steroid may have been 
overwhelmed by the ARV. However, in the authors hands, lower doses of the ARVs (1 nM and 
100 nM) were not significantly protective against HIV-1 infection in PBMCs (data not shown), 
thus a higher concentration was used.  
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Figure 3.7: DEX, MPA and LNG do not alter the HIV-1 inhibitory effects of DPV or TDF. PBMCs 
were stimulated with 1 µM DPV or TDF, in the absence or presence of 100 nM DEX, MPA or LNG, or 
vehicle (0.1% v/v EtOH and DMSO) for 48 hours. Thereafter, cells were infected with HIV-1BaL-Renilla 
which was allowed to propagate for 5 days. Infection was determined by measuring luminescence and 
normalized to cell viability, as determined by an MTT assay. Pooled results from 3 donors in quadruplicate 
are shown. Relative infection was determined by setting vehicle control to 100%. Data are plotted as mean 
± SEM. Individual donors are depicted with specific black symbols. Statistical significance was determined 
using a one-way ANOVA with a Tukey’s multiple comparisons post-test. Asterisks or p values above bars 
indicate significance compared to vehicle control (black bar), unless otherwise indicated with lines. ****, 
***, ** and * indicate p<0.0001, p<0.001, p<0.01 and p<0.05, respectively. 
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CHAPTER 4 
DISCUSSION  
___________________________________________________________________________ 
 
With the development of DPV and TDF PrEP for the prevention of HIV-1 acquisition, it is 
important to characterize the immunomodulatory effects of these ARVs. Increased access to 
HAART, as well as HCs, has led to an increase in their concurrent use. Moreover, this is likely to 
increase, owing to the development of MPTS; ARV and progestin combination products for the 
simultaneous prevention of HIV-1 acquisition and unintended pregnancy. Intracellularly, ARVs 
are in the presence of GCs during times of stress or GC therapy. As such, it is important to 
investigate possible reciprocal modulation of ARV and steroid receptor intracellular actions, which 
may alter their efficacy. This study evaluated the capacity of DPV and TDF to transcriptionally 
activate the GR, modulate the efficacy and potency of a GR agonist via the GR, affect mRNA 
levels of GR target genes, as well as the effects of these ARVs on GR expression levels and GR 
phosphorylation in an in vitro cell line model. Their effects on mRNA levels of immunomodulatory 
genes were assessed in PBMCs, as were the effects of DEX, MPA and LNG on the HIV-1 
inhibitory effects of DPV and TDF.  
 
This study showed DPV and TDF can modulate the reporter gene transcriptional efficacy of DEX 
via the GR in the model system used, as well as DEX-induced changes in mRNA levels of 
immunoregulatory genes, at physiologically relevant concentrations (see Table 1.2 & 1.3 for ARV 
and GC serum concentrations). In the U2OS cell line model, TDF significantly decreased DEX-
induced anti-inflammatory GILZ mRNA expression and to decrease CORT- and MPA-induced 
GILZ mRNA expression. In the presence of TDF, an apparent increase in DEX-induced 
phosphorylation of the GR at Ser226 was observed in U2OS cells. In PBMCs, the ARVs decreased 
basal GILZ mRNA expression, and had varied, donor-specific apparent effects on the expression 
of IL-6, IL-8 and IFN-γ. This study showed no effect of DEX, LNG or MPA on the HIV-1 
inhibitory effects of DPV or TDF in PBMCs from the majority of donors tested. 
 
4.1  Effects of DPV and TDF on GR-mediated transcriptional activity and mRNA 
expression  
 
A variety of signals, notably TNF and GnRH, have been shown to transcriptionally activate the 
GR, in the absence of GCs (Kotitschke et al., 2009; Verhoog et al., 2011; Hapgood et al., 2016). 
 62 
The ability of DPV and TDF to transcriptionally activate the GR was assessed in U2OS cells 
exogenously expressing the GR, using GRE-luciferase reporter assays (Fig. 3.1). DPV and TDF 
did not activate the GR at any of the concentrations tested, alone or in the presence of 100 nM 
DEX (Fig. 3.1), LNG or MPA (Appendix Fig. A1). These results are consistent with a previous 
study for TDF (Svärd et al., 2014), while the result for DPV is novel. Svärd et al. found that a panel 
of 26 ARVs, which included TFV but not DPV, had no LBD interactions with the GR, or ability 
to induce GR transactivation in vitro (Svärd et al., 2014). Theoretically, it is unlikely that TDF and 
DPV can bind to the GR LBD, given that the GR LBD predominantly binds to four-ring steroidal 
compounds (Schmit and Rousseau, 1979), dissimilar from the chemical structures of TDF or DPV 
(see Fig. 1.2). The results of the present study suggest DPV and TDF, at physiologically relevant 
concentrations, do not transactivate gene expression via the unliganded GR in vitro or in vivo. 
Therefore, ligand-independent activation of the GR by these ARVs is unlikely to be a mechanism 
contributing to their effects on immunomodulatory gene expression in U2OS cells and PBMCs in 
this study, or responsible for the adverse side effects observed in users of the ARVs. 
 
The capacity of DPV and TDF to alter the transcriptional activity of DEX via the GR was also 
assessed using reporter assays (Fig. 3.2). TDF significantly increased the efficacy of DEX via the 
GR by approximately 33%, and DPV had a similar apparent effect. This is the first study to show 
that ARVs affect GC-induced transcriptional activity via the GR. In this study, the EC50 of DEX, 
which was approximately 1 nM, was not altered in the presence of DPV or TDF (Fig. 3.2d & e). 
The EC50 is dependent on the cell type, promoter and receptor concentrations, ligand affinity for 
the receptor and, as is apparent in Fig. 3.2d & e, is variable between experiments (Robertson et 
al., 2013; Hapgood et al., 2014). The EC50 of DEX in this experiment is similar to reported EC50 
values for the GR of 1.66 nM and 1.03 nM, determined by others in U2OS cells using reporter 
genes (Sedlák et al. 2011). The efficacy is influenced by the affinity of the ligand for the receptor, 
receptor concentrations and the cell specific relative concentrations of co-regulators (Ronacher et 
al., 2009; Simons and Chow, 2012). Growth factors, cytokines and LABAs have been shown to 
prime the unliganded GR, increasing its sensitivity to GCs, but not transcriptionally activating it, 
via mechanisms involving altered GR and/or cofactor recruitment or binding to the promoters of 
genes, altering the activity or levels of signaling proteins in the GR pathway, including kinases and 
cofactors, and changes in site-specific phosphorylation of the GR (Hapgood et al., 2016). It is 
possible DPV and TDF sensitize GR signaling via similar mechanisms in U2OS cells, although 
this remains to be determined. The present study found DPV and TDF had no significant effect 
on GR protein levels in U2OS cells, alone, or in the presence of DEX (Fig. 3.5). Therefore ARV-
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induced alterations in GR concentrations are unlikely to be a mechanism through which the ARVs 
modulate GC activity in U2OS cells. An obvious mechanism through which ARVs may alter GR-
mediated responses is through altering cell viability. This study demonstrated that 1 µM DPV and 
TDF, alone and in the presence of DEX, CORT and MPA, did not significantly alter the cell 
viability of U2OS cells exogenously expressing the GR, after 24 hours (Fig. 3.3). Moreover, the 
steroids did not significantly alter the viability of these cells either. Therefore, the effects of DPV 
and TDF on cell viability cannot account for their effects on steroid-induced responses via the 
GR. 
 
Contrary to the results of the promoter-reporter assays, TDF significantly decreased DEX-
induced GILZ mRNA expression by approximately 5-fold, whereas DPV had no significant effect 
(Fig 3.4a & b). Several factors may explain the discrepancy between the ARVs effects on DEX-
induced reporter gene transcription, and DEX-induced endogenous GILZ mRNA expression. 
Inherent to promoter-reporter assays is the absence of adjacent condensed regions of chromatin 
and epigenetic modifications, which regulate transcriptional responses through influencing the 
three-dimensional spatial arrangement of the linear genome in the nucleus, in this way dictating 
promoter and enhancer element accessibility to transcription factors and co-regulators (Burd and 
Archer, 2013). Chromatin also dictates GR genomic interactions with distal enhancer elements 
(which are absent in the context of reporter assays) for example, the GR-regulated genes Ciz1 and 
Lcn2 are regulated cell-specifically through a chromatin loop which spans 30 kb (Hakim et al., 
2011). Besides, hundreds of promoter-reporter plasmids may be transfected into a cell, but 
transcription factors and co-regulators are typically present at low concentrations (Smith and 
Hager, 1997; Karimi et al., 2009). As such, only a small proportion of the reporter genes entering 
a cell receive all necessary transcription factors, and the remaining promoter-reporter constructs 
may be atypically transcribed, resulting in transcriptional effects which differ from those of 
endogenous genes (Smith and Hager, 1997; Karimi et al., 2009).  
 
It should also be noted that regulatory elements present on the promoter-reporter plasmid used 
in this thesis differ substantially from those of the endogenous GILZ gene. On the reporter 
plasmid, two GREs from the rat TAT gene are cloned upstream of the luciferase gene, whereas 
the endogenous human GILZ gene promoter includes five GREs, three Forkhead box class O3 
binding sites, as well as putative signal transducer and activator of transcription 6, NFAT and c-
myc response elements (Asselin-Labat et al., 2004). These represent potential targets through 
which ARVs may alter GC-induced gene expression. It is therefore conceivable that the GR exists 
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in distinct transcription initiation complexes endogenously and on the promoter-reporter plasmid, 
which differentially influence their interactions with co-regulators, ultimately resulting in 
differential responses. Apart from control at the level of transcription initiation, mRNA post-
transcriptional processing contributes to gene regulation (see Section 1.6.2) (Kumar. et al., 2014). 
If post-transcriptional regulation occurs differentially between luciferase and GILZ mRNA, this 
may contribute to the differences observed in the present study. 
 
Although TDF induced a significant decrease in DEX-induced GILZ mRNA expression, this 
effect was not replicated on the other GC-induced gene, IκB-α, investigated in this study (Fig. 
3.4c). This may be due to differences in the promoters of the two genes. DEX did not significantly 
alter IκB-α mRNA expression compared to basal levels after 24 hours; it was therefore not 
possible to determine whether the ARVs modulate GC-induced expression of this gene. As such, 
it is not clear from the results of the current study, if TDF has gene-specific effects on DEX-
induced mRNA expression in U2OS cells. The presence of TDF also appeared to decrease CORT- 
and MPA-induced GILZ mRNA expression, but this result was not statistically significant (Fig. 
3.4d & e). Parallel comparison of the effects of TDF on DEX-, CORT- and MPA-induced GILZ 
mRNA expression also showed apparent decreases (Fig. 3.4f). Given that mRNA expression 
induced by more efficacious agonists was repressed to a greater degree (Fig. 3.2a, d &e), one may 
speculate that TDF-induced repression of GR-mediated GILZ mRNA expression is dependent 
on the efficacy of the GR agonist. Given that cells vary in their expression of co-regulators, which 
influence ligand efficacy (Ronacher et al., 2009), the effects of ARVs on GC activity via the GR 
may also be dependent on cell type. Findings that TDF did not significantly alter DEX-induced 
GILZ mRNA expression in PBMCs in the present study (Fig. 3.6a) are consistent with this idea. 
  
TDF has been reported to reduce the expression of genes involved in the MAPK signaling 
pathway in human primary osteocytes (Grigsby et al., 2010; Espocito et al., 2015). Similarly, Hladik 
et al. showed some genes involved in the MAPK signaling pathway were downregulated in rectal 
biopsies in the presence of a 1% TFV gel (Hladik et al., 2015). MAPK is known to induce activation 
of the GR through site-specific phosphorylation (Nader et al., 2010). If TDF has similar effects on 
MAPK signaling in U2OS cells, and reduces GR activation, it is a possible mechanism through 
which it may decrease GC-induced GILZ expression. Alteration of GC-induced gene expression 
through modulating co-regulatory recruitment has previously been described (see Section 
1.6.6). It is conceivable DPV or TDF could alter the function of one or more of the numerous 
co-regulators involved in GR signaling, thereby modulating GC responses as observed in the 
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present study. Intriguingly, in rectal biopsies, Hladik et al. showed a 1% TFV gel downregulated 
the expression of CREB and CBP, which are cofactors which mediate GR transactivation (Kamei 
et al., 1996; Vo and Goodman, 2001; Hladik et al., 2015). If TDF similarly downregulates CREB 
and CBP expression in U2OS cells, this may explain how it decreases DEX-induced GILZ mRNA 
expression. Moreover, because CBP has histone acetyltransferase activity, which is not a 
requirement for reporter gene transcription, TDF-induced downregulation of CBP would be 
consistent with findings in this study that TDF decreased DEX-induced GILZ mRNA expression, 
but not reporter gene transcription. A major mechanism through which the ARVs may modulate 
GC activity via the GR is through altering site-specific phosphorylation of the GR, which 
modulates all aspects of GR signaling, including cofactor recruitment, nuclear translocation, DNA 
binding, transactivation and transrepression (Hu et al., 2013; Hapgood et al., 2016; Kino, 2018). 
 
4.2 Effects of DPV and TDF on GR site-specific phosphorylation  
 
This study evaluated the effects of DPV and TDF on pSer226-GR levels in U2OS cells, alone, 
and in the presence of DEX (Fig. 3.5), and found that, analogous to their effects on DEX-induced 
GILZ mRNA expression, TDF induced a greater apparent increase in DEX-induced 
phosphorylation at Ser226 than did DPV. Phosphorylation at Ser226 modulates cofactor 
recruitment to DNA-bound GR (Kino et al., 2007), and enhances GR nuclear export (Itoh et al., 
2002), and is thus associated with blunting GR responses (Kino et al., 2007). Therefore, a 
mechanism by which TDF, but not DPV, may decrease GC-induced GILZ mRNA expression is 
through their differential effects on phosphorylation at Ser 226, resulting in nuclear export of the 
GR, and blunted GC-induced transcriptional responses. Phosphorylation at Ser226 has been 
shown to alter GR transcriptional activity in a promoter-selective manner, which may explain the 
varying effects of the ARVs on DEX-induced reporter gene transcription and GILZ mRNA 
expression (Avenant et al., 2010b). The results of these experiments assessing GR phosphorylation 
are consistent with TDF decreasing DEX-induced GILZ mRNA expression, but not with DPV 
and TDF increasing DEX transcriptional activity on a reporter gene via the GR. These results are 
limited by their lack of statistical significance. Other instances of ligands desensitizing GR 
responses gene-specifically by altering site-specific phosphorylation of the GR have been 
described (refer to Section 1.6.6) (Hapgood et al., 2016). It is tempting to speculate that DPV and 
TDF alter phosphorylation at other serine residues on the GR, which requires further 
investigation. Hindering the association of ARV effects on GR phosphorylation and their effects 
on GC-induced transcriptional activity or mRNA expression in the present study is the fact that 
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these experiments were not conducted in parallel, and samples assayed by western blotting were 
not transfected with the promoter-reporter construct, which potentially alters GR activity. 
 
4.3 Physiological implications of ARVs effects on GR activity 
 
GCs regulate all aspects of immune function, and modulate metabolic, cardiovascular and 
homeostatic physiological processes via the GR (Baschant and Tuckermann, 2010; Ramamoorthy 
and Cidlowski, 2013). This study did not investigate the effects of DPV and TDF on the efficacy 
and EC50 of CORT for reporter gene transcription via the GR but found that DPV and TDF 
increased the transcriptional efficacy of DEX at concentrations within the range it is used 
therapeutically (see Table 1.3). If one speculates the ARVs increase CORT transcriptional efficacy 
via the GR as with DEX, the results of this study have several implications, if translated in vivo. 
The reporter gene results suggest DPV and TDF may potentiate GC effects via the ubiquitous 
GR, particularly at times when circulating GC levels are high, for example, during times of 
psychological or physiological stress and GC therapy (Wenting-Van Wijk et al., 1999, Dickerson 
and Kemeny, 2004). As such, systemically, DPV and TDF, used prophylactically or therapeutically, 
may have off-target adverse effects via the GR, modulating a wide array of GR-regulated 
physiological processes. Consistent with this premise, numerous clinical, animal and in vitro studies 
indicate the use of TDF is associated with decreases in BMD and increases in markers of bone 
turnover (Grant and Cotter, 2017). Likewise, GCs, increase the risk of osteoporosis and stimulate 
bone resorption, in part through inducing transactivation of the gene RANKL via the GR in 
osteoblasts (Canalis and Delany, 2002). In the present study, TDF potentiated the efficacy of a 
GC for reporter gene transcription in an osteoid cell line; if it similarly potentiates GC-induced 
RANKL expression in osteoblasts in vivo, this may be a mechanism which contributes to its adverse 
effects on bone.  
 
 However, the results of experiments using reporter genes were contrary to experiments evaluating 
endogenous mRNA transcription, which are more physiologically relevant, and suggest TDF but 
not DPV, can repress GC-induced mRNA expression via the GR. CORT and DEX 
concentrations used in this study were similar to those achieved during major-stress or GC-therapy 
(Table 1.3). If the results of the present study are translated in vivo, they imply TDF may have 
pronounced effects on DEX-induced gene expression in individuals using DEX therapeutically, 
perhaps decreasing its therapeutic efficacy by reducing its ability to induce anti-inflammatory gene 
expression. DEX and CORT differ substantially in their binding affinities (Ponec et al., 1986), EC50 
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values and efficacies via the GR in some cell types (Smit et al., 2005; Ronacher et al., 2009) 
Moreover, DEX has a half-life substantially longer than that of CORT (Peterson, 1959). For 
example, in PBMCs, when evaluating GILZ mRNA expression, the EC50 values and efficacies of 
DEX have been reported to be approximately 14-fold and 2-fold higher than for CORT, 
respectively (Smit et al., 2005). However, because ligand- and promoter-selective responses are 
dependent on cell-specific co-regulator recruitment, in some cell types, CORT and DEX have 
similar efficacies and EC50 values (Ronacher et al., 2009). Under such contexts, TDF may therefore 
also alter (exogenous or endogenous) CORT-induced anti-inflammatory gene expression in vivo. 
As such, the use of TDF prophylactically or therapeutically may result in a decreased ability to 
blunt immune responses and therefore increase inflammation and immune activation, the 
consequences of which are discussed in Section 4.5. One may speculate that TDF also has cell-
specific effects on MPA-induced GR-mediated mRNA expression, although, given the supra-
physiological doses of MPA (Table 1.1) at which TDF induced relatively small apparent decreases 
in GILZ mRNA expression in this study, TDF would probably not alter MPA-induced mRNA 
expression via the GR in vivo. It is possible TDF has more pronounced effects on steroid-induced 
mRNA expression at higher micromolar concentrations (as found in cervical tissue when used as 
a vaginal microbicide), in which case it might alter gene expression locally in the FGT.  
 
4.4 DPV and TDF have cell-specific effects on cell viability 
 
In contrast to their effects in U2OS cells (after 24 hours), in PBMCs, DPV and TDF reduced cell 
viability by approximately 5% and 6% relative to vehicle, respectively (after 48 hours) (Fig. 3.6f). 
Taken together, the suggestion of these results is that the ARVs alter cell viability in a cell-type 
and/or time-dependent manner, but the interpretation of these results is confounded by the fact 
that incubations in experiments in the two model systems were of different lengths. Given that 
the concentrations of DPV and TDF tested in the current study were up to 1000-fold higher than 
reported peak serum concentrations in individuals using these ARVs prophylactically (Table 1.2), 
the results of the current study suggest the ARVs are unlikely to alter cell viability systemically 
when used as PrEP. The concentrations of TDF tested approached peak serum concentrations in 
some individuals using the ARV therapeutically (see Table 1.2). In these individuals, the results 
of the current study suggest TDF may alter the viability of some systemic immune cells by a small 
degree, but whether this would alter their function, and if TDFs effects would be compounded 
over time is unclear. DEX reduced cell viability by approximately 20% in PBMCS, and there was 
no significant change in viability in the presence of the ARVs. The effects of DEX in these 
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experiments is consistent with other studies; DEX has long been known to induce apoptosis in 
lymphocytes (Migliorati et al., 1994; Andreau et al., 1998). It is unclear if reduced cell viability in 
PBMCs in the presence of the ARVs generally altered mRNA expression, but comparison of 
GAPDH mRNA levels in ARV- and non-ARV-treated PBMCs in these experiments (data not 
shown) suggests this was not the case. The inclusion of a cytotoxic positive control experiments 
assessing cell viability in the present study would increase the credibility of the observed results. 
 
Findings in this study that DPV and TDF have cell-specific and/or time dependent effects on 
cell-viability are consistent with those previously reported by others, using different cell lines. The 
50% cytotoxic concentration (concentration of the drug at which the cell viability was reduced to 
50% of the drug-free control value) of DPV in TZM-bl cells, PM-1 CD4+ T cells and 
macrophages is approximately 10–20 µM after 14 days (Fletcher et al., 2009). In cervical explants, 
and in the HEC-1A human endometrial adenocarcinoma cell line, TFV has been shown to have 
no cytotoxic effects at concentrations up to 100 µM after 24 hours (Gali et al., 2010). Conversely, 
Grigsby et al. showed treatment of murine primary osteoblasts with TDF, at concentrations of 50 
µM or more, over a period of 3 days significantly reduced their viability (Grigsby et al., 2010). The 
present study did not evaluate the effects of higher micromolar concentrations of DPV and TDF 
on cell viability, as found in cervical tissue following intravaginal delivery of these ARVs, but from 
the findings of others, one can conclude the ARVs have dose-, time- and concentration-dependent 
effects on cell viability. The GCs, progestins and ARVs tested do not appear to modulate each 
other’s effects on cell viability.  
 
DEX, CORT and MPA have previously been shown to have differential, cell-line-dependent 
cytotoxic effects in various carcinoma cell lines (Sutherland et al., 1988; Dran et al., 1995; Lu et al., 
2005). The highest concentration of CORT used in this study (1 µM), induced an apparent 
decrease in cell viability of approximately 15%. Interestingly, in the presence of TDF, this apparent 
decline in viability was abrogated. Unlike other NRTIs, TFV has been shown by others to induce 
minimal or no mitochondrial toxicity in human hepatoblastoma (HepG2) cells, skeletal muscle 
cells, or renal proximal tubule epithelial cells in vitro, even following long-term incubations with 
supra-physiological concentrations (Birkus et al., 2002; Venhoff et al., 2007). Given these reports, 
and the lack of effect on cell viability observed in U2OS cells in this study, effects on mitochondrial 
function are unlikely to be a mechanism through which the relatively low concentration of TDF 
affects steroid function in this in vitro study. The broader implications of ARV effects on cell 
viability in the presence of steroid in the FGT and systemically are difficult to extrapolate, given 
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GCs, progestins and ARVs have highly varied, cell-, dose- and time-dependent effects on cell 
viability.  
 
4.5 Effects of MVC, DPV and TDF on GR-mediated mRNA expression in PBMCs 
 
This study investigated the capacity of MVC, DPV and TDF to alter GR-regulated 
immunoregulatory gene mRNA expression in PBMCs (Fig. 3.6). In PBMCs from the majority 
(67%) of donors, the ARVs decreased basal GILZ mRNA expression after 48 hours (Fig. 3.6a). 
To the best of the present authors knowledge, this is the first study showing MVC, TDF and DPV 
reduce basal GILZ mRNA expression in PBMCs. These findings were in contrast to observations 
in U2OS cells; although TDF decreased DEX-induced GILZ mRNA levels, neither DPV nor 
TDF reduced basal GILZ mRNA expression (after 24 hours) (Fig. 3.4a). Therefore, it would 
appear the ARVs have cell- and/or time-dependent effects on GILZ mRNA expression, but this 
cannot be determined conclusively from the results of this study, because incubations in 
experiments in the two model systems were of different lengths. The ARVs did not significantly 
alter DEX-induced GILZ expression in PBMCs from the majority of donors. Differing responses 
in PBMCs and U2OS cells could be explained by differential co-regulator, transcription factor 
and/or signaling protein expression, differences in responses to endogenous and exogenously 
expressed GR, or varying GR levels. GILZ is a critical mediator of the anti-inflammatory and 
immunosuppressive effects of GCs, through preventing the transcription of pro-inflammatory 
cytokines and preventing activation in macrophages (Berrebi et al., 2003; Riccardi, 2010). Hladik et 
al. showed a 1% TFV gel reduced (GR-transactivated) IL-10 mRNA expression in rectal biopsies, 
which was associated with TFV-induced downregulation of CREB and CBP (Hladik et al., 2015). 
It is possible TDF has similar effects on CREB and CBP expression in PBMCs, which would 
explain how it reduces basal GILZ mRNA expression in these cells.  
 
Consistent with decreasing basal GILZ mRNA levels, when examining pooled data, the ARVs 
appeared to increase basal IL-6 and IL-8 mRNA expression in PBMCs. Therefore, in PBMCs, the 
ARVs appear to alter GR-regulated mRNA expression in a gene-dependent manner. The effects 
of the ARVs on cytokine and chemokine gene expression observed in PBMCs in the present study 
are consistent with their effects in other cell types, reported by others. TFV has been shown to 
increase IL-8 expression in endometrial and endocervical cells, and DPV has been reported to 
induce small increases in IL-8 in some FGT cell lines, genital ECs and cervical tissue in vitro (Gali 
et al., 2010; das Neves et al., 2013 Biswas et al., 2014). TDF selectively modulates cytokine 
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production in human PBMCs, consistent with the results of the present study; after TLR 
stimulation or stimulation with TNF-α, TFV has been shown to decrease IL-10, and increase pro-
inflammatory IL-12 gene expression in vitro, suggesting TFV and immune activators may co-
regulate cytokines in a synergistic manner (Melchjorsen et al., 2011).  
 
In this study, MVC had marked pro-inflammatory effects in PBMCs from 44% donors; 
simultaneously decreasing basal GILZ mRNA expression and increasing basal IL-6 and IL-8 
mRNA expression by 2-fold or greater (see Appendix Fig. A7-A9). DPV and TDF had similar 
effects in PBMCs from 10% and 20% of donors, respectively. Interestingly, the observation that 
MVC had proinflammatory effects in the more donors than did DPV or TDF is consistent with 
reports that MVC activates NF-κB via binding to CCR5, consequently inducing proinflammatory 
cytokine expression in CD4+ T cells (Madrid-Elena et al., 2018). In combination with DEX, the 
ARVs proinflammatory effects were mostly abolished, which is consistent with the GC-bound 
GR antagonizing the activity of AP-1, NFAT and NF-κB (De Bosscher et al. 2000; Nissen and 
Yamamoto, 2000). Like DPV and TDF, MVC was found to not transcriptionally activate the GR 
in an in vitro COS-1 cell line model, alone or in the presence of DEX, MPA or LNG in the present 
study (Appendix Fig. A2). COS-1 cells do not express CCR5 (Geiger et al., 2012), so in these cells, 
MVC most likely has no effects on GR-regulated gene expression caused by activating NF-κB. In 
addition to potential mechanisms outlined elsewhere in this chapter, a mechanism by which DPV 
and TDF may induce their pro-inflammatory effects is through modulating NF-κB activity, as has 
been reported with MVC. However, Melchjorsen et al. found no effect of TDF on NF-κB activity 
in monocytes (Melchjorsen et al., 2011). In PBMCs from all the donors in which the combined 
pro-inflammatory effects on GILZ, IL-6 and IL-8 mRNA expression outlined above were 
observed, the ARVs also increased basal IFN-γ expression. IFN-γ has varied immunoregulatory 
effects, including inducing lymphocyte activation, antigen presentation and pro-inflammatory 
antiviral responses (Roff et al., 2013). Although its ability to inhibit HIV-1 replication in monocytes 
and macrophages (Kornbluth et al., 1990; Roff et al. 2013) may be protective against HIV-1 
infection in vivo, it’s enhancement of lymphocyte activation and recruitment may increase the risk 
of HIV-1 acquisition (Roff et al. 2013).  
 
Chronic immune activation and inflammation drive HIV-1 disease progression and are also 
associated with an increased risk of cardiovascular and liver disease, cancer and metabolic 
disorders, and therefore non-AIDS mortality (Currier et al., 2008; Deeks, 2011; Manabe, 2011; 
Smith et al., 2014; Korniluk et al., 2017). Systemically, and in the FGT, inflammation and immune 
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activation are associated with an increased risk of HIV-1 acquisition (Fowke et al., 2012; Card et 
al., 2013; Masson et al., 2015; McKinnon et al., 2018). Therefore, if the effects observed in the 
presence of ARVs in PBMCs in this study are translated in vivo, and assuming they persist 
indefinitely, the implication is that DPV, TDF and MVC may have proinflammatory effects in 
some individuals, which may undermine their effectiveness when used prophylactically, through 
enhancing HIV-1 target cell recruitment and activation, and inducing inflammatory tissue damage. 
Theoretically, the ARVs anti-HIV-1 activity mitigates the increased susceptibility to HIV-1 
infection posed by their proinflammatory effects, but not susceptibility to the acquisition of other 
STIs. Conversely, enhanced immune activation and immune cell recruitment may lead to 
augmented responses to pathogens, thereby reducing the risk of HIV-1 acquisition. Confounding 
interpretation of these results is the fact that IL-8 and IFN-γ have been reported to both stimulate 
and inhibit HIV-1 infection (Kornbluth et al., 1990; Mackewicz et al., 1994; Lane et al., 2001; Roff 
et al. 2013), and that IL-6 may have both proinflammatory and anti-inflammatory effects, which 
are dependent on the levels and identity of other cytokines present (Xing et al., 1998; Tanaka et al., 
2014). 
 
Proinflammatory effects were abrogated in the presence of DEX, which supports suggestions by 
others that the inclusion of immunosuppresive agents in microbicides and PrEP may mitigate the 
increased susceptibility to HIV-1 infection posed by their proinflammatory effects (Naranbhai et 
al., 2012). In some individuals using TDF and MVC therapeutically, this study suggests these 
ARVs may contribute to the chronic inflammation and immune activation which are central to 
the pathogenesis of HIV-1 infection or may increase the risk of non-AIDS mortality. It should be 
noted that the downstream effects of the present studies in vitro findings are difficult to determine 
and would require further study of resulting downstream signaling and cytokine networks to 
determine in vivo effects. 
 
PBMCs abundantly express the GR endogenously (Cabrera-Munoz et al., 2012; Tomasicchio et al., 
2013), and some studies report detectable PR protein (Cabrera-Munoz et al., 2012) while others 
do not (Tomasicchio et al., 2013). Detectable AR and MR protein have not been reported in 
PBMCs (Cabrera-Munoz et al., 2012; Tomasicchio et al., 2013). It is possible the presence of PR in 
PBMCs may influence the activity of the ARVs, but this has not been investigated. ARV effects 
on IL-6, IL-8, and IFN-γ mRNA expression were variable and donor-specific, which is not 
surprising; it is well established that PBMC responses are highly variable and dependent on 
multiple physiological factors, including the presence of infection, inflammation, age, race, 
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nutritional status, concentrations of circulating hormones and the relative proportion of specific 
cell populations (Longo et al., 2012; Klein and Flanagan, 2016). In addition, varying GR/PR levels 
between donors may have contributed to the variable, donor-specific effects observed in this 
study, but this was not investigated. Although all PBMC donors were negative for HIV-1, syphilis 
and hepatitis A and B, they may have had other infections which were not tested for, which may 
have influenced their immune activation status and therefore immunoregulatory gene expression. 
With the exception of age and sex of PBMC donors, other details regarding donors were not 
available; it was therefore not possible to make any population-level inferences from the data.  
 
. 4.6 Steroid effects on the antiviral efficacy of DPV and TDF in PBMCs 
 
Encouragingly, this study found that neither DEX nor MPA significantly affected the antiviral 
efficacy of DPV or TDF in PBMCs from all three donors tested, at concentrations higher than 
those typically reported in the serum of users of these steroids (see Table 1.1 & 1.3). LNG did 
not affect the inhibitory efficacy of DPV in PBMCs from all three donors tested. However, LNG 
decreased the inhibitory efficacy of TDF in PBMCs from one donor. The results of this study 
suggest that at physiological concentrations, in the majority of individuals, GCs and progestins are 
unlikely to affect the anti-HIV-1 efficacy of PrEP ARVs in vivo. When steroids do affect the anti-
HIV-1 efficacy of ARVs, the effect appears to be individual- and steroid-specific, but 
interpretation of the results of these experiments is limited by the relatively low number of donors 
for which effects were assessed. The implications of these findings in HIV-1 positive women using 
HAART, which involves the use of different ARVs in combination, are unclear. Moreover, ARVs 
may be present together with multiple steroids, for example MPA and CORT in DMPA users, 
combinations of which were not assessed in this study. 
 
Contrary to the results of the present study, Shen et al. found MPA, but not LNG or P4, suppressed 
the anti-HIV effect of TFV by reducing intracellular TFV-DP in peripheral blood CD4+ T cells 
(Shen et al., 2017). In genital CD4+ T cells, this group found MPA decreased TAF (a prodrug of 
TFV) inhibition of HIV-1 infection and lowered TFV-DP concentrations, suggesting MPA 
influences the efficacy and potency of ARVs in an ARV- and cell-specific manner (Shen et al., 
2017). These findings, and those of the current study, suggest progestogens modulate the antiviral 
effects of TDF in a steroid-specific manner. However, whether the in vitro changes described above 
correlate to decreased HIV-1 protection in vivo remains to be determined. Of concern, in this 
study, the presence of LNG appeared to decrease the antiviral efficacy of TDF in PBMCs from 
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one donor. In contrast, Shen et al. showed no effect of LNG on intracellular TFV-DP levels or 
TFV antiviral activity in CD4+ T cells, as observed in PBMCs from two of three donors in the 
present study (Shen et al., 2017). PBMCs are comprised of a heterogenous population of HIV-1 
target cells, including monocytes and macrophages, as well as CD4+T cells (Autissier et al., 2010). 
Macrophages, like CD4+ T cells are productively infected by HIV-1 and contribute to the 
infection of CD4+ T cells (Waki and Freed, 2010). There are no studies which have determined 
the effects of progestins on TFV-DP in monocytes or macrophages specifically, which may 
account for the variance between the present study and published literature.  
 
There are no published studies assessing the effects of DEX or CORT on ARV antiviral efficacy. 
However, a study has shown pretreatment of macrophages with E2 and P4 induced dose-
dependent decreases in proinflammatory and antiviral responses, correlated with reduced HIV-1 
replication in the absence of ARVs, suggesting the immunosuppressive effects of steroids via 
steroid receptors may complement the antiviral effects of ARV (Devadas et al., 2018). Some 
progestin-based HCs are administered in combination with estrogenic compounds (Sitruk-Ware, 
2006; Sitruk-Ware and Nath, 2010). There is evidence suggesting E2 may be protective against 
HIV-1 infection. For example, E2 treatment has been shown to be protective against vaginal SIV 
transmission in macaques (Smith et al., 2000) and is protective against HIV-1 infection in human 
CD4+ T cells and macrophages in vitro (Rodriguez-Garcia et al., 2013). It is possible E2 in HCs is 
similarly protective against HIV-1 infection in women, although this remains to be determined. If 
so, the inclusion of E2 in MPTs may mitigate the inflammatory effects of the ARVs and any 
increased risk this may pose to HIV-1 acquisition. 
 
4.7  Limitations of the study  
 
This study has several limitations, which may limit the applicability of the observed results to those 
in vivo. In vivo testing in humans undoubtedly allows determination of physiologically relevant 
outcomes, but one cannot directly determine intracellular mechanisms of action. In vitro 
experiments, however, have the distinct advantage of allowing assessment of cellular intrinsic 
responses and the intracellular mechanisms involved. Thus, this thesis used in vitro models to 
investigate proof-of-concept hypotheses and mechanisms and interpreted the results with 
appropriate caution.  
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Immortalized cells, like the U2OS cell line used in this study, unlike primary cells, avert senescence 
through bypassing cell cycle checkpoints, often through the expression of oncogenes (Maqsood et 
al., 2013). As a result, some cell signaling and transcriptional responses in immortalized cells can 
differ from those in primary cells (reviewed by Kaur and Dufour, 2012). However, not all 
responses differ; for instance, DEX and MPA have been shown to have similar effects on GR-
regulated genes, including GILZ, IL-6 and IL-8, in immortalized endocervical cell lines, cervical 
explants and PBMCs (Govender et al., 2014; Ray et al., 2014). Moreover, many mechanisms have 
been identified in immortalized cells and have been shown to be consistent with in vivo results, 
such as the anti-inflammatory receptor-mediated cellular mechanisms of GCs (Fauci and Dale, 
1974; Guichard et al., 2015), the intracellular mechanism of action of ARVs (Fletcher et al., 2009; 
Rohan et al., 2010), and steroid-receptor activity and gene expression effects of progestogens 
currently in used in patients (Goldfien et al., 2015). The U2OS cell line has a large number of 
structural and numerical chromosomal alterations (Bayani et al., 2003), and expresses several proto-
oncogenes, which may influence some transcriptional and cell signaling responses (Niforou et al., 
2008). Whether GR-mediated responses determined in vitro in U2OS cells in this study occur in all 
cells expressing the GR in vivo remains to be determined. Nevertheless, many GC-mediated 
responses in U2OS cells are similar to those in primary cells, so it was a suitable model for use in 
the current study. For example, GCs and progestins have been shown to induce similar changes 
in GILZ mRNA expression in PBMCs and U2OS cells (Hadley et al., 2011; Govender et al., 2014; 
Ray et al., 2014). and the mechanisms through which some cellular stressors desensitize GC 
signaling via the GR were first identified in U2OS cells (Galliher-Beckley et al., 2011). 
 
Limitations of promoter-reporter assays, notably the absence of chromatin and the ratio of 
promoter-reporter constructs to transcription factors, have been discussed elsewhere in this 
chapter. Nevertheless, many results obtained with reporter assays have helped to identify 
transcriptional mechanisms that also occur on endogenous genes. For example, transcription 
elements regulating the expression of IL-2, IL-5 and CCR5 by the GR were identified using 
reporter genes (Bamberger et al., 1997; Zhang et al., 1997; Guignard et al., 1998). Transcriptional 
activity on reporter genes is often similar to that on endogenous genes; for example, Ronacher et 
al. showed similar effects of GCs and progestins on GILZ mRNA expression and a GRE-reporter 
gene in COS-1 and U2OS cells (Ronacher et al., 2009). A useful strategy, as employed in this thesis, 
is to compare results on reporter assays with those on endogenous genes. Determining GR-
regulated mRNA levels, although more physiologically relevant than reporter assays, carries its 
own limitations, so caution must be taken when extrapolating effects on mRNA expression to 
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phenotypic responses. This study determined changes in immunomodulatory gene mRNA 
expression, which may not necessarily correlate with transcriptional effects or changes in protein 
levels due to multiple mRNA post transcriptional mechanisms (Liu et al., 2016). Although mRNA 
post-transcriptional regulation is a critical determinant of final protein concentrations, particularly 
under conditions like differentiation or stress responses, under steady state conditions, mRNA 
abundance does primarily determine protein abundance (Liu et al., 2016). 
 
Effects induced by ARVs in U2OS cells and PBMCs in the present study have in some instances 
been extrapolated to in vivo effects on HIV-1 susceptibility and HIV-1 disease progression. It 
should be acknowledged that there are other more physiologically relevant models which would 
have been better suited to making such in vitro-to-in vivo extrapolations. For example FGT cell lines 
expressing the GR endogenously like the End1/E6E7 and HeLa FGT cell lines , or cervical 
explants, would have been better in vitro models from which effects on HIV-1 susceptibility in the 
FGT in vivo could be extrapolated. However, these models have some disadvantages when 
attempting to establish proof-of-concept hypotheses and mechanisms via steroid receptors, as in 
the present study. Unlike steroid deficient U2OS cells, most cells express multiple steroid 
receptors, which would confound interpretation of the results of this study. For example HeLa 
and like End1/E6E7 cells have been shown to express the GR and MR endogenously (Govender 
et al., 2014), and these two steroid receptors are known compete for the same ligands, bind to the 
same response elements, transcription factors and co-regulators, and can heterodimerize (Gomez-
Sanchez and Gomez-Sanchez, 2014). In addition to expressing all steroid receptors (Ray et al., 
2019), cervical explants are far less accessible than U2OS cells or PBMCs. Another limitation of 
the current study is that it is not clear how the amount of GR transfected into U2OS cells 
compares to that in cells expressing the GR in vivo.  
 
Whether responses observed in PBMCs in vitro in this study are replicated in immune cells in vivo 
remains to be established. It should be noted that responses in cultured PBMCs may differ from 
those in vivo, as the activity and activation status of PBMCs in vivo is influenced by numerous 
dynamically expressed cytokines and chemokines, as well as the endocrine system (Watkins et al., 
1999). It should also be considered that the phenotype and responses of immune cells found in 
lymphoid organs and the mucosal surfaces of the FGT and gut (which are most relevant to HIV-
1 transmission and disease progression), are distinct from immune cells in peripheral blood 
(Brenchley et al., 2004; Trifonova et al., 2014). Therefore, care must be taken when drawing 
conclusions from effects observed in PBMCs regarding HIV-1 susceptibility or disease 
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progression. Nevertheless, PBMCs consist of many of the lymphocyte, DC and macrophage 
subsets relevant to HIV-1 transmission and infection (Autissier et al., 2010). Indeed, much of what 
is known regarding CD4+ T cell depletion, T cell activation, T cell dynamics, and HIV-specific 
immune responses in HIV infection was first elucidated from the analysis of PBMCs (Clark et al., 
1991; Koot et al., 1992; Roederer et al., 1995; Haase, 1999).  
 
Another limitation of the present study is that infection assays made use of HIV-1 infectious 
molecular clones, whereas HIV-1 transmission in women typically occurs a following exposure to 
infected semen; a complex mixture of cells and immunoregulatory molecules, which actively 
modulates inflammation, immune cell activation and the efficiency of HIV-1 transmission in the 
FGT (Sharkey et al., 2012; Introini et al., 2017). The use of only infectible PBMCs (determined to 
be infectible by prescreening for infectability) may have biased the results of infection assays by 
selecting for donors with immune profiles at higher risk of HIV-1 infection. However, the reasons 
for non-infectability of isolated PBMCs not selected may not have been due to intrinsic donor 
factors, but due to subsequent damage during PBMC storage and isolation. Furthermore, this 
study did not assess the immunomodulatory effects of the ARVs in HIV-1-infected PBMCs, 
which would be more relevant to determining any effects on HIV-1 disease progression, and may 
differ from those in uninfected PBMCs due to their heightened state of activation (Ford, Puronen 
and Sereti, 2009). It is possible steroids differentially alter the ARVs anti-HIV-1 effects against X4 
tropic virus, which was not investigated in this study. Given that HIV-1 has been shown to convert 
from R5 tropic to X4 tropic with time in approximately 50% of HIV-1 infected individuals, 
determining the effects of progestins and GC on the efficacy of ARVs against X4 tropic viruses 
is important, but remains unexplored (Berger et al., 1999; Regoes and Bonhoeffer, 2005; Mosier, 
2009). This study did not investigate the effects of DPV, TDF or MVC on GR-regulated mRNA 
expression in PBMCs in the presence of CORT, MPA or LNG, which may differ from effects in 
the presence of DEX (as was observed in U2OS cells). This would have required PBMCs from 
more donors than were available for this study and was beyond the scope of this study. As such, 
from the results presented in this thesis, one cannot conclusively state the effects of the ARVs 
studied on GC- and progestin-induced immunomodulatory gene expression. Furthermore, in 
most experiments, the effects of a single ARV concentration, at a single time-point, were 
investigated; testing ARV effects at a range of concentrations spanning those reported in vivo (see 
Table 1.2), and at different time points, may be more informative regarding their possible in vivo 
effects on HIV-1 susceptibility and HIV-1 disease progression.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE PERSPECTIVES 
__________________________________________________________________________ 
 
5.1 Conclusions 
 
 This study has shown that DPV and TDF do not independently transcriptionally activate the GR, 
but increase GC transcriptional efficacy via the GR on a reporter gene in vitro, which is a novel 
finding. These findings, if extrapolated in vivo, suggest DPV and TDF may potentiate the 
transactivational effects of GCs via the GR during times of stress, or GC therapy, resulting in 
adverse side effects, for example osteoporosis (Baschant and Tuckermann, 2010; Ramamoorthy 
and Cidlowski, 2013). The results of the current study suggest TDF, but not DPV, may modulate 
DEX-induced anti-inflammatory gene expression during GC therapy or CORT- and MPA-
induced anti-inflammatory gene expression under cellular contexts where they act as a full agonists 
for the GR (Ronacher et al., 2009). As such, the use of TDF prophylactically or therapeutically 
may result in a decreased ability to blunt immune responses and therefore increase inflammation 
and immune activation. This may increase the risk of HIV-1 acquisition or promote HIV-1 disease 
progression and non-AIDS mortality (Deeks, 2011). In the present study, DPV and TDF did not 
significantly alter GR protein levels, or cell viability, alone or in the presence of steroid, in the cell 
line model, suggesting alterations in GR concentrations or cell viability are not likely to be the 
mechanisms through which the ARVs alter GR-mediated activity. This study showed TDF 
induced apparent increases in DEX-induced GR phosphorylation at Ser226, to a greater extent 
than did DPV. This is consistent with findings in this study that TDF, but not DPV, decreased 
DEX-induced anti-inflammatory gene mRNA expression in U2OS cells, as phosphorylation at 
this residue is associated with blunted GR transcriptional responses (Kino et al., 2007).  
 
In PBMCs from some donors, MVC, DPV and TDF had marked proinflammatory effects; 
simultaneously increasing pro-inflammatory cytokine mRNA expression and decreasing anti-
inflammatory GILZ mRNA expression. If similar effects occur in the FGT, in some women, PrEP 
ARVs may paradoxically increase the risk of acquiring sexually transmitted infections, including 
HIV-1, through increased recruitment and activation of HIV-1 target cells, and enhancing 
inflammation. Conversely, these women may benefit from enhanced immune responses against 
pathogens. In individuals using MVC and TDF therapeutically, the proinflammatory effects of the 
ARVs may contribute to HIV-1 disease progression, as well as non-AIDS mortality (Deeks, 2011). 
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In the presence of DEX, most ARV-induced proinflammatory effects were abrogated, suggesting 
the inclusion of an immunosuppressive agent in microbicides and MPTs may mitigate the 
unwanted proinflammatory effects of PrEP ARVs.  
 
This study found that DEX, MPA and LNG did not alter the antiviral efficacy of DPV or TDF 
in PBMCs from the vast majority of donors tested. Taking the results of the current study and 
those of others into consideration, DPV is proposed to be more suitable ARV for MPTs and 
microbicides than TDF or MVC. TDF was shown in this study to modulate GC-induced mRNA 
expression, whereas DPV did not. Furthermore, DPV induced pro-inflammatory changes in 
mRNA expression in PBMCs from less donors than did the other ARVs, which further favors its 
use for PrEP. Moreover, previous studies have found MPA reduces the antiviral efficacy of TDF 
in CD4+ T cells (Shen et al., 2017), and the long-term use of TDF is associated with adverse effects 
on bone (Grigsby et al., 2010; Komatsu et al., 2018). No such adverse effects have been reported 
with the use of DPV (Chen et al., 2015; Baeten et al., 2016). The combination of LNG and DPV 
may be the best choice for MPTs, considering evidence from clinical and biological studies 
indicating that MPA use is associated with increased risk of HIV-1 acquisition (Hapgood et al., 
2018). In this study, MVC induced pro-inflammatory effects in PBMCs from more donors than 
did DPV or TDF. MVC has been shown to induce proinflammatory cytokine expression via NF-
kB activation, and, as an early vaginal microbicide candidate, MVC was not protective against 
HIV-1 infection in cervical tissue (Chen et al., 2015; Fletcher et al., 2016; Madrid-Elena et al., 2018). 
Therefore, of the three ARVs whose immunomodulatory effects were assessed in the current 
study, MVC appears to be least suitable for PrEP. 
 
5.2 Future perspectives  
 
Given the relatively small apparent differences and inherent technical and biological error in the 
experiments presented in the current study, it was not possible to establish whether the apparent 
differences observed were significant or not. It is therefore necessary that some experiments be 
repeated, or that more experiments with fewer variables be performed. The following questions 
remained unresolved in this thesis:  
 
1. Do the ARVs alter steroid efficacy or potency for transrepression via the GR? To fully 
elucidate their actions via the GR, it is necessary to determine the ARVs effects on steroid-
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induced transrepression via the GR. This could be achieved using NF-kB- and AP-1-reporter 
genes and assessing mRNA expression of GR-transrepressed genes.  
 
2. Are the effects of TDF on GC-induced mRNA expression gene-, steroid-, cell-, time-, 
and/or dose-dependent? To provide clarity as to whether TDF has gene-specific effects, 
the effects of TDF on different GC-regulated genes, could be investigated. Ideally, one would 
assess the effects of TDF on the entire cell transcriptome, in the presence and absence of 
steroid, for example using microarray analysis. The current study suggested the effects of TDF 
on GC-induced gene expression in vivo may contribute to its adverse effects on BMD in some 
users (Grigsby et al., 2010; Komatsu et al., 2018). However, the effects of TDF on the 
expression of GC-induced genes which regulate BMD, for example RANKL and OPG 
(reviewed by Boyce and Xing, 2007), was not investigated; doing so would better inform this 
assumption. It is also important to determine if the changes in mRNA expression observed in 
this study are translated into changes in protein levels, using western blotting. TDF-induced 
repression of steroid-induced GILZ mRNA expression appeared to be dependent on the 
efficacy of the GR agonist in U2OS cells. It is important these experiments be repeated, 
possibly with fewer variables, to determine if the effects are steroid-specific. These 
experiments could be performed in different cell lines, including ones expressing the GR 
endogenously, for example HeLa or End1/E6E7 cells, to determine whether TDF alters GR-
regulated gene expression cell-specifically. It would be interesting to determine the effects of 
the ARVs on CORT- and MPA-induced gene expression in cell lines where these steroids 
induce GR transactivation to a degree approaching that of DEX, for example COS-1 cells 
(Ronacher et al., 2009). It would also be interesting to determine if GR protein levels in PBMCs 
from donors correlate with the donor-specific effects of the ARVs on immunomodulatory 
gene expression, and whether these ARV responses are cell-specific by cell-typing and 
quantification. The effects of DPV and TDF on GR-regulated gene expression, at several 
concentrations and time points, should be investigated to determine if their effects are dose- 
and/or time-dependent. It is possible pre-treatment of cells with ARVs prior to exposure to 
steroids would alter the results, given that on their own, the ARVs had immunomodulatory 
effects, which may impact steroid activity. This would require further investigation to 
determine. 
 
3. How do DPV and TDF alter cell viability in PBMCs? In this study DPV and TDF 
significantly reduced cell viability in PBMCs. As the MTT assay (employed in experiments 
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assessing the effects of the ARVs on cell viability) measures metabolic activity of cells based 
on NAD(P)H-dependent enzymes, it may reflect changes in the metabolic state of the cell, 
cellular proliferation and/or cell death. Further evidence is required to validate the conclusions 
of the MTT assays in this study. For example, cell counts before and after treatment to 
determine cell proliferation and death, cell cycle phase analysis and proliferation assays, could 
be performed. It would be interesting to determine in which cell populations death occurs and 
assess the expression of apoptotic markers, which could be achieved using flow cytometry. To 
determine if the effects of the ARVs on cell viability altered global gene expression, it would 
also be informative to assess the expression of several reference genes in ARV- vs non-ARV-
treated cells. 
 
4. What is the mechanism through which DPV and TDF alter GR-mediated mRNA 
expression in U2OS cells and PBMCs? The results of this study suggest the mechanism in 
U2OS cells may involve differential ARV-induced alterations in DEX-induced 
phosphorylation at Ser226 on the GR. Assessing the ARVs effects on CDK5 and JNK, which 
phosphorylate the GR at Ser226 (Kino, 2018) may inform on the mechanism through which 
this occurs. To further elucidate the ARVs effects on GR activity, phosphorylation at other 
serine residues (see Fig. 1.4), should be assessed by western blotting. The ARVs effects on 
nuclear translocation (using cell fractionation techniques and western blotting), GR cofactor 
recruitment (using ChIP) and changes in GR-regulated gene expression should be investigated 
in parallel. TDF has been shown to downregulate the expression of CREB, CBP and MAPK, 
which are involved in activating the GR (Hladik et al., 2015). It would be interesting to 
determine if TDF has similar effects in U2OS cells and PBMCs by comparing co-regulator 
recruitment in DEX- and non-DEX-treated cells, in the absence and presence of the ARVs 
using co-regulator microarray assays. TDF has also been shown to modulate expression of 
genes involved in the Wnt, TGF-b and Hedgehog signaling pathways in murine osteoblasts 
(Grigsby et al., 2010). Assesing the effects of TDF on these genes in U2OS cells and PBMCs 
may clarify the mechanism behind its effects on GR-regulated mRNA expression in these 
cells.  
 
This study found the ARVs tested induced pro-inflammatory effects in PBMCs from some 
donors tested. To determine if pro-inflammatory effects observed occur via NF-κB 
activation, as has been shown with MVC by others (Madrid-Elena et al., 2018), ARV effects 
on NF-κB recruitment to promoters (using ChiP), NF-κB nuclear translocation and 
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phosphorylation could be assessed. The experiments conducted in PBMCs in the current 
study provide no evidence that the effects observed are GR-dependent. To clarify this, 
experiments could be repeated with the addition of a GR antagonist, for example RU486, or 
GR small-interfering RNA knockdown. Furthermore, these experiments only assessed 
mRNA expression, which may not correlate to the amount of secreted protein. Secreted 
cytokines could be quantified over a time-course using enzyme-linked immunosorbent assays, 
which would assist in determining more physiologically relevant outcomes.  
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Figure A1: DPV and TDF have no effect on the transcriptional activity of LNG or MPA via the GR. 
U2OS cells were co-transfected with the GR expression vector (+GR) or its empty vector control (-GR), 
and the GRE luciferase reporter construct. Subsequently, cells were treated with DPV and TDF at the 
concentrations indicated in the presence or absence of 100 nM LNG (a & b) or MPA (c & d), or vehicle 
(0.1% v/v EtOH and DMSO). Luciferase activity was normalized to protein content per well, as determined 
by a Bradford assay. Data are plotted as mean ± SEM, and are the pooled results of two independent 
experiments performed in triplicate.  
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Fig A2: MVC does not independently activate the GR, or alter the transcriptional activity of LNG 
or MPA via the GR. COS-1 cells were co-transfected with the GR expression vector (+GR) or its empty 
vector control (-GR), and the GRE luciferase reporter construct. Subsequently, cells were treated with 
MVC at the concentrations indicated in the absence or presence of 100 nM DEX (a), LNG (b), MPA (c) 
or vehicle (0.1% v/v EtOH and DMSO) for 24 hours. Luciferase activity was normalized to protein content 
per well, as determined by a Bradford assay. Data are plotted as mean ± SEM, and are the pooled results 
of three independent experiments performed in triplicate. Statistical significance was determined using a 
two-way ANOVA with a Tukey’s multiple comparisons post-test. Asterisks or p values above bars indicate 
significance compared to vehicle control (in the absence of steroid, black bar), unless otherwise indicated 
with lines. ****, ***, ** and * indicate p<0.0001, p<0.001, p<0.01 and p<0.05, respectively. 
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Figure A3: DEX does not induce GILZ mRNA expression in U2OS cells, in the absence of the GR. 
U2OS cells were transfected with pcDNA3.1; the empty vector control of the GR expression vector. 
Subsequently, cells were treated with increasing concentrations of DEX or vehicle (0.1% v/v EtOH and 
DMSO) for 24 hours as indicated. cDNA was synthesized and the expression of GILZ mRNA was 
determined, and normalized to GAPDH mRNA levels. Data are plotted as mean ± SEM and are the pooled 
results of two independent experiments. All experiments were performed in triplicate. Relative fold change 
in expression was determined by setting vehicle control to 1.  
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Figure A4. DPV and TDF effect on GR protein levels and GR phosphorylation. U2OS cells were 
transfected with the GR expression vector and subsequently stimulated with 1 µM DPV or TDF in the 
absence or presence of 100 nM DEX, 1 µM DEX or vehicle (0.1% v/v EtOH and DMSO) for 24 hours. 
Equal volumes of cell lysate were analysed by western blotting with GR and pSer226-GR specific 
antibodies, with GAPDH as a loading control. A representative western blot is shown in (a). Quantification 
of GR protein levels is shown in (b) and relative pSer226-GR in (c). Data are plotted as means. 
 
Ve
hic
le
DP
V
TD
F
Ve
hic
le
DP
V
TD
F
Ve
hic
le
DP
V
TD
F
+ DEX 100 nM + DEX 1 µM
GR
 -V
E 
GR
 +V
E 
←pSer226-GR
←GR
←GAPDH37 → 
95 → 
95 → 
kDa
Ve
hic
le
DP
V
TD
F
DE
X 
10
0 n
M
DE
X 
10
0 n
M+
DP
V
DE
X 
10
0 n
M+
TD
F
DE
X 
1 µ
M
DE
X 
1 µ
M+
DP
V
DE
X 
1 µ
M+
TD
F
GR
 -V
E
GR
 +V
E
0
20
40
75
100
125
150
R
el
at
iv
e 
G
R
 p
ro
te
in
 
Ve
hic
le
DP
V
TD
F
DE
X 
10
0 n
M
DE
X 
10
0 n
M+
DP
V
DE
X 
10
0 n
M+
TD
F
DE
X 
1 µ
M
DE
X 
1 µ
M+
DP
V
DE
X 
1 µ
M+
TD
F
GR
 -V
E
GR
 +V
E
0
200
400
600
800
R
el
at
iv
e 
pS
er
22
6-
G
R
/G
R
 p
ro
te
in
a.
b. c.
U2OS
 108 
 
 
Figure A5. DPV and TDF effect on GR protein levels and GR phosphorylation. U2OS cells were 
transfected with the GR expression vector and subsequently stimulated with 1 µM DPV or TDF in the 
absence or presence of 100 nM DEX,1 µM DEX or vehicle (0.1% v/v EtOH and DMSO) for 24 hours. 
Equal volumes of cell lysate were analysed by western blotting with GR and pSer226-GR specific 
antibodies, with GAPDH as a loading control. A representative western blot is shown in (a). Quantification 
of GR protein levels is shown in (b) and relative pSer226-GR in (c). Data are plotted as means. 
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Figure A6. DPV and TDF effect on GR protein levels and GR phosphorylation. U2OS cells were 
transfected with the GR expression vector and subsequently stimulated with 1 µM DPV or TDF in the 
absence or presence of 100 nM DEX, 1 µM DEX or vehicle (0.1% v/v EtOH and DMSO) for 24 hours. 
Equal volumes of cell lysate were analysed by western blotting with GR and pSer226-GR specific 
antibodies, with GAPDH as a loading control. A representative western blot is shown in (a). Quantification 
of GR protein levels is shown in (b) and relative pSer226-GR in (c). Data are plotted as means. 
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Figure A7: DPV, TDF and MVC alter GILZ mRNA expression donor specifically. PBMCs were 
stimulated with 1 µM MVC, DPV or TDF, in the absence or presence of 100 nM DEX, or vehicle (0.1% 
v/v EtOH and DMSO) for 48 hours, following which relative changes in GILZ mRNA expression were 
determined by real time qPCR, and normalized to GAPDH mRNA levels. Donors in which there was a 2 
fold or greater decrease in GILZ mRNA expression upon treatment with MVC (a), DPV (b) and TDF (c) 
are shown in the top row, as are donors in which GILZ mRNA expression did not change by than 2-fold 
upon treatment with MVC (d), DPV (e) or TDF (f), in the bottom row. Relative fold change in expression 
was determined by setting vehicle control to 1. Data are plotted as mean ± SEM. Individual donors are 
depicted with specific black symbols.  
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Figure A8: DPV, TDF and MVC alter IL-6 mRNA expression donor specifically. PBMCs were 
stimulated with 1 µM MVC, DPV or TDF, in the absence or presence of 100 nM DEX, or vehicle (0.1% 
v/v EtOH and DMSO) for 48 hours, following which relative changes in IL-6 mRNA expression were 
determined by real time qPCR, and normalized to GAPDH mRNA levels. Donors in which there was a 2 
fold or greater decrease in IL-6 mRNA expression upon treatment with MVC (a), DPV (b) and TDF (c) 
are shown in the top row. Donors in which IL-6 mRNA expression changed less than 2 fold upon 
treatment with MVC (d), DPV (e) or TDF (f) are shown in the middle row. Donors in which there was a 
2 fold or greater increase in IL-6 mRNA expression upon treatment with MVC (g). DPV (h) and TDF (i) 
are shown in the bottom row. Relative fold change in expression was determined by setting vehicle control 
to 1. Data are plotted as mean ± SEM. Individual donors are depicted with specific black symbols. 
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Figure A9: DPV, TDF and MVC alter IL-8 mRNA expression donor specifically. PBMCs were 
stimulated with 1 µM MVC, DPV or TDF, in the absence or presence of 100 nM DEX, or vehicle (0.1% 
v/v EtOH and DMSO) for 48 hours, following which relative changes in IL-8 mRNA expression were 
determined by real time qPCR, and normalized to GAPDH mRNA levels. Donors in which there was a 2-
fold or greater decrease in IL-8 mRNA expression upon treatment with MVC (a), DPV (b) and TDF (c) 
are shown in the top row. Donors in which IL-8 mRNA expression changed less than 2-fold upon 
treatment with MVC (d), DPV (e) or TDF (f) are shown in the middle row. Donors in which there was a 
2-fold or greater increase in IL-8 mRNA expression upon treatment with MVC (g). DPV (h) and TDF (i) 
are shown in the bottom row. Relative fold change in expression was determined by setting vehicle control 
to 1. Data are plotted as mean ± SEM. Individual donors are depicted with specific black symbols. 
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Figure A10: DPV, TDF and MVC alter IFN-γ mRNA expression donor specifically. PBMCs were 
stimulated with 1 µM MVC, DPV or TDF, in the absence or presence of 100 nM DEX, or vehicle (0.1% 
v/v EtOH and DMSO) for 48 hours, following which relative changes in IFN-γ mRNA expression were 
determined by real time qPCR, and normalized to GAPDH mRNA levels. Donors in which there was a 2-
fold or greater decrease in IFN-γ mRNA expression upon treatment with MVC (a), DPV (b) and TDF (c) 
are shown in the top row. Donors in which IFN-γ mRNA expression changed less than 2-fold upon 
treatment with MVC (d), DPV (e) or TDF (f) are shown in the middle row. Donors in which there was a 
2-fold or greater increase in IFN-γ mRNA expression upon treatment with MVC (g). DPV (h) and TDF 
(i) are shown in the bottom row. Relative fold change in expression was determined by setting vehicle 
control to 1. Data are plotted as mean ± SEM. Individual donors are depicted with specific black symbols. 
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